<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230002756</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>4</s160></s100><s200><s210>1</s210><s211>1307</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>AsCas12a</s223></s220></s200><s400> 1Met Thr Gln Phe Glu Gly Phe Thr Asn Leu Tyr Gln Val Ser Lys Thr1               5                   10                  15Leu Arg Phe Glu Leu Ile Pro Gln Gly Lys Thr Leu Lys His Ile Gln            20                  25                  30Glu Gln Gly Phe Ile Glu Glu Asp Lys Ala Arg Asn Asp His Tyr Lys        35                  40                  45Glu Leu Lys Pro Ile Ile Asp Arg Ile Tyr Lys Thr Tyr Ala Asp Gln    50                  55                  60Cys Leu Gln Leu Val Gln Leu Asp Trp Glu Asn Leu Ser Ala Ala Ile65                  70                  75                  80Asp Ser Tyr Arg Lys Glu Lys Thr Glu Glu Thr Arg Asn Ala Leu Ile                85                  90                  95Glu Glu Gln Ala Thr Tyr Arg Asn Ala Ile His Asp Tyr Phe Ile Gly            100                 105                 110Arg Thr Asp Asn Leu Thr Asp Ala Ile Asn Lys Arg His Ala Glu Ile        115                 120                 125Tyr Lys Gly Leu Phe Lys Ala Glu Leu Phe Asn Gly Lys Val Leu Lys    130                 135                 140Gln Leu Gly Thr Val Thr Thr Thr Glu His Glu Asn Ala Leu Leu Arg145                 150                 155                 160Ser Phe Asp Lys Phe Thr Thr Tyr Phe Ser Gly Phe Tyr Glu Asn Arg                165                 170                 175Lys Asn Val Phe Ser Ala Glu Asp Ile Ser Thr Ala Ile Pro His Arg            180                 185                 190Ile Val Gln Asp Asn Phe Pro Lys Phe Lys Glu Asn Cys His Ile Phe        195                 200                 205Thr Arg Leu Ile Thr Ala Val Pro Ser Leu Arg Glu His Phe Glu Asn    210                 215                 220Val Lys Lys Ala Ile Gly Ile Phe Val Ser Thr Ser Ile Glu Glu Val225                 230                 235                 240Phe Ser Phe Pro Phe Tyr Asn Gln Leu Leu Thr Gln Thr Gln Ile Asp                245                 250                 255Leu Tyr Asn Gln Leu Leu Gly Gly Ile Ser Arg Glu Ala Gly Thr Glu            260                 265                 270Lys Ile Lys Gly Leu Asn Glu Val Leu Asn Leu Ala Ile Gln Lys Asn        275                 280                 285Asp Glu Thr Ala His Ile Ile Ala Ser Leu Pro His Arg Phe Ile Pro    290                 295                 300Leu Phe Lys Gln Ile Leu Ser Asp Arg Asn Thr Leu Ser Phe Ile Leu305                 310                 315                 320Glu Glu Phe Lys Ser Asp Glu Glu Val Ile Gln Ser Phe Cys Lys Tyr                325                 330                 335Lys Thr Leu Leu Arg Asn Glu Asn Val Leu Glu Thr Ala Glu Ala Leu            340                 345                 350Phe Asn Glu Leu Asn Ser Ile Asp Leu Thr His Ile Phe Ile Ser His        355                 360                 365Lys Lys Leu Glu Thr Ile Ser Ser Ala Leu Cys Asp His Trp Asp Thr    370                 375                 380Leu Arg Asn Ala Leu Tyr Glu Arg Arg Ile Ser Glu Leu Thr Gly Lys385                 390                 395                 400Ile Thr Lys Ser Ala Lys Glu Lys Val Gln Arg Ser Leu Lys His Glu                405                 410                 415Asp Ile Asn Leu Gln Glu Ile Ile Ser Ala Ala Gly Lys Glu Leu Ser            420                 425                 430Glu Ala Phe Lys Gln Lys Thr Ser Glu Ile Leu Ser His Ala His Ala        435                 440                 445Ala Leu Asp Gln Pro Leu Pro Thr Thr Leu Lys Lys Gln Glu Glu Lys    450                 455                 460Glu Ile Leu Lys Ser Gln Leu Asp Ser Leu Leu Gly Leu Tyr His Leu465                 470                 475                 480Leu Asp Trp Phe Ala Val Asp Glu Ser Asn Glu Val Asp Pro Glu Phe                485                 490                 495Ser Ala Arg Leu Thr Gly Ile Lys Leu Glu Met Glu Pro Ser Leu Ser            500                 505                 510Phe Tyr Asn Lys Ala Arg Asn Tyr Ala Thr Lys Lys Pro Tyr Ser Val        515                 520                 525Glu Lys Phe Lys Leu Asn Phe Gln Met Pro Thr Leu Ala Ser Gly Trp    530                 535                 540Asp Val Asn Lys Glu Lys Asn Asn Gly Ala Ile Leu Phe Val Lys Asn545                 550                 555                 560Gly Leu Tyr Tyr Leu Gly Ile Met Pro Lys Gln Lys Gly Arg Tyr Lys                565                 570                 575Ala Leu Ser Phe Glu Pro Thr Glu Lys Thr Ser Glu Gly Phe Asp Lys            580                 585                 590Met Tyr Tyr Asp Tyr Phe Pro Asp Ala Ala Lys Met Ile Pro Lys Cys        595                 600                 605Ser Thr Gln Leu Lys Ala Val Thr Ala His Phe Gln Thr His Thr Thr    610                 615                 620Pro Ile Leu Leu Ser Asn Asn Phe Ile Glu Pro Leu Glu Ile Thr Lys625                 630                 635                 640Glu Ile Tyr Asp Leu Asn Asn Pro Glu Lys Glu Pro Lys Lys Phe Gln                645                 650                 655Thr Ala Tyr Ala Lys Lys Thr Gly Asp Gln Lys Gly Tyr Arg Glu Ala            660                 665                 670Leu Cys Lys Trp Ile Asp Phe Thr Arg Asp Phe Leu Ser Lys Tyr Thr        675                 680                 685Lys Thr Thr Ser Ile Asp Leu Ser Ser Leu Arg Pro Ser Ser Gln Tyr    690                 695                 700Lys Asp Leu Gly Glu Tyr Tyr Ala Glu Leu Asn Pro Leu Leu Tyr His705                 710                 715                 720Ile Ser Phe Gln Arg Ile Ala Glu Lys Glu Ile Met Asp Ala Val Glu                725                 730                 735Thr Gly Lys Leu Tyr Leu Phe Gln Ile Tyr Asn Lys Asp Phe Ala Lys            740                 745                 750Gly His His Gly Lys Pro Asn Leu His Thr Leu Tyr Trp Thr Gly Leu        755                 760                 765Phe Ser Pro Glu Asn Leu Ala Lys Thr Ser Ile Lys Leu Asn Gly Gln    770                 775                 780Ala Glu Leu Phe Tyr Arg Pro Lys Ser Arg Met Lys Arg Met Ala His785                 790                 795                 800Arg Leu Gly Glu Lys Met Leu Asn Lys Lys Leu Lys Asp Gln Lys Thr                805                 810                 815Pro Ile Pro Asp Thr Leu Tyr Gln Glu Leu Tyr Asp Tyr Val Asn His            820                 825                 830Arg Leu Ser His Asp Leu Ser Asp Glu Ala Arg Ala Leu Leu Pro Asn        835                 840                 845Val Ile Thr Lys Glu Val Ser His Glu Ile Ile Lys Asp Arg Arg Phe    850                 855                 860Thr Ser Asp Lys Phe Phe Phe His Val Pro Ile Thr Leu Asn Tyr Gln865                 870                 875                 880Ala Ala Asn Ser Pro Ser Lys Phe Asn Gln Arg Val Asn Ala Tyr Leu                885                 890                 895Lys Glu His Pro Glu Thr Pro Ile Ile Gly Ile Asp Arg Gly Glu Arg            900                 905                 910Asn Leu Ile Tyr Ile Thr Val Ile Asp Ser Thr Gly Lys Ile Leu Glu        915                 920                 925Gln Arg Ser Leu Asn Thr Ile Gln Gln Phe Asp Tyr Gln Lys Lys Leu    930                 935                 940Asp Asn Arg Glu Lys Glu Arg Val Ala Ala Arg Gln Ala Trp Ser Val945                 950                 955                 960Val Gly Thr Ile Lys Asp Leu Lys Gln Gly Tyr Leu Ser Gln Val Ile                965                 970                 975His Glu Ile Val Asp Leu Met Ile His Tyr Gln Ala Val Val Val Leu            980                 985                 990Glu Asn Leu Asn Phe Gly Phe Lys  Ser Lys Arg Thr Gly  Ile Ala Glu        995                 1000                 1005Lys Ala  Val Tyr Gln Gln Phe  Glu Lys Met Leu Ile  Asp Lys Leu    1010                 1015                 1020Asn Cys  Leu Val Leu Lys Asp  Tyr Pro Ala Glu Lys  Val Gly Gly    1025                 1030                 1035Val Leu  Asn Pro Tyr Gln Leu  Thr Asp Gln Phe Thr  Ser Phe Ala    1040                 1045                 1050Lys Met  Gly Thr Gln Ser Gly  Phe Leu Phe Tyr Val  Pro Ala Pro    1055                 1060                 1065Tyr Thr  Ser Lys Ile Asp Pro  Leu Thr Gly Phe Val  Asp Pro Phe    1070                 1075                 1080Val Trp  Lys Thr Ile Lys Asn  His Glu Ser Arg Lys  His Phe Leu    1085                 1090                 1095Glu Gly  Phe Asp Phe Leu His  Tyr Asp Val Lys Thr  Gly Asp Phe    1100                 1105                 1110Ile Leu  His Phe Lys Met Asn  Arg Asn Leu Ser Phe  Gln Arg Gly    1115                 1120                 1125Leu Pro  Gly Phe Met Pro Ala  Trp Asp Ile Val Phe  Glu Lys Asn    1130                 1135                 1140Glu Thr  Gln Phe Asp Ala Lys  Gly Thr Pro Phe Ile  Ala Gly Lys    1145                 1150                 1155Arg Ile  Val Pro Val Ile Glu  Asn His Arg Phe Thr  Gly Arg Tyr    1160                 1165                 1170Arg Asp  Leu Tyr Pro Ala Asn  Glu Leu Ile Ala Leu  Leu Glu Glu    1175                 1180                 1185Lys Gly  Ile Val Phe Arg Asp  Gly Ser Asn Ile Leu  Pro Lys Leu    1190                 1195                 1200Leu Glu  Asn Asp Asp Ser His  Ala Ile Asp Thr Met  Val Ala Leu    1205                 1210                 1215Ile Arg  Ser Val Leu Gln Met  Arg Asn Ser Asn Ala  Ala Thr Gly    1220                 1225                 1230Glu Asp  Tyr Ile Asn Ser Pro  Val Arg Asp Leu Asn  Gly Val Cys    1235                 1240                 1245Phe Asp  Ser Arg Phe Gln Asn  Pro Glu Trp Pro Met  Asp Ala Asp    1250                 1255                 1260Ala Asn  Gly Ala Tyr His Ile  Ala Leu Lys Gly Gln  Leu Leu Leu    1265                 1270                 1275Asn His  Leu Lys Glu Ser Lys  Asp Leu Lys Leu Gln  Asn Gly Ile    1280                 1285                 1290Ser Asn  Gln Asp Trp Leu Ala  Tyr Ile Gln Glu Leu  Arg Asn    1295                 1300                 1305</s400><s200><s210>2</s210><s211>1264</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>MbCas12a</s223></s220></s200><s400> 2Met Leu Phe Gln Asp Phe Thr His Leu Tyr Pro Leu Ser Lys Thr Val1               5                   10                  15Arg Phe Glu Leu Lys Pro Ile Gly Lys Thr Leu Glu His Ile His Ala            20                  25                  30Lys Asn Phe Leu Ser Gln Asp Glu Thr Met Ala Asp Met Tyr Gln Lys        35                  40                  45Val Lys Ala Ile Leu Asp Asp Tyr His Arg Asp Phe Ile Thr Lys Met    50                  55                  60Met Ser Glu Val Thr Leu Thr Lys Leu Pro Glu Phe Tyr Glu Val Tyr65                  70                  75                  80Leu Ala Leu Arg Lys Asn Pro Lys Asp Asp Thr Leu Gln Lys Gln Leu                85                  90                  95Thr Glu Ile Gln Thr Ala Leu Arg Glu Glu Val Val Lys Pro Ile Asp            100                 105                 110Ser Gly Gly Lys Tyr Lys Ala Gly Tyr Glu Arg Leu Phe Gly Ala Lys        115                 120                 125Leu Phe Lys Asp Gly Lys Glu Leu Gly Asp Leu Ala Lys Phe Val Ile    130                 135                 140Ala Gln Glu Gly Glu Ser Ser Pro Lys Leu Pro Gln Ile Ala His Phe145                 150                 155                 160Glu Lys Phe Ser Thr Tyr Phe Thr Gly Phe His Asp Asn Arg Lys Asn                165                 170                 175Met Tyr Ser Ser Asp Asp Lys His Thr Ala Ile Ala Tyr Arg Leu Ile            180                 185                 190His Glu Asn Leu Pro Arg Phe Ile Asp Asn Leu Gln Ile Leu Val Thr        195                 200                 205Ile Lys Gln Lys His Ser Val Leu Tyr Asp Gln Ile Val Asn Glu Leu    210                 215                 220Asn Ala Asn Gly Leu Asp Val Ser Leu Ala Ser His Leu Asp Gly Tyr225                 230                 235                 240His Lys Leu Leu Thr Gln Glu Gly Ile Thr Ala Tyr Asn Thr Leu Leu                245                 250                 255Gly Gly Ile Ser Gly Glu Ala Gly Ser Arg Lys Ile Gln Gly Ile Asn            260                 265                 270Glu Leu Ile Asn Ile His His Asn Gln His Cys Gln Lys Ser Glu Arg        275                 280                 285Ile Ala Lys Leu Arg Pro Leu His Lys Gln Ile Leu Ser Asp Gly Met    290                 295                 300Gly Val Ser Phe Leu Pro Ser Lys Phe Ala Asp Asp Ser Glu Val Cys305                 310                 315                 320Gln Ala Val Asn Glu Phe Tyr Arg His Tyr Ala His Val Phe Ala Lys                325                 330                 335Val Gln Ser Leu Phe Asp Arg Phe Asp Asp Tyr Arg Lys Asp Gly Ile            340                 345                 350Tyr Val Glu His Lys Asn Leu Asn Glu Leu Ser Lys Gln Ala Phe Gly        355                 360                 365Asp Phe Ala Leu Leu Gly Arg Val Leu Asp Gly Tyr Tyr Val Asp Val    370                 375                 380Val Asn Pro Glu Phe Asn Glu Arg Phe Ala Lys Ala Lys Thr Asp Asn385                 390                 395                 400Ala Lys Glu Lys Leu Thr Lys Glu Lys Asp Lys Phe Ile Lys Gly Val                405                 410                 415His Ser Leu Ala Ser Leu Glu Gln Ala Ile Glu His Tyr Ile Ala Gly            420                 425                 430His Asp Asp Glu Ser Val Gln Ala Gly Lys Leu Gly Gln Tyr Phe Lys        435                 440                 445His Gly Leu Ala Gly Val Asp Asn Pro Ile Gln Lys Ile His Asn Ser    450                 455                 460His Ser Thr Ile Lys Gly Phe Leu Glu Arg Glu Arg Pro Ala Gly Glu465                 470                 475                 480Arg Ala Leu Pro Lys Ile Lys Ser Asp Lys Ser Pro Glu Met Thr Gln                485                 490                 495Leu Arg Gln Leu Lys Glu Leu Leu Asp Asn Ala Leu Asn Val Val His            500                 505                 510Phe Ala Lys Leu Leu Thr Thr Lys Thr Thr Leu Asp Asn Gln Asp Gly        515                 520                 525Asn Phe Tyr Gly Glu Phe Gly Ala Leu Tyr Asp Glu Leu Ala Lys Ile    530                 535                 540Ala Thr Leu Tyr Asn Lys Val Arg Asp Tyr Leu Ser Gln Lys Pro Phe545                 550                 555                 560Ser Thr Glu Lys Tyr Lys Leu Asn Phe Gly Asn Pro Thr Leu Leu Asn                565                 570                 575Gly Trp Asp Leu Asn Lys Glu Lys Asp Asn Phe Gly Val Ile Leu Gln            580                 585                 590Lys Asp Gly Cys Tyr Tyr Leu Ala Leu Leu Asp Lys Ala His Lys Lys        595                 600                 605Val Phe Asp Asn Ala Pro Asn Ala Gly Lys Ser Val Tyr Gln Lys Met    610                 615                 620Val Tyr Lys Leu Leu Pro Gly Pro Asn Lys Met Leu Pro Lys Val Phe625                 630                 635                 640Phe Ala Lys Ser Asn Leu Asp Tyr Tyr Asn Pro Ser Ala Glu Leu Leu                645                 650                 655Asp Lys Tyr Ala Gln Gly Thr His Lys Lys Gly Asn Asn Phe Asn Leu            660                 665                 670Lys Asp Cys His Ala Leu Ile Asp Phe Phe Lys Ala Ser Ile Asn Lys        675                 680                 685His Pro Glu Trp Gln His Phe Gly Phe Glu Phe Ser Pro Thr Ser Ser    690                 695                 700Tyr Gln Asp Leu Ser Asp Phe Tyr Arg Glu Val Glu Pro Gln Gly Tyr705                 710                 715                 720Gln Val Lys Phe Val Asp Ile Asn Ala Glu Tyr Ile Asp Glu Leu Val                725                 730                 735Glu Gln Gly Gln Leu Tyr Leu Phe Gln Ile Tyr Asn Lys Asp Phe Ser            740                 745                 750Pro Lys Ala His Gly Lys Pro Asn Leu His Thr Leu Tyr Phe Lys Ala        755                 760                 765Leu Phe Ser Glu Asn Asn Leu Ala Asn Pro Ile Tyr Lys Leu Asn Gly    770                 775                 780Glu Ala Glu Ile Phe Tyr Arg Lys Ala Ser Leu Asp Met Asn Glu Thr785                 790                 795                 800Thr Ile His Arg Ala Gly Glu Val Leu Glu Asn Lys Asn Pro Asp Asn                805                 810                 815Pro Lys Lys Arg Gln Phe Val Tyr Asp Ile Ile Lys Asp Lys Arg Tyr            820                 825                 830Thr Gln Asp Lys Phe Met Leu His Val Pro Ile Thr Met Asn Phe Gly        835                 840                 845Val Gln Gly Met Thr Ile Lys Glu Phe Asn Lys Lys Val Asn Gln Ser    850                 855                 860Ile Gln Gln Tyr Asn Asp Val Asn Val Ile Gly Ile Asp Arg Gly Glu865                 870                 875                 880Arg His Leu Leu Tyr Leu Thr Val Ile Asn Ser Lys Gly Glu Ile Leu                885                 890                 895Glu Gln Arg Ser Leu Asn Asp Ile Ile Thr Thr Ser Ala Asn Gly Thr            900                 905                 910Gln Met Thr Thr Pro Tyr His Lys Ile Leu Asp Lys Arg Glu Ile Glu        915                 920                 925Arg Leu Asn Ala Arg Val Gly Trp Gly Glu Ile Glu Thr Ile Lys Glu    930                 935                 940Leu Lys Ser Gly Tyr Leu Ser His Val Val His Gln Ile Ser Gln Leu945                 950                 955                 960Met Leu Lys Tyr Asn Ala Ile Val Val Leu Glu Asp Leu Asn Phe Gly                965                 970                 975Phe Lys Arg Gly Arg Phe Lys Val Glu Lys Gln Ile Tyr Gln Asn Phe            980                 985                 990Glu Asn Ala Leu Ile Lys Lys Leu  Asn His Leu Ala Leu  Lys Asp Lys        995                 1000                 1005Ala Asp  Asp Glu Ile Gly Ser  Tyr Lys Asn Ala Leu  Gln Leu Thr    1010                 1015                 1020Asn Asn  Phe Thr Asp Leu Lys  Ser Ile Gly Lys Gln  Thr Gly Phe    1025                 1030                 1035Leu Phe  Tyr Val Pro Ala Trp  Asn Thr Ser Lys Ile  Asp Pro Ala    1040                 1045                 1050Thr Gly  Phe Val Asp Leu Leu  Lys Pro Arg Tyr Glu  Asn Ile Ala    1055                 1060                 1065Gln Ser  Gln Ala Phe Phe Gly  Lys Phe Asp Lys Ile  Phe Tyr Asn    1070                 1075                 1080Ala Asp  Lys Gly Tyr Phe Glu  Phe Tyr Val Asp Tyr  Ala Lys Phe    1085                 1090                 1095Thr Asp  Lys Ala Lys Asn Ser  Arg Gln Thr Trp Val  Ile Cys Ser    1100                 1105                 1110His Gly  Asp Lys Arg Tyr Val  Tyr Asp Lys Thr Ala  Asn Gln Asn    1115                 1120                 1125Lys Gly  Ala Thr Ile Gly Ile  Asn Val Asn Asp Glu  Leu Lys Ser    1130                 1135                 1140Leu Phe  Ala Arg Tyr His Ile  Asn Asp Lys Gln Pro  Asn Leu Val    1145                 1150                 1155Met Asp  Ile Cys Gln Asn Asn  Asp Lys Glu Phe His  Lys Ser Leu    1160                 1165                 1170Met Tyr  Leu Leu Lys Ala Leu  Leu Ala Leu Arg Tyr  Ser Asn Ala    1175                 1180                 1185Ser Ser  Asp Glu Asp Phe Ile  Leu Ser Pro Val Ala  Asp Asp Lys    1190                 1195                 1200Gly Val  Phe Phe Asn Ser Ala  Leu Ala Asp Asp Thr  Gln Pro Gln    1205                 1210                 1215Asn Ala  Asp Ala Asn Gly Ala  Tyr His Ile Ala Leu  Lys Gly Leu    1220                 1225                 1230Trp Leu  Leu Asn Glu Leu Lys  Asn Ser Asn Asp Leu  Asp Lys Ile    1235                 1240                 1245Lys Leu  Ala Ile Asp Asn Gln  Thr Trp Leu Asn Phe  Ala Gln Asn    1250                 1255                 1260Arg</s400><s200><s210>3</s210><s211>1228</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>LbCas12a</s223></s220></s200><s400> 3Met Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys Thr1               5                   10                  15Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile Asp            20                  25                  30Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr Lys        35                  40                  45Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn Asp    50                  55                  60Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser Leu65                  70                  75                  80Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu Asn                85                  90                  95Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly Asn            100                 105                 110Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile Leu        115                 120                 125Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser Phe    130                 135                 140Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu Asn145                 150                 155                 160Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys Ile                165                 170                 175Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu Lys            180                 185                 190Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu Lys        195                 200                 205Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu Phe    210                 215                 220Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala Ile225                 230                 235                 240Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu Asn                245                 250                 255Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro Lys            260                 265                 270Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu Ser        275                 280                 285Phe Tyr Gly Glu Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val Phe    290                 295                 300Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys Lys305                 310                 315                 320Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly Ile                325                 330                 335Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile Phe            340                 345                 350Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp Asp        355                 360                 365Ile His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp Asp    370                 375                 380Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln Leu385                 390                 395                 400Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys Glu                405                 410                 415Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser Ser            420                 425                 430Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys Lys        435                 440                 445Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val Lys    450                 455                 460Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu Thr465                 470                 475                 480Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp Ile                485                 490                 495Leu Leu Lys Val Asp His Ile Tyr Asp Ala Ile Arg Asn Tyr Val Thr            500                 505                 510Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn Pro        515                 520                 525Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg Ala    530                 535                 540Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Tyr Leu Ala Ile Met Asp Lys545                 550                 555                 560Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Asp Val Asn Gly                565                 570                 575Asn Tyr Glu Lys Ile Asn Tyr Lys Leu Leu Pro Gly Pro Asn Lys Met            580                 585                 590Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn Pro        595                 600                 605Ser Glu Asp Ile Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Lys Gly    610                 615                 620Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe Lys625                 630                 635                 640Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe Asn                645                 650                 655Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg Glu            660                 665                 670Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser Lys Lys        675                 680                 685Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met Phe Gln Ile    690                 695                 700Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro Asn Leu His705                 710                 715                 720Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His Gly Gln Ile                725                 730                 735Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala Ser Leu Lys            740                 745                 750Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro Ile Ala Asn Lys        755                 760                 765Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu Ser Tyr Asp Val Tyr    770                 775                 780Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu Leu His Ile Pro Ile785                 790                 795                 800Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys Ile Asn Thr Glu Val                805                 810                 815Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr Val Ile Gly Ile Asp            820                 825                 830Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp Gly Lys Gly        835                 840                 845Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn Asn Phe Asn    850                 855                 860Gly Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu Asp Lys Lys Glu865                 870                 875                 880Lys Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr Ser Ile Glu Asn Ile                885                 890                 895Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln Val Val His Lys Ile Cys            900                 905                 910Glu Leu Val Glu Lys Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu Asn        915                 920                 925Ser Gly Phe Lys Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr Gln    930                 935                 940Lys Phe Glu Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys945                 950                 955                 960Lys Ser Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile                965                 970                 975Thr Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe            980                 985                 990Ile Phe Tyr Ile Pro Ala Trp Leu  Thr Ser Lys Ile Asp  Pro Ser Thr        995                 1000                 1005Gly Phe  Val Asn Leu Leu Lys  Thr Lys Tyr Thr Ser  Ile Ala Asp    1010                 1015                 1020Ser Lys  Lys Phe Ile Ser Ser  Phe Asp Arg Ile Met  Tyr Val Pro    1025                 1030                 1035Glu Glu  Asp Leu Phe Glu Phe  Ala Leu Asp Tyr Lys  Asn Phe Ser    1040                 1045                 1050Arg Thr  Asp Ala Asp Tyr Ile  Lys Lys Trp Lys Leu  Tyr Ser Tyr    1055                 1060                 1065Gly Asn  Arg Ile Arg Ile Phe  Arg Asn Pro Lys Lys  Asn Asn Val    1070                 1075                 1080Phe Asp  Trp Glu Glu Val Cys  Leu Thr Ser Ala Tyr  Lys Glu Leu    1085                 1090                 1095Phe Asn  Lys Tyr Gly Ile Asn  Tyr Gln Gln Gly Asp  Ile Arg Ala    1100                 1105                 1110Leu Leu  Cys Glu Gln Ser Asp  Lys Ala Phe Tyr Ser  Ser Phe Met    1115                 1120                 1125Ala Leu  Met Ser Leu Met Leu  Gln Met Arg Asn Ser  Ile Thr Gly    1130                 1135                 1140Arg Thr  Asp Val Asp Phe Leu  Ile Ser Pro Val Lys  Asn Ser Asp    1145                 1150                 1155Gly Ile  Phe Tyr Asp Ser Arg  Asn Tyr Glu Ala Gln  Glu Asn Ala    1160                 1165                 1170Ile Leu  Pro Lys Asn Ala Asp  Ala Asn Gly Ala Tyr  Asn Ile Ala    1175                 1180                 1185Arg Lys  Val Leu Trp Ala Ile  Gly Gln Phe Lys Lys  Ala Glu Asp    1190                 1195                 1200Glu Lys  Leu Asp Lys Val Lys  Ile Ala Ile Ser Asn  Lys Glu Trp    1205                 1210                 1215Leu Glu  Tyr Ala Gln Thr Ser  Val Lys His    1220                 1225</s400><s200><s210>4</s210><s211>1300</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>FnCas12a</s223></s220></s200><s400> 4Met Ser Ile Tyr Gln Glu Phe Val Asn Lys Tyr Ser Leu Ser Lys Thr1               5                   10                  15Leu Arg Phe Glu Leu Ile Pro Gln Gly Lys Thr Leu Glu Asn Ile Lys            20                  25                  30Ala Arg Gly Leu Ile Leu Asp Asp Glu Lys Arg Ala Lys Asp Tyr Lys        35                  40                  45Lys Ala Lys Gln Ile Ile Asp Lys Tyr His Gln Phe Phe Ile Glu Glu    50                  55                  60Ile Leu Ser Ser Val Cys Ile Ser Glu Asp Leu Leu Gln Asn Tyr Ser65                  70                  75                  80Asp Val Tyr Phe Lys Leu Lys Lys Ser Asp Asp Asp Asn Leu Gln Lys                85                  90                  95Asp Phe Lys Ser Ala Lys Asp Thr Ile Lys Lys Gln Ile Ser Glu Tyr            100                 105                 110Ile Lys Asp Ser Glu Lys Phe Lys Asn Leu Phe Asn Gln Asn Leu Ile        115                 120                 125Asp Ala Lys Lys Gly Gln Glu Ser Asp Leu Ile Leu Trp Leu Lys Gln    130                 135                 140Ser Lys Asp Asn Gly Ile Glu Leu Phe Lys Ala Asn Ser Asp Ile Thr145                 150                 155                 160Asp Ile Asp Glu Ala Leu Glu Ile Ile Lys Ser Phe Lys Gly Trp Thr                165                 170                 175Thr Tyr Phe Lys Gly Phe His Glu Asn Arg Lys Asn Val Tyr Ser Ser            180                 185                 190Asn Asp Ile Pro Thr Ser Ile Ile Tyr Arg Ile Val Asp Asp Asn Leu        195                 200                 205Pro Lys Phe Leu Glu Asn Lys Ala Lys Tyr Glu Ser Leu Lys Asp Lys    210                 215                 220Ala Pro Glu Ala Ile Asn Tyr Glu Gln Ile Lys Lys Asp Leu Ala Glu225                 230                 235                 240Glu Leu Thr Phe Asp Ile Asp Tyr Lys Thr Ser Glu Val Asn Gln Arg                245                 250                 255Val Phe Ser Leu Asp Glu Val Phe Glu Ile Ala Asn Phe Asn Asn Tyr            260                 265                 270Leu Asn Gln Ser Gly Ile Thr Lys Phe Asn Thr Ile Ile Gly Gly Lys        275                 280                 285Phe Val Asn Gly Glu Asn Thr Lys Arg Lys Gly Ile Asn Glu Tyr Ile    290                 295                 300Asn Leu Tyr Ser Gln Gln Ile Asn Asp Lys Thr Leu Lys Lys Tyr Lys305                 310                 315                 320Met Ser Val Leu Phe Lys Gln Ile Leu Ser Asp Thr Glu Ser Lys Ser                325                 330                 335Phe Val Ile Asp Lys Leu Glu Asp Asp Ser Asp Val Val Thr Thr Met            340                 345                 350Gln Ser Phe Tyr Glu Gln Ile Ala Ala Phe Lys Thr Val Glu Glu Lys        355                 360                 365Ser Ile Lys Glu Thr Leu Ser Leu Leu Phe Asp Asp Leu Lys Ala Gln    370                 375                 380Lys Leu Asp Leu Ser Lys Ile Tyr Phe Lys Asn Asp Lys Ser Leu Thr385                 390                 395                 400Asp Leu Ser Gln Gln Val Phe Asp Asp Tyr Ser Val Ile Gly Thr Ala                405                 410                 415Val Leu Glu Tyr Ile Thr Gln Gln Ile Ala Pro Lys Asn Leu Asp Asn            420                 425                 430Pro Ser Lys Lys Glu Gln Glu Leu Ile Ala Lys Lys Thr Glu Lys Ala        435                 440                 445Lys Tyr Leu Ser Leu Glu Thr Ile Lys Leu Ala Leu Glu Glu Phe Asn    450                 455                 460Lys His Arg Asp Ile Asp Lys Gln Cys Arg Phe Glu Glu Ile Leu Ala465                 470                 475                 480Asn Phe Ala Ala Ile Pro Met Ile Phe Asp Glu Ile Ala Gln Asn Lys                485                 490                 495Asp Asn Leu Ala Gln Ile Ser Ile Lys Tyr Gln Asn Gln Gly Lys Lys            500                 505                 510Asp Leu Leu Gln Ala Ser Ala Glu Asp Asp Val Lys Ala Ile Lys Asp        515                 520                 525Leu Leu Asp Gln Thr Asn Asn Leu Leu His Lys Leu Lys Ile Phe His    530                 535                 540Ile Ser Gln Ser Glu Asp Lys Ala Asn Ile Leu Asp Lys Asp Glu His545                 550                 555                 560Phe Tyr Leu Val Phe Glu Glu Cys Tyr Phe Glu Leu Ala Asn Ile Val                565                 570                 575Pro Leu Tyr Asn Lys Ile Arg Asn Tyr Ile Thr Gln Lys Pro Tyr Ser            580                 585                 590Asp Glu Lys Phe Lys Leu Asn Phe Glu Asn Ser Thr Leu Ala Asn Gly        595                 600                 605Trp Asp Lys Asn Lys Glu Pro Asp Asn Thr Ala Ile Leu Phe Ile Lys    610                 615                 620Asp Asp Lys Tyr Tyr Leu Gly Val Met Asn Lys Lys Asn Asn Lys Ile625                 630                 635                 640Phe Asp Asp Lys Ala Ile Lys Glu Asn Lys Gly Glu Gly Tyr Lys Lys                645                 650                 655Ile Val Tyr Lys Leu Leu Pro Gly Ala Asn Lys Met Leu Pro Lys Val            660                 665                 670Phe Phe Ser Ala Lys Ser Ile Lys Phe Tyr Asn Pro Ser Glu Asp Ile        675                 680                 685Leu Arg Ile Arg Asn His Ser Thr His Thr Lys Asn Gly Ser Pro Gln    690                 695                 700Lys Gly Tyr Glu Lys Phe Glu Phe Asn Ile Glu Asp Cys Arg Lys Phe705                 710                 715                 720Ile Asp Phe Tyr Lys Gln Ser Ile Ser Lys His Pro Glu Trp Lys Asp                725                 730                 735Phe Gly Phe Arg Phe Ser Asp Thr Gln Arg Tyr Asn Ser Ile Asp Glu            740                 745                 750Phe Tyr Arg Glu Val Glu Asn Gln Gly Tyr Lys Leu Thr Phe Glu Asn        755                 760                 765Ile Ser Glu Ser Tyr Ile Asp Ser Val Val Asn Gln Gly Lys Leu Tyr    770                 775                 780Leu Phe Gln Ile Tyr Asn Lys Asp Phe Ser Ala Tyr Ser Lys Gly Arg785                 790                 795                 800Pro Asn Leu His Thr Leu Tyr Trp Lys Ala Leu Phe Asp Glu Arg Asn                805                 810                 815Leu Gln Asp Val Val Tyr Lys Leu Asn Gly Glu Ala Glu Leu Phe Tyr            820                 825                 830Arg Lys Gln Ser Ile Pro Lys Lys Ile Thr His Pro Ala Lys Glu Ala        835                 840                 845Ile Ala Asn Lys Asn Lys Asp Asn Pro Lys Lys Glu Ser Val Phe Glu    850                 855                 860Tyr Asp Leu Ile Lys Asp Lys Arg Phe Thr Glu Asp Lys Phe Phe Phe865                 870                 875                 880His Cys Pro Ile Thr Ile Asn Phe Lys Ser Ser Gly Ala Asn Lys Phe                885                 890                 895Asn Asp Glu Ile Asn Leu Leu Leu Lys Glu Lys Ala Asn Asp Val His            900                 905                 910Ile Leu Ser Ile Asp Arg Gly Glu Arg His Leu Ala Tyr Tyr Thr Leu        915                 920                 925Val Asp Gly Lys Gly Asn Ile Ile Lys Gln Asp Thr Phe Asn Ile Ile    930                 935                 940Gly Asn Asp Arg Met Lys Thr Asn Tyr His Asp Lys Leu Ala Ala Ile945                 950                 955                 960Glu Lys Asp Arg Asp Ser Ala Arg Lys Asp Trp Lys Lys Ile Asn Asn                965                 970                 975Ile Lys Glu Met Lys Glu Gly Tyr Leu Ser Gln Val Val His Glu Ile            980                 985                 990Ala Lys Leu Val Ile Glu Tyr Asn  Ala Ile Val Val Phe  Glu Asp Leu        995                 1000                 1005Asn Phe  Gly Phe Lys Arg Gly  Arg Phe Lys Val Glu  Lys Gln Val    1010                 1015                 1020Tyr Gln  Lys Leu Glu Lys Met  Leu Ile Glu Lys Leu  Asn Tyr Leu    1025                 1030                 1035Val Phe  Lys Asp Asn Glu Phe  Asp Lys Thr Gly Gly  Val Leu Arg    1040                 1045                 1050Ala Tyr  Gln Leu Thr Ala Pro  Phe Glu Thr Phe Lys  Lys Met Gly    1055                 1060                 1065Lys Gln  Thr Gly Ile Ile Tyr  Tyr Val Pro Ala Gly  Phe Thr Ser    1070                 1075                 1080Lys Ile  Cys Pro Val Thr Gly  Phe Val Asn Gln Leu  Tyr Pro Lys    1085                 1090                 1095Tyr Glu  Ser Val Ser Lys Ser  Gln Glu Phe Phe Ser  Lys Phe Asp    1100                 1105                 1110Lys Ile  Cys Tyr Asn Leu Asp  Lys Gly Tyr Phe Glu  Phe Ser Phe    1115                 1120                 1125Asp Tyr  Lys Asn Phe Gly Asp  Lys Ala Ala Lys Gly  Lys Trp Thr    1130                 1135                 1140Ile Ala  Ser Phe Gly Ser Arg  Leu Ile Asn Phe Arg  Asn Ser Asp    1145                 1150                 1155Lys Asn  His Asn Trp Asp Thr  Arg Glu Val Tyr Pro  Thr Lys Glu    1160                 1165                 1170Leu Glu  Lys Leu Leu Lys Asp  Tyr Ser Ile Glu Tyr  Gly His Gly    1175                 1180                 1185Glu Cys  Ile Lys Ala Ala Ile  Cys Gly Glu Ser Asp  Lys Lys Phe    1190                 1195                 1200Phe Ala  Lys Leu Thr Ser Val  Leu Asn Thr Ile Leu  Gln Met Arg    1205                 1210                 1215Asn Ser  Lys Thr Gly Thr Glu  Leu Asp Tyr Leu Ile  Ser Pro Val    1220                 1225                 1230Ala Asp  Val Asn Gly Asn Phe  Phe Asp Ser Arg Gln  Ala Pro Lys    1235                 1240                 1245Asn Met  Pro Gln Asp Ala Asp  Ala Asn Gly Ala Tyr  His Ile Gly    1250                 1255                 1260Leu Lys  Gly Leu Met Leu Leu  Gly Arg Ile Lys Asn  Asn Gln Glu    1265                 1270                 1275Gly Lys  Lys Leu Asn Leu Val  Ile Lys Asn Glu Glu  Tyr Phe Glu    1280                 1285                 1290Phe Val  Gln Asn Arg Asn Asn    1295                 1300</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002757A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002757</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17434722</doc-number><date>20200828</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>10</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>5</main-group><subgroup>0781</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>28</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>18</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>1037</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>5</main-group><subgroup>0635</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>2863</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>18</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>2818</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>2878</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>22</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>565</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>569</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>567</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>10</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>24</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>92</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>76</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">Sequence-Based High Throughput Method Generating Camelids Antibodies to Cover Broad Epitopes with High-Resolution</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>62811302</doc-number><date>20190227</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Zhejiang NanomAb Technology Center Co. Ltd.</orgname><address><city>Shaoxing City, Zhejiang Province</city><country>CN</country></address></addressbook><residence><country>CN</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Zhu</last-name><first-name>Weimin</first-name><address><city>Danville</city><state>CA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/US2020/020248</doc-number><date>20200828</date></document-id><us-371c12-date><date>20210827</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">A method for generating a plurality of diverse camelid antibodies to cover functional epitopes of the target with high-resolution. Also provided is a method for generating camelid antibodies.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="53.85mm" wi="158.75mm" file="US20230002757A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="242.82mm" wi="144.78mm" orientation="landscape" file="US20230002757A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="143.43mm" wi="73.58mm" file="US20230002757A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="206.76mm" wi="137.67mm" orientation="landscape" file="US20230002757A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="222.59mm" wi="156.21mm" orientation="landscape" file="US20230002757A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="189.15mm" wi="125.22mm" orientation="landscape" file="US20230002757A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="179.58mm" wi="126.32mm" orientation="landscape" file="US20230002757A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="196.26mm" wi="127.00mm" orientation="landscape" file="US20230002757A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="189.06mm" wi="136.06mm" orientation="landscape" file="US20230002757A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="124.29mm" wi="142.07mm" file="US20230002757A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="164.59mm" wi="166.54mm" file="US20230002757A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="177.55mm" wi="118.79mm" orientation="landscape" file="US20230002757A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00012" num="00012"><img id="EMI-D00012" he="144.86mm" wi="123.44mm" file="US20230002757A1-20230105-D00012.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00013" num="00013"><img id="EMI-D00013" he="228.52mm" wi="109.98mm" orientation="landscape" file="US20230002757A1-20230105-D00013.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00014" num="00014"><img id="EMI-D00014" he="169.84mm" wi="132.16mm" orientation="landscape" file="US20230002757A1-20230105-D00014.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00015" num="00015"><img id="EMI-D00015" he="239.44mm" wi="122.17mm" orientation="landscape" file="US20230002757A1-20230105-D00015.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00016" num="00016"><img id="EMI-D00016" he="228.94mm" wi="123.19mm" orientation="landscape" file="US20230002757A1-20230105-D00016.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00017" num="00017"><img id="EMI-D00017" he="160.36mm" wi="146.90mm" file="US20230002757A1-20230105-D00017.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00018" num="00018"><img id="EMI-D00018" he="154.18mm" wi="133.35mm" file="US20230002757A1-20230105-D00018.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00019" num="00019"><img id="EMI-D00019" he="231.39mm" wi="114.38mm" orientation="landscape" file="US20230002757A1-20230105-D00019.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00020" num="00020"><img id="EMI-D00020" he="189.31mm" wi="91.95mm" orientation="landscape" file="US20230002757A1-20230105-D00020.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00021" num="00021"><img id="EMI-D00021" he="221.32mm" wi="119.97mm" orientation="landscape" file="US20230002757A1-20230105-D00021.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00022" num="00022"><img id="EMI-D00022" he="152.48mm" wi="138.51mm" file="US20230002757A1-20230105-D00022.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00023" num="00023"><img id="EMI-D00023" he="234.53mm" wi="132.42mm" orientation="landscape" file="US20230002757A1-20230105-D00023.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00024" num="00024"><img id="EMI-D00024" he="240.62mm" wi="123.44mm" orientation="landscape" file="US20230002757A1-20230105-D00024.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00025" num="00025"><img id="EMI-D00025" he="241.89mm" wi="133.27mm" orientation="landscape" file="US20230002757A1-20230105-D00025.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00026" num="00026"><img id="EMI-D00026" he="239.18mm" wi="122.26mm" orientation="landscape" file="US20230002757A1-20230105-D00026.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00027" num="00027"><img id="EMI-D00027" he="236.98mm" wi="121.58mm" orientation="landscape" file="US20230002757A1-20230105-D00027.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00028" num="00028"><img id="EMI-D00028" he="234.53mm" wi="131.83mm" orientation="landscape" file="US20230002757A1-20230105-D00028.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00029" num="00029"><img id="EMI-D00029" he="252.39mm" wi="132.93mm" orientation="landscape" file="US20230002757A1-20230105-D00029.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00030" num="00030"><img id="EMI-D00030" he="228.26mm" wi="112.44mm" orientation="landscape" file="US20230002757A1-20230105-D00030.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00031" num="00031"><img id="EMI-D00031" he="207.86mm" wi="151.55mm" orientation="landscape" file="US20230002757A1-20230105-D00031.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00032" num="00032"><img id="EMI-D00032" he="235.46mm" wi="122.17mm" orientation="landscape" file="US20230002757A1-20230105-D00032.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00033" num="00033"><img id="EMI-D00033" he="237.57mm" wi="113.03mm" orientation="landscape" file="US20230002757A1-20230105-D00033.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00034" num="00034"><img id="EMI-D00034" he="230.46mm" wi="133.94mm" orientation="landscape" file="US20230002757A1-20230105-D00034.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00035" num="00035"><img id="EMI-D00035" he="229.95mm" wi="110.49mm" orientation="landscape" file="US20230002757A1-20230105-D00035.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00036" num="00036"><img id="EMI-D00036" he="216.41mm" wi="140.21mm" orientation="landscape" file="US20230002757A1-20230105-D00036.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00037" num="00037"><img id="EMI-D00037" he="215.22mm" wi="131.40mm" orientation="landscape" file="US20230002757A1-20230105-D00037.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00038" num="00038"><img id="EMI-D00038" he="199.73mm" wi="149.10mm" orientation="landscape" file="US20230002757A1-20230105-D00038.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00039" num="00039"><img id="EMI-D00039" he="196.26mm" wi="141.99mm" orientation="landscape" file="US20230002757A1-20230105-D00039.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00040" num="00040"><img id="EMI-D00040" he="200.49mm" wi="137.24mm" orientation="landscape" file="US20230002757A1-20230105-D00040.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00041" num="00041"><img id="EMI-D00041" he="219.20mm" wi="117.43mm" orientation="landscape" file="US20230002757A1-20230105-D00041.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00042" num="00042"><img id="EMI-D00042" he="215.39mm" wi="133.94mm" orientation="landscape" file="US20230002757A1-20230105-D00042.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">BACKGROUND OF THE INVENTION</heading><p id="p-0002" num="0001">Targeting functional epitopes of a disease target for therapeutics is a big challenge with current antibody technologies because each target has hundreds or thousands of epitopes and only a very limited number of epitopes among them are involved in the biological function, but current technologies are taking approaches to generate binders randomly and sporadically, thus, inadequate coverage of epitopes, redundant selection and low successful rate are the bottle-neck.</p><p id="p-0003" num="0002"><i>Camelus dromedarius, bactrianus </i>belong to old world Camelidae and Lama, Alpaca belong to new world Camelidae. Only Camelidae (common name Camelid) have a dichotomous adaptive humoral immune system with both conventional and homodimeric antibodies (HcAb). In addition, HcAbs have evolved comprehensive paratope architecture as one of the driving factors for recognizing the very wide range of epitopes of the antigen, and IgG1 antibodies complement HcAb binding architecture for more diverse recognitions.</p><p id="p-0004" num="0003">Camelidae have unique humoral immune system consisting of 2 types of HcAb, IgG2 and IgG3 with short and long length of hinge regions. Phylogenetic analyses have confirmed that HcAbs diverged from a conventional antibody, IgG1 as a result of recent adaptive changes. It was reported that IgG1 and IgG3 neutralize West Nile virus, whereas IgG2 seems less effective in an infected or vaccinated animal (Daley L P, Clin. Vaccine Immunol. 17:239-46, 2010). Furthermore, the range of epitopes sampled by HcAb and IgG1 can overlap, but HcAb can also reach sites inaccessible to IgG1. Understanding of the exact roles and functions of the various Camelids IgG isotypes is still in its infancy. However, the diverse paratope architecture such as prolate, convex, concave, protrude, and flat surfaces of HcAb (IgG2 and IgG3) offer a great opportunity to develop antibody to challenging targets, especially for diagnostic and therapeutic applications. The simplicity of HcAb without light chain pairing also makes gene cloning and antibody engineering much easier. Furthermore, the conventional IgG1 contributing to 25-50% of total IgG of Camelids play important role to expand an antigen-binding repertoire since the HcAb repertoire of an immunized dromedary or llama displays a recognition pattern different from that of conventional IgG1 (McCoy L E, J. Exp. Med. 2012), and certain unique epitopes or druggable target hotspots are accessible to IgG1 with high affinity and desired functionality (Cristina Basilico, The Journal of Clinical Investigation, Volume 124 Number 7 July, 2014; Basvan der Woninga, MABS, VOL. 8, NO. 6, 1126-1135, 2016). Camelids have two types of light chains (V&#x3ba; or V&#x3bb; pairing with VH<sup>1 </sup>to form conventional IgG1 and their germline organizations have been revealed recently (Laura M. Griffin, Journal of Immunological Methods Volume 405, Pages 35-46, March 2014; Alex Klarenbeek, mAbs 7:4, 693-706; 2015).</p><p id="p-0005" num="0004">Extensive somatic hypermutation and gene conversion are significantly higher among the VHHs than among the VHs (30% versus 1.5%) in the primary VHH B-cells repertoire, which supports further diversification of HcAb repertoire to compensate the lack of light chain. Equally importantly, VHH domain of HcAb enlarges overall antigen-binding repertoire, for example by creating prolate (rugby ball-shaped) structure with a convex paratope surface, which makes it extremely suitable to insert in cavities or clefts (such as active and allosteric sites) on the surface of the antigen. In contrast, the VH-VL domain of conventional IgG contains more flat or concave paratope surface. Following mechanisms of B-cell repertoire diversification largely contribute to the unique binding characteristics of VHH: (i) most of VHH contains the Framework Region 2 (FR2) with hydrophilic amino acid substitutions comparing to conventional FR2 (Val37&#x2192;Phe/Tyr, Gly44&#x2192;Glu, Leu45&#x2192;Arg, and Trp47&#x2192;Gly), which participates in the light chain binding (ii) extended CDR1 region with extensive somatic hypermutation in immune B-cells in residues 27-30 according to Kabat's numbering (iii) extra disulfide bonds between CDR1-CDR3 (Camels) or FR2-CDR3 (Lama and Alpaca) in large portion of VHH (iv) extra disulfide bonds within CDR1 and CDR3 in certain portion of VHH (v) longer CDR3 loop is also identified possibly due to additional non-templated nucleotide insertions in some VHH (Adhdi Arbabi-Ghahroudi, Frontiers in Immunology, Vol 8, 2017; Viet Khong Nguyen, The EMBO Journal Vol. 19 No. 5 2000; Mehdi Arbabi-Ghahroudi et al, Front. Immunol., 20 Nov. 2017; Nguyen V K, Immunogenetics 54:39-47, 2002; Conrath K E, Dev Comp Immunol 27:87-103, 2003). It was also found that there are sets of non-classical VHH (without FR2 hydrophilic amino acids) which are derived from the same gene locus, IGHV3 or IGHV4, D and J as conventional IgG1 do, and these heavy chain antibodies may recognize the same or similar epitopes as IgG1 since both category antibodies share the same or similar CDR3 which is responsible for epitope recognition (Conrath K E Dev Comp Immunol 27:87-103, 2003; Nick Deschacht, The Journal of Immunology. 184 (10) 5696-5704, 2010). The HcAb germline organization and VHH structure are illustrated in <figref idref="DRAWINGS">FIGS. <b>1</b></figref>. A and B.</p><p id="p-0006" num="0005">Functional and physical-chemical advantages such as high affinity, specificity, simple gene cloning, high expression yield, ease of purification, highly soluble and stable single-domain fold provide the foundation for HcAb technology. In addition, the antigen-binding repertoire expanded by conventional IgG1 allow even broader epitopes coverage. Furthermore, the close homologies of VHH, VH, V&#x3ba; and V&#x3bb; to human counterparts offers a great advantage for humanization and therapeutics development. By taking the advantages of Camelids unique antibody organizations and NGS technology to capture entire B-cells antibody repertoire, a novel method is developed here to generate hundreds or thousands of diverse antibodies to cover broad epitopes of the target with high-resolution, which enables targeting these important and functional epitopes in systematic and rational manners.</p><heading id="h-0002" level="1">SUMMARY OF THE INVENTION</heading><p id="p-0007" num="0006">This invention disclosed a high-throughput method generating a camelid antibody against an antigen, comprising: a) enriching and proliferating B-cells from immunized camelids specific to the antigen, b) generating antibody Next Generation Sequencing (NGS) libraries comprising VHH<sup>2</sup>, VHH<sup>3</sup>, and VH<sup>1 </sup>chain sequences from the antigen-specific B-cells, c) grouping sequences of VHH<sup>2</sup>, VHH<sup>3</sup>, and VH<sup>1 </sup>in the NGS libraries by lineages, d) ranking the lineages comprising the VHH heavy chain (VHH<sup>2</sup>, VHH<sup>3</sup>) by one or more lineage priority factors, e) selecting a representative sequence from lineages of VHH heavy chain (VHH<sup>2 </sup>and VHH<sup>3</sup>) with a top ranking in the NGS database library, and f) testing an antibody comprising the selected VHH heavy chain sequences to determine if the antibody binds to the antigen or portion thereof. In one embodiment, the antigen comprises a plurality of epitopes.</p><p id="p-0008" num="0007">In one embodiment, minimal CDR3 distance of a specific CDR3 is equal or less than 1 among the group of CDR3s from a lineage, wherein minimal CDR3 distance of a specific CDR3 is the smallest hamming distance of this CDR3 comparing with all other CDR3 of the same length.</p><p id="p-0009" num="0008">In some embodiments, the lineage priority factors are selected from a group consisting of lineages from high to low sequences abundancy, lineages from high to low amplification factor after in vitro B-cells enrichment and proliferation, lineages sequences abundancy change during immunization course, lineages sequences abundancy change before and after depleting certain unwanted B cells, lineages which share the same na&#xef;ve B-cell origin between VHH and VH, avoidance of developability liability sequences, and a combination thereof.</p><p id="p-0010" num="0009">In some embodiments, VHH<sup>2 </sup>and/or VHH<sup>3 </sup>lineages are chosen from the top 100 lineages in e).</p><p id="p-0011" num="0010">In some embodiments, the method further comprises repeating e)-f) to generate camelid antibodies, wherein the representative sequences are selected from top 101-200, 201-300, 301-400, 401-500, 501-600, 601-700, 701-800, 801-900, 901-1000, 1001-1100,1101-1200, 1201-1300, 1301-1400, 1401-1500, 1501-1600, 1601-1700, 1701-1800, 1801-1900, or 1901-2000 ranking lineages. In some embodiments, the method further comprises repeating e)-f) to generate camelid antibodies, wherein the representative sequences are selected from top 2,000 to 10,000 ranking lineages.</p><p id="p-0012" num="0011">In some embodiments, the testing antibody is expressed by prokaryotic or eukaryotic cells.</p><p id="p-0013" num="0012">In a preferred embodiment, the method further comprises monitoring immune responses of IgG2, 3 (HcAb) and IgG1 (conventional IgG).</p><p id="p-0014" num="0013">In some embodiments, the sequences within the same lineage group of the selected IgG2 or IgG3 heavy chain only antibodies can be chosen for optimization of the antibodies by repeating e)-f) of the method.</p><p id="p-0015" num="0014">In some embodiments, the antigen or immunogen can be cells, a tissue, or a biofluid.</p><p id="p-0016" num="0015">In some embodiments, the antigen can be a complex immunogen, and the method further include: using an antibody which has been determined in step (f) to bind with the complex immunogen to identify individual antigens included in the complex immunogen by protein array, cells/tissue antigen cDNA library, or mass spectrometry-based immunoprecipitation.</p><p id="p-0017" num="0016">In one aspect of the invention, the method further comprises lineage subgrouping with certain VHH features selected from a group consisting of i) FR2 hydrophilic region; ii) extended CDR1; iii) extra disulfide bond between CDR1-CDR3 or FR2-CDR3; iv) extra disulfide bond within CDR3; v) long CDR3 (&#x2265;15 aa); vi) extra disulfide bond within CDR1; vii) Non-classic VHH which have the same V and J germlines as conventional IgG1; viii) Non-classic VHH which have certain predetermined sequence signatures; ix) certain predetermined canonical binding loop structure; x) convergent motif or sequence signature among individual animals from the same immunization group; xi) CDR2 length; xii) CDR3 length; xiii) CDR3 length and identity; xiv) presence of 3 or more positive charges in CDR3 region; xv) the number of cysteines in the amino acid sequence; and xvi) 2-4 amino acid motifs found in the CDR regions. The motif is identified from the 3D structures of a ligand/receptor complex.</p><p id="p-0018" num="0017">In another aspect of the invention, a method for high-throughput generating a camelid antibody against an antigen is provided, the method comprising: a) enriching and proliferating antigen-specific B-cells from immunized camelids; b) generating antibody NGS libraries comprising VHH<sup>2</sup>, VHH<sup>3</sup>, VH<sup>1 </sup>and VL<sup>1 </sup>chain sequences from said antigen-specific B-cells; c) grouping VHH<sup>2</sup>, VHH<sup>3</sup>, VH<sup>1 </sup>and VL<sup>1 </sup>NGS sequences by lineages; d) VH<sup>1</sup>/VL<sup>1 </sup>lineage pairing according to an anchor binder generated by single B-cell sorting and heterohybridoma approaches; e) ranking lineages and lineage pairs from step c) and step d) by lineage priority factors; f) selecting a representative sequence or sequence pair from lineages of VHH<sup>2</sup>, VHH<sup>3 </sup>and lineage pairs of VH<sup>1</sup>/VL<sup>1 </sup>with the top ranking in the NGS library; g) testing an antibody comprising the selected heavy chain/light chain sequence pair or heavy chain VHH<sup>2</sup>, VHH<sup>3 </sup>sequence to determine if the antibody binds to the antigen or portion thereof. In one embodiment, an antigen comprises a plurality of epitopes.</p><p id="p-0019" num="0018">In one embodiment, minimal CDR3 distance of a specific CDR3 is equal or less than 1 among the group of CDR3s from a lineage, wherein minimal CDR3 distance of a specific CDR3 is the smallest hamming distance of this CDR3 comparing with all other CDR3 of the same length.</p><p id="p-0020" num="0019">In one embodiment, the ranking of lineage pairs in step e) is based on lineage priority factors of VH<sup>1 </sup>lineages of said lineage pairs.</p><p id="p-0021" num="0020">In some embodiments, the lineage priority factors are selected from a group consisting of lineages from high to low sequences abundancy, lineages from high to low amplification factor after in vitro B-cells enrichment and proliferation, lineages sequences abundancy change during immunization course, lineages sequences abundancy change before and after depleting certain unwanted B cells, lineages which share the same na&#xef;ve B-cell origin between VHH and VH, avoidance of developability liability sequences, and a combination thereof.</p><p id="p-0022" num="0021">In some embodiments, anchors for IgG1 repertoire are generated with single B-cell sorting and heterohybridoma approaches.</p><p id="p-0023" num="0022">In some embodiments, testing antibody is expressed by prokaryotic or eukaryotic cells.</p><p id="p-0024" num="0023">In some embodiments, one representative sequence of VHH or one representative pair VH<sup>1</sup>/VL<sup>1 </sup>from each top 100 lineages or lineage pairs are selected. In some embodiments, 100 lineages/lineage-pairs include 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15 or 10 VHHs lineage and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90 or 95 VH<sup>1</sup>/VL<sup>1 </sup>lineage pairs respectively, wherein VL<sup>1 </sup>comprises V&#x3ba; and V&#x3bb;.</p><p id="p-0025" num="0024">In some embodiments, the method further comprises repeating f)-g) to generate camelid antibodies, wherein the representative sequences are selected from top 101-200, 201-300, 301-400, 401-500, 501-600, 601-700, 701-800, 801-900, 901-1000, 1001-1100,1101-1200, 1201-1300, 1301-1400, 1401-1500, 1501-1600, 1601-1700, 1701-1800, 1801-1900, or 1901-2000 ranking lineages. In some embodiments, the method further comprises repeating f)-g) to generate camelid antibodies, wherein the representative sequences are selected from top 2000 to 10,000 ranking lineages.</p><p id="p-0026" num="0025">In some embodiments, the criteria for lineage ranking/selection are selected from a group consisting of lineages from high to low sequences abundancy, lineages from high to low amplification factor, lineages sequences abundancy change during immunization course, lineages sequences abundancy change before and after depleting certain unwanted B cells, Lineages which share the same na&#xef;ve B-cell origin between VHH and VH<sup>1</sup>, avoidance of developability liability sequences, and a combination thereof.</p><p id="p-0027" num="0026">In some embodiments, the antigen or immunogen can be cells or tissue, and generated VHHs are used to identify individual corresponding antigens by protein array or cells/tissue antigen cDNA library or immunoprecipitation-based mass spectrometry method.</p><p id="p-0028" num="0027">In another aspect of the invention, the method for high-throughput generating camelid antibody against a plurality of epitopes of a specific antigen further comprises subgrouping VHHs lineages having a feature selected from a group consisting of i) FR2 hydrophilic region; ii) extended CDR1; iii) extra disulfide bond within CDR1 or/and CDR3; iv) long CDR3 (&#x2265;15 aa); v) sequences sharing the same na&#xef;ve B cells origin among VHH<sup>2</sup>, VHH<sup>3 </sup>and VH<sup>1</sup>; vi) sequence-based prediction for antigen-binding loops structure; x) convergent motif or sequence signature among individual animals from the same immunization group; xi) CDR2 length; xii) CDR3 length; xiii) CDR3 length and identity; xiv) presence of 3 or more positive charges in CDR3 region; xv) the number of cysteines in the amino acid sequence; and xvi) 2-4 amino acid motifs found in the CDR regions. The motif is identified from the 3D structures of a ligand/receptor complex.</p><p id="p-0029" num="0028">In some embodiments, sequences within the same lineage group of tested antibodies in the first round can be chosen for optimization of the antibodies by repeating f)-g) in the second round.</p><p id="p-0030" num="0029">In some embodiments, the method for high-throughput generating camelid antibodies against an antigen further comprises applying the selected VHH sequences to guide VH<sup>1</sup>-VL<sup>1 </sup>pair selection for these clones which share the same na&#xef;ve B-cell origin, wherein the selection criteria comprise 1) CDR1 and CDR2 differences; 2) FR1, 2, 3 and 4 differences.</p><p id="p-0031" num="0030">In another aspect of the invention, a method for generating humanized VHH antibody comprises a) enriching and proliferating antigen-specific B-cells from immunized camelids; b) generating antibody NGS libraries comprising VHH<sup>2</sup>, VHH<sup>3</sup>, and VH<sup>1 </sup>chain sequences from antigen-specific B-cells; c) grouping VHH<sup>2</sup>, VHH<sup>3</sup>, and VH<sup>1 </sup>NGS sequences by lineages; d) identifying a substitutable position in a parent VHH<sup>2</sup>, VHH<sup>3 </sup>antibody or VH<sup>1 </sup>sharing the same na&#xef;ve B-cell origin by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same epitope as the parent antibody in the same lineage; e) substituting amino acids at one or more of the substitutable positions of the parental VHH<sup>2 </sup>or VHH<sup>3 </sup>antibody by correspondingly positioned amino acids in the human antibody; f) testing an antibody comprising the substituted residues within the selected sequences to determine if the antibody binds to the antigen or portion thereof.</p><p id="p-0032" num="0031">In one embodiment, the substituted position of humanized VHH antibody is in the FRs regions. In one embodiment, the substituted position of humanized VHH antibody is in the CDRs regions.</p><p id="p-0033" num="0032">In one embodiment, the parent antibody is a camelid antibody. In one embodiment, the parent antibody is a humanized camelid antibody.</p><p id="p-0034" num="0033">In another aspect of the invention, an isolated camelid antibody or antigen-binding portion comprising an antibody sequence generated by this invention.</p><p id="p-0035" num="0034">In another aspect of the invention, a pharmaceutical composition comprising the camelid antibody of this invention and a pharmaceutically acceptable carrier.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0003" level="1">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p-0036" num="0035">Exemplary embodiments are illustrated in referenced figures. It is intended that the embodiments and figures disclosed herein are to be considered illustrative rather than restrictive.</p><p id="p-0037" num="0036"><figref idref="DRAWINGS">FIG. <b>1</b>A</figref> shows the organization of camelids locus that encode VHH, VH and CH immunoglobulins. <figref idref="DRAWINGS">FIG. <b>1</b>B</figref> shows camelids VHH structure.</p><p id="p-0038" num="0037"><figref idref="DRAWINGS">FIG. <b>2</b></figref> shows Camelids immunization and antigen-specific B cells enrichment/proliferation. At (i), Camelidae (a camel or llama) is immunized with an immunogen, which can be a cDNA, small molecule, peptide, or protein, or a complex immunogen&#x2014;normal or diseased cells or tissue. The VHHs generated are used to identify individual corresponding antigens by protein array or cells/tissue antigen cDNA library or immunoprecipitation-based mass spectrometry. At (ii) the antisera are evaluated by isolating IgG isotypes (IgG2, IgG3, IgG1/k, IgG1/l) and testing titer and bioactivity, respectively. At (iii), immune B cells are isolated from PBMC, spleen, bone marrow, lymph-notes and other lymphatic tissues. At (iv) Antigen-specific B cells, antigen-specific memory B-cells and plasmablasts are enriched with immunogen, desired domain or epitopes or complex immunogen by panning (enriching and/or depleting unwanted B-cells); magnetic bead purification or FACS sorting. At (v), antigen-specific B-cells are tested for activation and proliferation by camelid CD40-L cells, cytokines and/or immunogen.</p><p id="p-0039" num="0038"><figref idref="DRAWINGS">FIG. <b>3</b></figref> shows IgG isotype specific primer sets to amplify VHH<sup>2</sup>, VHH<sup>3</sup>, VH<sup>1</sup>, V&#x3ba; and V&#x3bb;. At Ia/b, lead sequences (VH/VHH) CH2 sequences are identified. At IIa/b PCR is performed using primer sets for VH and VHH; at IIIa, a &#x2dc;600 bp VHH fragment is purified; at IIIb &#x2dc;900 bp VH fragment is purified; at IVa, nested primers for VHH2 are used to amplify VHH2 (short-hinge) sequences by PCR, and at IVb nested primers for VH1 and VHH3 (long-hinge) sequences by PCR. At IIc, primer sets for V&#x3ba; are used to amplify these sequences and at IId primer sets for V&#x3bb; are used to amplify these sequences by PCR.</p><p id="p-0040" num="0039"><figref idref="DRAWINGS">FIG. <b>4</b></figref> shows generating VHH<sup>2</sup>, VHH<sup>3</sup>, VH<sup>1</sup>, V&#x3ba; and V&#x3bb; NGS libraries and grouping lineages. At I, data relating to VHH2, VHH3, VH1, V&#x3ba; and V&#x3bb; sequences are generated by adding NGS adapters and indexing; at II&#x2014;nucleotide sequences are of the clones are determined by Illumina MiSeq 300x2 and data construction; at III&#x2014;the sequences are grouped by lineage based on heavy chain CDR3 or light chain CDR3 sequences using bioinformatics.</p><p id="p-0041" num="0040"><figref idref="DRAWINGS">FIG. <b>5</b></figref> shows further grouping VHH<sup>2 </sup>and VHH<sup>3 </sup>lineages with sequence signatures. The further grouping is performed based on one or more of the criteria:<ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0000">    <ul id="ul0002" list-style="none">        <li id="ul0002-0001" num="0041">1) FR2 hydrophilic region (37Phe/Tyr, 44Glu, 45Arg, and 47Gly)</li>        <li id="ul0002-0002" num="0042">2) Extended CDR1</li>        <li id="ul0002-0003" num="0043">3) Disulfide bonds: CDR1-CDR3 or FR2-CDR3</li>        <li id="ul0002-0004" num="0044">4) Disulfide bonds: within CDR1 or within CDR3</li>        <li id="ul0002-0005" num="0045">5) CDR3&#x3e;15 aa</li>        <li id="ul0002-0006" num="0046">6) Non-classic VHH: sequences sharing the same na&#xef;ve B-cells origin with conventional VH</li>        <li id="ul0002-0007" num="0047">7) Non-classic VHH: conserved Trp118 substituted with Arg118</li>        <li id="ul0002-0008" num="0048">8) Non-classic VHH: lower hydrophobicity profile in FR3</li>        <li id="ul0002-0009" num="0049">9) Sequence-based novel Ag-binding loop conformation prediction</li>        <li id="ul0002-0010" num="0050">10) Convergent motif or sequence signature among individual animals</li>        <li id="ul0002-0011" num="0051">11) CDR2 length</li>        <li id="ul0002-0012" num="0052">12) CDR3 length</li>        <li id="ul0002-0013" num="0053">13) CDR3 length and identity</li>        <li id="ul0002-0014" num="0054">14) Presence of 3 or more positive charges in CDR3 region</li>        <li id="ul0002-0015" num="0055">15) The number of cysteines in the amino acid sequence</li>        <li id="ul0002-0016" num="0056">16) 2-4 amino acid motifs found in CDR regions. The motif is identified from 3-d structures of a ligand/receptor complex.</li>    </ul>    </li></ul></p><p id="p-0042" num="0057"><figref idref="DRAWINGS">FIG. <b>6</b></figref> shows pairing VH-V&#x3ba; or VH-V&#x3bb; lineages with anchors developed with single B-cells sorting and heterohybridoma. At (ia) antigen specific B-cells are sorted, at (iia) VH-V&#x3ba; or VH-V&#x3bb; pairs are identified by single-cell linkage PCR. At (ib), cells of mouse cell line Sp/20 and immune Camelid lymphocytes are fused to create heterohybridomas. At (iib) the heterohybridomas are screened to identify VH-V&#x3ba; and/or VH-V&#x3bb; pairs. At (iii), H and L (k or l) lineages are paired by anchors from B-cell sorting or heterohybridomas.</p><p id="p-0043" num="0058"><figref idref="DRAWINGS">FIG. <b>7</b></figref> shows sequences selection from each lineage for binder and bioactivity screening using lineage priority factors of:<ul id="ul0003" list-style="none">    <li id="ul0003-0001" num="0000">    <ul id="ul0004" list-style="none">        <li id="ul0004-0001" num="0059">1) High to low lineage sequences abundancy</li>        <li id="ul0004-0002" num="0060">2) High to low lineage sequence amplification factor</li>        <li id="ul0004-0003" num="0061">3) Dynamic change of lineage sequence before and after depleting unwanted B-cells</li>        <li id="ul0004-0004" num="0062">4) Dynamic change of lineage sequence abundancy during immunization course</li>        <li id="ul0004-0005" num="0063">5) Lineage sequences sharing the same na&#xef;ve B-cell origin between VHH with conventional VH</li>        <li id="ul0004-0006" num="0064">6) Avoidance of developability liability sequences.<br/>The resulting selected antibodies are expected to bind different epitopes of the target antigen, providing broad epitope coverage of the target antigen.</li>    </ul>    </li></ul></p><p id="p-0044" num="0065"><figref idref="DRAWINGS">FIG. <b>8</b></figref> shows optimization of the selected lead within the same lineage. Leads from the first round of selection are marked with @ and +. Criteria for selection of optimized sequences include:<ul id="ul0005" list-style="none">    <li id="ul0005-0001" num="0000">    <ul id="ul0006" list-style="none">        <li id="ul0006-0001" num="0066">1) CDR1 and/or CDR2 differences&#x3e;2aa;</li>        <li id="ul0006-0002" num="0067">2) FR1 and/or 2 and/or 3 and/or 4 differences&#x3e;2aa;</li>        <li id="ul0006-0003" num="0068">3) Sequences sharing the same na&#xef;ve B-cell origin between VHH with conventional VH;</li>        <li id="ul0006-0004" num="0069">4) VH sequences which can pair with both V&#x3ba; and V&#x3bb;;</li>        <li id="ul0006-0005" num="0070">5) The same epitope recognized by various antibody formats with different characteristics.</li>    </ul>    </li></ul></p><p id="p-0045" num="0071"><figref idref="DRAWINGS">FIG. <b>9</b></figref> shows workflow for humanization of VHH and VH-VL through lineage analysis. At I, Camilidae are immunized with an antigen; then two alternative screens are applied. At IIa, sequences of VHH that bind to antigen are obtained through NGS; at IIIa phylogenetically related groups (lineages) of antibodies are identified; at IVa substitutable positions within the same lineages of VHH are identified; at Va human amino acids at variation tolerant positions both on FRs and CDRs are substituted. In an alternative screening method, at IIb sequences of VH and V&#x3ba; or V&#x3bb; (conventional IgG) that bind to antigen are identified through NGS; at IIIb phylogenetically related groups (lineages) of antibodies are identified; at IVb substitutable positions within the same lineages of VH and V&#x3ba; or V&#x3bb; are identified; at Vb human amino acids at variation tolerant positions both on FRs and CDRs are substituted.</p><p id="p-0046" num="0072"><figref idref="DRAWINGS">FIG. <b>10</b></figref> shows the fluorescence signal from selected antibodies binding to EGFR.</p><p id="p-0047" num="0073"><figref idref="DRAWINGS">FIG. <b>11</b></figref> shows ELISA assays of antibodies secreted from selected co-cultures of anti-KLH antibody-secreting B cells and alpaca feeder cells. The B-cells only without the feeder cells will not grow or amplify. It was used as a negative control. The immunized animal serum was diluted 1:1000 with the control media as a positive control for ELISA.</p><p id="p-0048" num="0074"><figref idref="DRAWINGS">FIG. <b>12</b></figref>, shows the amplification of B cells obtained from co-cultures of feeder cells and antibody secreting B cells vs. B-cell only without feeder cells.</p><p id="p-0049" num="0075"><figref idref="DRAWINGS">FIG. <b>13</b></figref> shows results of ELISA assay of supernatants of selected clones from KLH NGS data.</p><p id="p-0050" num="0076"><figref idref="DRAWINGS">FIG. <b>14</b></figref> shows workflow for identification of blocking antibodies based on CDR region 2-4 amino acid motif identified from 3-d structure of ligand/receptor complex.</p><p id="p-0051" num="0077"><figref idref="DRAWINGS">FIG. <b>15</b></figref> shows two views of the complex formed between PD-1 and PD-L1 highlighting two peptides of PD-1 at the interface of the complex.</p><p id="p-0052" num="0078"><figref idref="DRAWINGS">FIG. <b>16</b></figref> shows analysis of the interaction of interfacial peptides in a PD-1:PD-L1 complex.</p><p id="p-0053" num="0079"><figref idref="DRAWINGS">FIG. <b>17</b></figref> shows a phylogenetic tree illustrating lineage grouping of selected anti-PD-1 VHH antibodies. The root of the phylogenetic tree serves as an anchor that defines a lineage group that includes the subgroups 1, 2 and 3.</p><p id="p-0054" num="0080"><figref idref="DRAWINGS">FIG. <b>18</b></figref> shows a Venn diagram illustrating the overlap in CDR3 domain amino acid sequences in clone libraries from immunized alpacas A1 and A2.</p><p id="p-0055" num="0081"><figref idref="DRAWINGS">FIG. <b>19</b>A</figref> shows a selection scheme to identify overlapping clones from alpacas A1 and A2 having hinge region and CDR3 domain sequences in common. <figref idref="DRAWINGS">FIG. <b>19</b>B</figref> shows a Venn diagram illustrating the overlap in hinge region amino acid sequences in clone libraries from immunized alpacas A1 and A2.</p><p id="p-0056" num="0082"><figref idref="DRAWINGS">FIG. <b>20</b>A</figref> shows a selection scheme to identify overlapping clones from alpacas A1 and A2 having hinge region and CDR3 domain sequences in common. <figref idref="DRAWINGS">FIG. <b>20</b>B</figref> shows a Venn diagram illustrating the overlap in hinge region amino acid sequences in clone libraries from immunized alpacas A1 and A2.</p><p id="p-0057" num="0083"><figref idref="DRAWINGS">FIG. <b>21</b>A</figref> shows a Venn diagram illustrating the overlapping clones of VH, VHH2 and VHH3 antibodies in a library from a single alpaca that have common CDR3 domain sequences. <figref idref="DRAWINGS">FIG. <b>21</b>B</figref> shows the CDR3 sequences in common.</p><p id="p-0058" num="0084"><figref idref="DRAWINGS">FIG. <b>22</b></figref> is a Venn diagram showing the number of CDR3 domain sequences in common among alpacas A1 and A2, VH, VHH2 and VHH3 antibodies.</p><p id="p-0059" num="0085"><figref idref="DRAWINGS">FIG. <b>23</b></figref> shows the antigen-binding affinity by FACS using RPMI8226 cells expressing BCMA of selected antibody clones of classical VHH type and non-classical VHH type.</p><p id="p-0060" num="0086"><figref idref="DRAWINGS">FIG. <b>24</b></figref> shows the proportion of unique FR2 domain sequences in each of three libraries of antibodies binding to three different antigens.</p><p id="p-0061" num="0087"><figref idref="DRAWINGS">FIG. <b>25</b></figref> shows the frequency of certain amino acid substitutions in the FR2 domain of antibodies in each of three libraries of antibodies binding to three different antigens.</p><p id="p-0062" num="0088"><figref idref="DRAWINGS">FIG. <b>26</b></figref> shows the proportion of clones having a CDR1 domain length from 11 to 15 amino acids in each of three libraries of antibodies binding to three different antigens.</p><p id="p-0063" num="0089"><figref idref="DRAWINGS">FIG. <b>27</b></figref> shows the distribution of binding affinity by ELISA of antibodies having &#x201c;long CDR2&#x201d; domains in antibodies from three libraries targeting three different antigens.</p><p id="p-0064" num="0090"><figref idref="DRAWINGS">FIG. <b>28</b></figref> shows the proportion of clones having extra disulfide bonds within the CDR3 domain in antibodies from three libraries targeting three different antigens.</p><p id="p-0065" num="0091"><figref idref="DRAWINGS">FIG. <b>29</b></figref> and <figref idref="DRAWINGS">FIG. <b>30</b></figref> show the proportion of clones having extra disulfide bonds between the CDR1 and CDR2 domains in antibodies from three targeting three different antigens.</p><p id="p-0066" num="0092"><figref idref="DRAWINGS">FIG. <b>31</b></figref> shows analysis of the number of cysteine residues in the amino acid sequence of V-region in antibodies from three libraries targeting three different antigens.</p><p id="p-0067" num="0093"><figref idref="DRAWINGS">FIG. <b>32</b></figref> shows the proportion of clones having extra disulfide bonds between the CDR1 and CDR3 domains in antibodies from three libraries targeting three different antigens.</p><p id="p-0068" num="0094"><figref idref="DRAWINGS">FIG. <b>33</b></figref> shows the proportion of clones having extra disulfide bonds between the FR2 and CDR2 domains or between the FR2 and CDR3 domains in antibodies from three libraries targeting three different antigens.</p><p id="p-0069" num="0095"><figref idref="DRAWINGS">FIG. <b>34</b></figref> shows the correlation between the number of cysteine amino acids in a VHH antibody sequence and the supernatant OD value.</p><p id="p-0070" num="0096"><figref idref="DRAWINGS">FIG. <b>35</b></figref> shows the proportion of clones having a &#x201c;long CDR3&#x201d; domain in each of three libraries of antibodies binding to three different antigens.</p><p id="p-0071" num="0097"><figref idref="DRAWINGS">FIG. <b>36</b></figref>, <figref idref="DRAWINGS">FIG. <b>37</b></figref> and <figref idref="DRAWINGS">FIG. <b>38</b></figref> show the correlation between length of the CDR3 domain and antibody affinity assayed by FACS or ELISA for VHH anti-BCMA antibodies.</p><p id="p-0072" num="0098"><figref idref="DRAWINGS">FIG. <b>39</b></figref> shows the range of CDR3 length for a population of VHH antibodies binding to nearly identical epitopes or the same epitope of a certain antigen.</p><p id="p-0073" num="0099"><figref idref="DRAWINGS">FIG. <b>40</b></figref> shows the results of an experiment assessing competition of selected anti-PD1 clones with KEYTRUDA and OPDIVO for binding to PD1.</p><p id="p-0074" num="0100"><figref idref="DRAWINGS">FIG. <b>41</b></figref> shows the proportion of clones having the Trp118 amino acid substituted with Arg in VHH antibodies in each of three libraries of antibodies binding to three different antigens.</p><p id="p-0075" num="0101"><figref idref="DRAWINGS">FIG. <b>42</b></figref> shows the positive correlation between length of the CDR3 and ELISA binding activity for anti-KLH VHH antibodies.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0004" level="1">DETAILED DESCRIPTION</heading><p id="p-0076" num="0102">The following embodiments and aspects thereof are described and illustrated in conjunction with systems, compositions and methods which are meant to be exemplary and illustrative, not limiting in scope.</p><heading id="h-0005" level="1">Definitions</heading><p id="p-0077" num="0103">As used herein the term &#x201c;comprising&#x201d; or &#x201c;comprises&#x201d; is used in reference to compositions, methods, and respective component(s) thereof, that are useful to an embodiment, yet open to the inclusion of unspecified elements, whether useful or not. It is understood by those within the art that, in general, terms used herein are generally intended as &#x201c;open&#x201d; terms (e.g., the term &#x201c;including&#x201d; should be interpreted as &#x201c;including but not limited to,&#x201d; the term &#x201c;having&#x201d; should be interpreted as &#x201c;having at least,&#x201d; the term &#x201c;includes&#x201d; should be interpreted as &#x201c;includes but is not limited to,&#x201d; etc.).</p><p id="p-0078" num="0104">Unless stated otherwise, the terms &#x201c;a&#x201d; and &#x201c;an&#x201d; and &#x201c;the&#x201d; and similar references used in the context of describing a particular embodiment of the application (especially in the context of claims) can be construed to cover both the singular and the plural. The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (for example, &#x201c;such as&#x201d;) provided with respect to certain embodiments herein is intended merely to better illuminate the application and does not pose a limitation on the scope of the application otherwise claimed. The abbreviation, &#x201c;e.g.&#x201d; is derived from the Latin exempli gratia, and is used herein to indicate a non-limiting example. Thus, the abbreviation &#x201c;e.g.&#x201d; is synonymous with the term &#x201c;for example.&#x201d; No language in the specification should be construed as indicating any non-claimed element essential to the practice of the application.</p><p id="p-0079" num="0105">The term &#x201c;plurality&#x201d; refers to more than 1, for example more than 2, more than about 5, more than about 10, more than about 20, more than about 50, more than about 100, more than about 200, more than about 500, more than about 1000, more than about 2000, more than about 5000, more than about 10,000, more than about 20,000, more than about 50,000, more than about 100,000, usually no more than about 200,000. A &#x201c;population&#x201d; contains a plurality of items.</p><p id="p-0080" num="0106">As used herein, the term &#x201c;about&#x201d; refers to a measurable value such as an amount, a time duration, and the like, and encompasses variations of 20%, +10%, +5%, +1%, &#xb1;0.5% or &#xb1;0.1% from the specified value.</p><p id="p-0081" num="0107">The term &#x201c;epitope&#x201d; as used herein can include any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the equilibrium dissociation constant is &#x2264;1 &#x3bc;M, preferably &#x2264;100 nM and most preferably &#x2264;10 nM.</p><p id="p-0082" num="0108">The term &#x201c;K<sub>D</sub>&#x201d; can refer to the equilibrium dissociation constant of a particular antibody-antigen interaction.</p><p id="p-0083" num="0109">The term &#x201c;immune response&#x201d; as used herein can refer to the action of, for example, lymphocytes, antigen presenting cells, phagocytic cells, granulocytes, and soluble macromolecules produced by the above cells or the liver (including antibodies, cytokines, and complement) that results in selective damage to, destruction of, or elimination from an organism of invading pathogens, cells or tissues infected with pathogens, cancerous cells, or, in cases of autoimmunity or pathological inflammation, normal organismal cells or tissues.</p><p id="p-0084" num="0110">An &#x201c;antigen-specific T cell response&#x201d; as used herein can refer to responses by a T cell that result from stimulation of the T cell with the antigen for which the T cell is specific. Non-limiting examples of responses by a T cell upon antigen-specific stimulation include proliferation and cytokine production (e.g., IL-2 production).</p><p id="p-0085" num="0111">As used herein, the term &#x201c;antibody&#x201d; refers to an intact immunoglobulin or to a monoclonal or polyclonal antigen-binding fragment with the Fc (crystallizable fragment) region or FcRn binding fragment of the Fc region, referred to herein as the &#x201c;Fc fragment&#x201d; or &#x201c;Fc region&#x201d;. Antigen-binding fragments may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding fragments include, inter alia, Fab, Fab&#x2032;, F(ab&#x2032;)2, Fv, dAb, and complementarity determining region (CDR) fragments, single-chain antibodies (scFv), single region antibodies, chimeric antibodies, diabodies and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to the polypeptide. The Fc region includes portions of two heavy chains contributing to two or three classes of the antibody. The Fc region may be produced by recombinant DNA techniques or by enzymatic (e.g. papain cleavage) or via chemical cleavage of intact antibodies.</p><p id="p-0086" num="0112">The term &#x201c;antibody fragment,&#x201d; as used herein, refers to a protein fragment that comprises only a portion of an intact antibody, generally including an antigen binding site of the intact antibody and thus retaining the ability to bind antigen. Examples of antibody fragments encompassed by the present definition include: (i) the Fab fragment, having VL, CL, VH and CH1 regions; (ii) the Fab&#x2032; fragment, which is a Fab fragment having one or more cysteine residues at the C-terminus of the CH1 region; (iii) the Fd fragment having VH and CH1 regions; (iv) the Fd&#x2032; fragment having VH and CH1 regions and one or more cysteine residues at the C-terminus of the CH1 region; (v) the Fv fragment having the VL and VH regions of a single arm of an antibody; (vi) the dAb fragment (Ward et al., Nature 341, 544-546 (1989)) which consists of a VH region; (vii) isolated CDR regions; (viii) F(ab&#x2032;)2 fragments, a bivalent fragment including two Fab&#x2032; fragments linked by a disulfide bridge at the hinge region; (ix) single chain antibody molecules (e.g., single chain Fv; scFv) (Bird et al., Science 242:423-426 (1988); and Huston et al., PNAS (USA) 85:5879-5883 (1988)); (x) &#x201c;diabodies&#x201d; with two antigen binding sites, comprising a heavy chain variable region (VH) connected to a light chain variable region (VL) in the same polypeptide chain (see, e.g., EP 404,097; WO 93/11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); (xi) &#x201c;linear antibodies&#x201d; comprising a pair of tandem Fd segments (VH-CH1-VH-CH1) which, together with complementary light chain polypeptides, form a pair of antigen binding regions (Zapata et al. Protein Eng. 8(10):1057-1062 (1995); and U.S. Pat. No. 5,641,870).</p><p id="p-0087" num="0113">&#x201c;Single-chain variable fragment&#x201d;, &#x201c;single-chain antibody variable fragments&#x201d; or &#x201c;scFv&#x201d; antibodies as used herein refers to forms of antibodies comprising the variable regions of only the heavy (VH) and light (VL) chains, connected by a linker peptide. The scFvs are capable of being expressed as a single chain polypeptide. The scFvs retain the specificity of the intact antibody from which it is derived. The light and heavy chains may be in any order, for example, VH-linker-VL or VL-linker-VH, so long as the specificity of the scFv to the target antigen is retained.</p><p id="p-0088" num="0114">An &#x201c;isolated antibody&#x201d;, as used herein, can refer to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds a TRAIL protein can be substantially free of antibodies that specifically bind antigens other than TRAIL proteins). An isolated antibody that specifically binds a human TRAIL protein can, however, have cross-reactivity to other antigens, such as TRAIL proteins from other species. Moreover, an isolated antibody can be substantially free of other cellular material and/or chemicals.</p><p id="p-0089" num="0115">The terms &#x201c;monoclonal antibody&#x201d; or &#x201c;monoclonal antibody composition&#x201d; as used herein can refer to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.</p><p id="p-0090" num="0116">The term &#x201c;recombinant human antibody&#x201d;, as used herein, can refer to all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as (a) antibodies isolated from an animal (e.g., a mouse) that is transgenic or transchromosomal for human immunoglobulin genes or a hybridoma prepared therefrom (described below), (b) antibodies isolated from a host cell transformed to express the human antibody, e.g., from a transfectoma, (c) antibodies isolated from a recombinant, combinatorial human antibody library, and (d) antibodies prepared, expressed, created or isolated by any other means that involve splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable regions in which the framework and CDR regions are derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies can be subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.</p><p id="p-0091" num="0117">The term &#x201c;isotype&#x201d; can refer to the antibody class (e.g., IgM or IgG1) that is encoded by the heavy chain constant region genes. An antibody can be an immunoglobulin G (IgG), an IgM, an IgE, an IgA or an IgD molecule, or is derived therefrom.</p><p id="p-0092" num="0118">The term &#x201c;VHH<sup>2</sup>&#x201d;, &#x201c;VHH<sup>3</sup>&#x201d; and &#x201c;VH&#x201d; are representing the heavy chains of three camelid IgG isotypes IgG2, IgG3 and IgG1 respectively. VL<sup>3 </sup>is representing the light chain of camelid IgG1. Camelid VL<sup>3 </sup>includes, but not limited to V&#x3ba; and V&#x3bb;.</p><p id="p-0093" num="0119">The term &#x201c;correspondingly positioned amino acids&#x201d; and &#x201c;corresponding amino acids&#x201d; used herein interchangeably, are amino acid residues that are at an identical position (i.e., they lie across from each other) When two or more amino acid sequences are aligned. Methods for aligning and numbering antibody sequences are set forth in great detail in Chothia, supra, Kabat supra, and others. As is known in the art (see, e.g. Kabat 1991 Sequences of Proteins of Immunological Interest, DHHS, Washington, D.C.), sometimes one, two or three gaps and/or insertions of up to one, two, three or four residues, or up to about 15 residues (particularly in the Light chain and Heavy chain CDR3) may be made to one or both of the amino acids of an antibody in order to accomplish an alignment.</p><p id="p-0094" num="0120">The term &#x201c;natural&#x201d; antibody refers to an antibody in which the heavy and light chains of the antibody have been made and paired by the immune system of a multicellular organism. Spleen, lymph nodes, bone marrow, blood and other lymphatic tissues are examples of tissues that contain cells that produce natural antibodies. For example, the antibodies produced by B cells isolated from a first animal immunized with an antigen are natural antibodies. Natural antibodies contain naturally&#x2014;paired heavy and light chains.</p><p id="p-0095" num="0121">The term &#x201c;naturally paired&#x201d; refers to heavy and light chain sequences that have been paired by the immune system of a multi-cellular organism.</p><p id="p-0096" num="0122">The term &#x201c;mixture&#x201d;, as used herein, refers to a combination of elements, e. g., cells, that are interspersed and not in any particular order. A mixture is homogeneous and not spatially separated into its different constituents. Examples of mixtures of elements include a number of different cells that are present in the same aqueous solution in a spatially undressed manner.</p><p id="p-0097" num="0123">The term &#x201c;assessing&#x201d; includes any form of measurement, and includes determining if an element is present or not. The terms &#x201c;determining&#x201d;, &#x201c;measuring&#x201d;, &#x201c;evaluating&#x201d;, &#x201c;assessing&#x201d; and &#x201c;assaying&#x201d; are used interchangeably and may include quantitative and/or qualitative determinations. Assessing may be relative or absolute. &#x201c;Assessing the presence of&#x201d; includes determining the amount of something present, and/or determining whether it is present or absent.</p><p id="p-0098" num="0124">The term &#x201c;enriched&#x201d; is intended to refer to component of a composition (e.g., a particular type of cells) that is more concentrated (e.g., at least 2&#xd7;, at least 5&#xd7;, at least 10&#xd7;, at least 50&#xd7;, at least 100&#xd7;, at least 500&#xd7;, at least 1,000&#xd7;), relative to other components in the sample (e.g., other cells) than prior to enrichment. In some cases, something that is enriched may represent a significant percent (e.g., greater than 2%, greater than 5%, greater than 10%, greater than 20%, greater than 50%, or more, usually up to about 90%-100%) of the sample in which it resides.</p><p id="p-0099" num="0125">The term &#x201c;enriching&#x201d; is intended to any way by which antigen&#x2014;specific cells can be obtained from a larger population of B cells. As described in greater detail below, enriching may be done by panning, using a bead or cell sorting, for example.</p><p id="p-0100" num="0126">The term &#x201c;obtaining&#x201d; in the context of obtaining an element, e. g., cells or sequences, is intended to include receiving the element as well as physically producing the element.</p><p id="p-0101" num="0127">The term &#x201c;peripheral blood mononucleated cells&#x201d; or &#x201c;PBMCs&#x201d; refers to blood cells that have a single approximately round nucleus (as opposed to a lobed nucleus) and includes lymphocytes (T cells, B cells and NK cells), monocytes and macrophage. PBMCs can be enriched from whole blood using a Ficoll gradient.</p><p id="p-0102" num="0128">The term &#x201c;antigen-specific B cells&#x201d; refers to memory B cells that have an antibody that specifically binds to an antigen on their surface, as well as progenitors thereof.</p><p id="p-0103" num="0129">A cell is &#x201c;derived from&#x201d; a host if the cell, or the progeny thereof, was obtained from the host. The progeny of a progenitor cell is derived from the progenitor cell.</p><p id="p-0104" num="0130">The term &#x201c;support comprising the antigen&#x201d; comprises any type of support (e.g., a solid or semi-solid support, including plates and beads) that contains an antigen, or a portion thereof, immobilized thereon. An antigen may be immobilized on a support directly or indirectly, e.g., via a linker, via a biotin-streptavidin interaction or via a cell, for example. Methods that enrich for antigen-specific B cells by panning or using beads make use of such a support.</p><p id="p-0105" num="0131">The term &#x201c;panning&#x201d; is used to refer to a method by which B cells are applied to a container (e.g., a plate) that has one or more surfaces that are coated in an antigen or portion thereof. Unbound cells can be removed by washing the surface after the cells are applied to it.</p><p id="p-0106" num="0132">The term &#x201c;bead-based enrichment&#x201d; is used to refer to a method by which B cells are mixed with beads, e.g., magnetic beads, that are linked to an antigen or portion thereof.</p><p id="p-0107" num="0133">The term &#x201c;cell sorting&#x201d; is used to refer to a method by which B cells are mixed a detectable antigen (e.g., a fluorescently detectable antigen) in solution. In cell sorting methods, cells that are bound to the antigen are sorted from the unbound cells. Fluorescence-activated cell sorting (FACS) is an example of a cell sorting method.</p><p id="p-0108" num="0134">The term &#x201c;complex immunogen&#x201d; is intended to refer to an immunogen that contains a plurality of antigens. A complex immunogen can be composed of a plurality of different antigens that have been separately made and then mixed together, or they may be naturally complex (e.g., as is the case when one uses an entire cell and tissue or a fraction thereof) in an immunization.</p><p id="p-0109" num="0135">The term &#x201c;activating&#x201d; is referred to the stimulation of B cells to a) proliferate and b) differentiate into plasma blasts and/or plasma cells and c) secrete antibodies. B cell activation can be done by contacting the B cells with antigen, T cells expressing CD40L and cytokines, although other methods are known (see, e.g., Wykes, Imm. Cell. Biol. 2003 81: 328-331).</p><p id="p-0110" num="0136">The term &#x201c;activated B cells&#x201d; refers to a cell population that comprises the progeny of a B cell that was activated. As noted above, activation causes B cells to proliferate, and the progeny of such cells are referred to herein as activated B cells.</p><p id="p-0111" num="0137">The term &#x201c;collecting&#x201d; refers to the act of separating the cells that in the culture medium from a substrate. Collecting may be done by pipetting or by decanting, for example.</p><p id="p-0112" num="0138">The term &#x201c;immunized by an antigen&#x201d; and grammatical equivalents thereof (e.g., &#x201c;immunized animal&#x201d;) is intended to refer to any animal (humans, rabbits, mice, rats, sheep, cows, chickens, camels) that is mounting an immune response an antigen. An animal may be exposed to a foreign antigen via exposure to an infectious agent, a vaccination, or by administrating an antigen and adjuvant (e.g., by injection), for example. The term &#x201c;immunized by an antigen&#x201d; is also intended to include animals that are mounting an immune response against a &#x201c;self&#x201d; antigen, i.e., have an autoimmune disease.</p><p id="p-0113" num="0139">The terms &#x201c;ranking&#x201d; and &#x201c;ranked order of abundance&#x201d; refer to the order of sequences when they are listed by their abundance, i.e., with the most abundant sequence first, the second most abundant sequence next, and the third most abundant sequence next, and so on. In certain cases, sequences may be ranked by making a frequency distribution, and then ordering the sequences by their frequency.</p><p id="p-0114" num="0140">The term &#x201c;corresponding rank&#x201d; or &#x201c;correspondingly ranked&#x201d; refer to two sequences that have the same positions in two ranks. For example, the first, second and third positions in a first rank correspond to the first, second and third positions in a second rank, respectively.</p><p id="p-0115" num="0141">The term &#x201c;lineage rank&#x201d; refers to the order of lineages when they are listed by their priority factors. The priority factors include but not limited to abundancy of lineage sequences, amplification factor, dynamic change of lineage sequence before and after depleting certain unwanted B cells, dynamic change of lineage sequence abundancy during immunization course, lineages which share the same na&#xef;ve B-cell origin between VHH and VH, avoidance of developability liability sequences and a combination thereof.</p><p id="p-0116" num="0142">The term &#x201c;hamming distance&#x201d; refers to the number of positions at which the corresponding symbols are different between two sequences of equal length.</p><p id="p-0117" num="0143">As used herein, the term &#x201c;grouped antibodies by lineage&#x201d;, &#x201c;lineage-related antibodies&#x201d; and &#x201c;antibodies that related by lineage&#x201d; as well as grammatically-equivalent variants thereof, are antibodies that are produced by cells that share a common B cell ancestor. Antibodies that are related by lineage bind to the same epitope of an antigen and are typically very similar in sequence, particularly in their light chain and heavy chain CDR3s. Both the heavy chain and light chain CDR3s of lineage-related antibodies can have an identical length and a near identical sequence (i.e., differ by up to 5, i.e., 0, 1, 2, 3, 4 or 5 residues). Among the group of CDR3s from a lineage, minimal CDR3 distance of a specific CDR3 is the smallest hamming distance of this CDR3 comparing with all other CDR3 of the same length. In some embodiments, the minimal CDR3 distance is equal to or less than 1. In certain cases, the B cell ancestor contains a genome having a rearranged light chain VIC region and a rearranged heavy chain VDJ region, and produces an antibody that has not yet undergone affinity maturation. &#x201c;Na&#xef;ve&#x201d; or &#x201c;virgin&#x201d; B cells present in spleen tissue, are exemplary B cell common ancestors.</p><p id="p-0118" num="0144">Related antibodies are related via a common antibody ancestor, e.g., the antibody produced in the na&#xef;ve B cell ancestor. The term &#x201c;lineage related antibodies&#x201d; is intended to describe a group of antibodies that are produced by cells that arise from the same ancestor B-cell. A &#x201c;lineage group&#x201d; contains a group of antibodies that are related to one another by lineage.</p><p id="p-0119" num="0145">As used herein, the term &#x201c;at least the CDR3s&#x201d; or &#x201c;at least the CDR3 sequences&#x201d; refers to only CDR3 sequences, CDR3 sequences in conjunction with CDR1 and/or CDR2 sequences or a sequences of at least 50 contiguous amino acids of the variable domain, up to the entire length of the variable domain, where the sequence contains a CDR3 sequence.</p><p id="p-0120" num="0146">As used herein, the terms &#x201c;lineage tree&#x201d; refers to a diagram, resulting from a cladistics analysis, which depicts a hypothetical branching sequence of lineages leading to the individual species of interest. The points of branching within a lineage tree are called nodes.</p><p id="p-0121" num="0147">As used herein, the term &#x201c;constructing a phylogenetic tree&#x201d; refers to the computational act of making a phylogenetic tree from sequences.</p><p id="p-0122" num="0148">As used herein, the term &#x201c;lineage&#x201d; refers to a theoretical line of descent. &#x201c;Lineage&#x201d; is used interchangeably with &#x201c;group&#x201d;, and sometimes a group of antibodies related by lineage is referred to as a &#x201c;lineage group&#x201d;. The term &#x201c;group&#x201d; or &#x201c;lineage&#x201d; is exclusive, in that a sequence can belong to only one group or lineage.</p><p id="p-0123" num="0149">As used herein, the term &#x201c;subgrouping&#x201d; refers to a further grouping of sequences in a lineage based on unique features or signatures. &#x201c;Subgroup&#x201d; is not exclusive, which means one sequence can be in different subgroups. For example, one sequence can have two, three, four, five, or six unique features at the same time. &#x201c;Subgrouping&#x201d; is only for VHH. Applying VHH sequence signatures can help to select/narrow-down testing lineages (representative sequences) in a better manner, which may have better biological function/bioactivity outcomes.</p><p id="p-0124" num="0150">As used herein, the term &#x201c;lineage analysis&#x201d; refers to the analysis of the theoretical line of descent of an antibody, which is usually done by analyzing a lineage tree.</p><p id="p-0125" num="0151">As used herein, the term &#x201c;sequence read&#x201d; refers to a sequence of nucleotides determined by a sequencer, which determination is made, for example, by means of base calling software associated with the technique.</p><p id="p-0126" num="0152">As used herein, the term &#x201c;obtaining the amino acid sequences&#x201d; refers to obtaining a file containing amino acid sequences. As is well known, a nucleic acid sequence can be translated into an amino acid sequence in silico.</p><p id="p-0127" num="0153">As used herein, the term &#x201c;most abundantly expressed&#x201d;, with reference to a protein sequence, that is most abundant in a sample. The abundance of a protein can be determined by, e.g., counting sequence reads encoding that protein. The protein encoded by the most sequence reads is the most abundant protein.</p><p id="p-0128" num="0154">The term &#x201c;anchor&#x201d; and &#x201c;anchor binder&#x201d; as used herein interchangeably, is referred to conventional antibody generated with single B-cells sorting or heterohybridoma having native H and L pairing, with that, ones can &#x201c;position/pair&#x201d; heavy chain lineage and light chain lineage which consist of a group of sequences derived from clonal expansion of na&#xef;ve B-cell H and L sequences after encountering the epitope of antigen. Lineages can be &#x201c;anchored&#x201d; considering the amino acid sequences of heavy and light chains that are known to pair with one another. In these embodiments, the branches are rotated around their nodes until there is a minimal number of cross-overs (e.g., no crossovers) between the anchored sequences. After the trees have been &#x201c;aligned&#x201d; by tanglegram analysis, the leaves that are known to pair can be connected by an edge. If the leaves that are known to pair are connected by an edge, the intervening leaves, in theory, can pair with one another as long as they do not create a cross-over event with an edge or one another.</p><p id="p-0129" num="0155">The phrases &#x201c;a monoclonal antibody recognizing an epitope on the antigen&#x201d;, &#x201c;an antibody recognizing an antigen&#x201d; and &#x201c;an antibody specific for an antigen&#x201d; are used interchangeably herein with the term &#x201c;an antibody which binds specifically to an antigen.&#x201d;</p><p id="p-0130" num="0156">The term &#x201c;specific binding&#x201d; refers to the ability of an antibody to preferentially bind to a particular antigen that is present in a homogeneous mixture of different molecules. In certain embodiments, a specific binding interaction will discriminate between desirable and undesirable molecules in a sample, in some embodiments more than about 10 to 100 fold or more than e.g., about 1000- or 10,000 fold.</p><p id="p-0131" num="0157">The term &#x201c;does not substantially bind&#x201d; to a protein or cells, as used herein, can mean that it cannot bind or does not bind with a high affinity to the protein or cells, i.e., binds to the protein or cells with an K<sub>D </sub>of 2&#xd7;10<sup>&#x2212;6 </sup>M or more, more preferably 1&#xd7;10<sup>&#x2212;5 </sup>M or more, more preferably 1&#xd7;10<sup>&#x2212;4 </sup>M or more, more preferably 1&#xd7;10<sup>&#x2212;3 </sup>M or more, even more preferably 1&#xd7;10<sup>&#x2212;2 </sup>M or more.</p><p id="p-0132" num="0158">The term &#x201c;high affinity&#x201d; for an IgG antibody can refer to an antibody having a K<sub>D </sub>of 1&#xd7;10<sup>&#x2212;6 </sup>M or less, preferably 1&#xd7;10<sup>&#x2212;7 </sup>M or less, more preferably 1&#xd7;10<sup>&#x2212;8 </sup>M or less, even more preferably 1&#xd7;10<sup>&#x2212;9 </sup>M or less, even more preferably 1&#xd7;10<sup>&#x2212;10</sup>M or less for a target antigen. However, &#x201c;high affinity&#x201d; binding can vary for other antibody isotypes.</p><p id="p-0133" num="0159">The term &#x201c;pharmaceutical formulation&#x201d; refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.</p><p id="p-0134" num="0160">A &#x201c;therapeutically effective amount&#x201d; of an agent, e.g., a pharmaceutical formulation or cells, refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result, such as for treatment of a disease, condition, or disorder, and/or pharmacokinetic or pharmaco-dynamic effect of the treatment. The therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the subject, and the populations of cells administered. In some embodiments, the provided methods involve administering the cells and/or compositions at effective amounts, e.g., therapeutically effective amounts.</p><p id="p-0135" num="0161">A &#x201c;CDR grafted antibody&#x201d; is an antibody comprising one or more CDRs derived from an antibody of a particular species or isotype and the framework of another antibody of the same or different species or isotype.</p><p id="p-0136" num="0162">A &#x201c;humanized antibody&#x201d; has a sequence that differs from the sequence of an antibody derived from a non-human species by one or more amino acid substitutions, deletions, and/or additions, such that the humanized antibody is less likely to induce an immune response, and/or induces a less severe immune response, as compared to the non-human species antibody, when it is administered to a human subject. In one embodiment, certain amino acids in the framework and constant regions of the heavy and/or light chains of the non-human species antibody are mutated to produce the humanized antibody. In another embodiment, the constant region(s) from a human antibody are fused to the variable region(s) of a non-human species. In another embodiment, a humanized antibody is a CDR grafted antibody comprising one or more CDRs derived from an antibody of a particular species or isotype and the framework of human antibodies. In another embodiment, one or more amino acid residues in one or more CDR sequences of a non-human antibody are changed to reduce the likely immunogenicity of the non-human antibody when it is administered to a human subject, wherein the changed amino acid residues either are not critical for immunospecific binding of the antibody to its antigen, or the changes to the amino acid sequence that are made are conservative changes, such that the binding of the humanized antibody to the antigen is not significantly worse than the binding of the non-human antibody to the antigen. Examples of how to make humanized antibodies may be found in U.S. Pat. Nos. 6,054,297, 5,886,152 and 5,877,293.</p><p id="p-0137" num="0163">The term &#x201c;chimeric antibody&#x201d; refers to an antibody that contains one or more regions from one antibody and one or more regions from one or more other antibodies. In one embodiment, one or more of the CDRs are derived from a human antibody. In another embodiment, all of the CDRs are derived from a human antibody. In another embodiment, the CDRs from more than one human antibodies are mixed and matched in a chimeric antibody. For instance, a chimeric antibody may comprise a CDR1 from the light chain of a first human antibody, a CDR2 and a CDR3 from the light chain of a second human antibody, and the CDRs from the heavy chain from a third antibody. Other combinations are possible.</p><p id="p-0138" num="0164">The term &#x201c;biparatopic antibody&#x201d; refers to an antibody binds to two non-overlapping epitopes of an antigen. In some embodiments, the biparatopic antibody comprises heavy chain only VHHs without light chain. In some embodiments, the biparatopic antibody comprises both heavy chain only VHHs and conventional VH<sup>1</sup>/VL<sup>1 </sup>pairs. In some embodiments, the biparatopic antibody comprises two conventional VH<sup>1</sup>/VL<sup>1 </sup>pairs. In some embodiments, the biparatopic antibody has a first heavy chain and a first light chain from a monoclonal antibody targeting one epitope, and an additional antibody heavy chain and light chain targeting another epitope. In some embodiments, the additional light chain or heavy chain can be different from the first light or heavy chains.</p><p id="p-0139" num="0165">The binding of an antibody of the disclosed invention to an antigen can be assessed using one or more techniques well established in the art. For example, in a preferred embodiment, an antibody can be tested by ELISA assays, for example using a recombinant antigen protein. Still other suitable binding assays include but are not limited to a flow cytometry assay in which the antibody is reacted with a cell line that expresses the human antigen, such as HEK293 cells. Additionally or alternatively, the binding of the antibody, including the binding kinetics (e.g., K<sub>D </sub>value) can be tested in BIAcore binding assays, Octet Red96 (Pall) and the like.</p><p id="p-0140" num="0166">The term &#x201c;single B-cell sorting&#x201d; refers to the sorting of isolated and separated single B cells based on antigen specificity. Technologies for single-cell separation, isolation, and sorting include but are not limited to: FACS (fluorescent activated cell sorting, e.g. using a fluorescent-tagged antigen to isolate cells that bind the antigen), ISAAC (immunospot array assays on a chip), LCM (laser-capture microdissection), microengraving, and droplet microfluidics.</p><p id="p-0141" num="0167">A method for generating a camelid heavy chain only antibody or binding portion thereof for recognizing an antigen, particularly for therapeutic applications, the method comprises: a) Enriching and amplifying antigen-specific B-cells from immunized Camelidae; b) generating antibody NGS libraries comprising VHH<sup>2</sup>, VHH<sup>3</sup>, and VH<sup>1 </sup>and VL<sup>1 </sup>chain sequences from the antigen-specific B-cells; c) Grouping VHH<sup>2</sup>, VHH<sup>3</sup>, and VH<sup>1 </sup>sequence data as phylogenetic lineage clonotypes based on CDR3&#x2014;for example by grouping together CDR3 amino acid sequences that differ by 0 or 1 amino acids and have the same length; d) ranking lineages comprising the VHH heavy chain (VHH<sup>2</sup>, VHH<sup>3</sup>) by lineage priority factors; e) Selecting a representative sequence from lineages of VHH<sup>2</sup>, VHH<sup>3 </sup>with top rankings in antibody sequence library according to the lineage priority factors; f) Testing an antibody comprising the selected representative sequence to determine if the antibody binds to the antigen or portion thereof. In one embodiment, the antigen comprises a plurality of epitopes.</p><p id="p-0142" num="0168">In one embodiment, sequences from a plurality of lineages can be selected and tested by repeating step f) and g). In one embodiment, f) can include 1) synthesizing DNA of the selected representative sequences, 2) constructing a vector comprising the DNA sequence, 3) expressing the vector in cells, 4) conducting an affinity and bioactivity test against the specific antigen. In one embodiment, b) can include 1) Making cDNA from the enriched population of antigen-specific B cells; 2) Sequencing the cDNA to obtain a plurality of VHH<sup>2</sup>, VHH<sup>3</sup>, VH<sup>1 </sup>heavy chain sequences and a plurality of VL<sup>1 </sup>(V&#x3ba; and V&#x3bb;) light chain sequences to generate a camelid IgG2 (HcAb), IgG3 (HcAb) and IgG1 (conventional Ab) library. In one embodiment, the generated camelid antibody comprises an IgG2. In one embodiment, the generated camelid antibody comprises an IgG3.</p><p id="p-0143" num="0169">Another aspect of the invention lies in a method for generating a camelid antibody or binding portion thereof for recognizing an antigen, particularly for therapeutic applications, the method comprises: a) Enriching and amplifying antigen-specific B-cells from immunized Camelidae; b) generating antibody NGS libraries comprising VHH<sup>2</sup>, VHH<sup>3</sup>, VH<sup>1 </sup>and VL<sup>1 </sup>chain sequences from said antigen-specific B-cells; c) grouping VHH<sup>2</sup>, VHH<sup>3</sup>, VH<sup>1</sup>, and VL<sup>1 </sup>sequence data as phylogenetic lineage clonotypes based on CDR3; d) IgG1 VH<sup>1</sup>/VL<sup>1 </sup>lineage pairing according to an anchor binder generated by single B-cell sorting and heterohybridoma approaches; e) ranking lineages and lineage pairs from step c) and step d) by lineage priority factors; f) selecting a representative sequence from lineages of VHH<sup>2</sup>, VHH<sup>3 </sup>and lineage pairs of VH<sup>1</sup>/VL<sup>1 </sup>with the top ranking in the NGS library; g) testing an antibody comprising the selected VH<sup>1</sup>/VL<sup>1 </sup>pair sequences or sequence of VHH<sup>2</sup>, VHH<sup>3 </sup>to determine if the antibody binds to the antigen or portion thereof. In one embodiment, the VL<sup>1 </sup>chain comprises V&#x3ba; and V&#x3bb;. In one embodiment, the antigen comprises a plurality of epitopes.</p><p id="p-0144" num="0170">In one embodiment, sequences from a plurality of lineages can be selected and tested by repeating step f) and g). In one embodiment, g) can include 1) synthesizing DNA encoding the selected representative amino acid sequences, 2) constructing a vector comprising the DNA sequence, 3) expressing the vector in cells, 4) conducting an affinity and bioactivity test against the specific antigen. In one embodiment, b) can include 1) Making cDNA from the enriched population of antigen-specific B cells; 2) sequencing the cDNA to obtain a plurality of VHH<sup>2</sup>, VHH<sup>3</sup>, VH<sup>1 </sup>heavy chain sequences and a plurality of VL<sup>1 </sup>(V&#x3ba; and V&#x3bb;) light chain sequences to generate a camelid IgG2 (HcAb), IgG3 (HcAb) and IgG1 (conventional Ab) library. In one embodiment, the generated camelid antibody comprises an IgG2. In one embodiment, the generated camelid antibody comprises an IgG3. In one embodiment, the generated camelid antibody comprises a conventional IgG1. In one embodiment, the ranking of lineage pairs in step e) is based on lineage priority factors of VH<sup>1 </sup>lineages of said lineage pairs. In one embodiment, the ranking of lineage pairs in step e) is based on lineage priority factors of VL<sup>1 </sup>lineages of said lineage pairs. The method can further comprise testing to determine if antibody binding to the antigen inhibits binding of the antigen to another protein, e.g. whether antibody binding inhibits a ligand from specifically binding to its cognate receptor.</p><p id="p-0145" num="0171">A method for generating humanized camelid antibodies targeting an antigen comprises a) enriching and proliferating antigen-specific B-cells from immunized camelids, b) generating antibody NGS libraries comprising VH<sup>2</sup>, VHH<sup>3</sup>, and VH<sup>1 </sup>chain sequences from antigen-specific B-cells, c) grouping sequences of VHH<sup>2</sup>, VHH<sup>3</sup>, and VH<sup>1 </sup>in the NGS library by lineages, d) identifying a substitutable position in a parent VHH antibody or VH<sup>1 </sup>sharing the same na&#xef;ve B-cell origin by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same epitope as the parent antibody in the same lineage, e) substituting amino acids at one or more of the substitutable positions of the parental VHH antibody or VH<sup>1 </sup>antibody by correspondingly positioned amino acids in the human antibody; f) testing an antibody comprising the substituted residues within the selected sequences to determine if the antibody binds to the antigen or portion thereof. In one embodiment, the antigen comprises a plurality of epitopes. In one embodiment, the substitutable position is in the CDRs regions. In one embodiment, the substitutable position is in the FRs regions.</p><p id="p-0146" num="0172">A camelid conventional IgG1 antibody generated in this invention can be humanized by substituting amino acids at one or more of the substitutable positions of the parental IgG1 antibody by corresponding positioned amino acids in the human antibody.</p><p id="p-0147" num="0173">An embodiment of the method for camelids immunization and antigen-specific B cells isolation/proliferation is schematically illustrated in <figref idref="DRAWINGS">FIG. <b>2</b></figref>; such embodiment comprises: 1) immunizing Camelidae with DNA or small molecule with carrier protein or peptide with carrier protein or protein or antigen complex such as cells or tissue; 2) monitoring the immune responses of IgG2, IgG3 and IgG1 separately; 3) obtaining a sample of cells which comprise B cells from PBMC, spleen, lymph nodes, lymphatic tissues. B cells are referred to memory cells, plasmablasts and different stages of B-cells which have cell membrane IgG2 (HcAb), IG3 (HcAb) and IgG1 (conventional IgG); 4) enriching antigen-specific B-cells with cell surface antibodies either through physical-surface antigen panning, or magnetic bead isolation or flow sorting; 5) activating the enriched B cells for cells proliferation in the presence of the antigen, camelid CD40-L expression cells and growth factors. The activation step allows one to selectively stimulate memory B-cells to differentiate and become plasma cells, which are rapidly dividing and expressing larger amounts of antibody. In some embodiments, immune responses of IgG2, IgG3 and IgG1 in antisera are monitored by a) purifying IgG2, IgG3 and IgG1 with Protein-A and Protein-G columns at different pH elution conditions; b) analyzing immune response titers of IgG2, 3 and IgG1; or c) testing bioactivities of IgG2, 3 and IgG1 with desired immunoassays.</p><p id="p-0148" num="0174">The activating step of the method, which only proliferate B cells that have surface-tethered antibodies that are actually bound to the antigen, has three effects (1) the activating step causes only those B cells that are specifically bound to the antigen to proliferate, thereby increasing the relative concentration of those cells relative to the cells that are non-specifically bound to the support (2) activating step of the method causes the expression of HcAb or conventional IgG heavy and light chain mRNA to be induced only in the B cells that are specifically bound to the antigen (3) these &#x201c;rare&#x201d; antigen-specific B cells, but express antibodies with high affinity or specificity or recognizing &#x201c;rare&#x201d; epitopes have been amplified to improve signal-to-noise ratio significantly.</p><p id="p-0149" num="0175">In some embodiments, antigens used for enrichment includes, but not limited to:</p><p id="p-0150" num="0176">a) an immunogen;</p><p id="p-0151" num="0177">b) a desired domain/epitopes of immunogen;</p><p id="p-0152" num="0178">c) a Complex Immunogen: an animal may be immunized with multiple antigens or cells or tissue, or biofluid, and antigen-specific B cells for each of a plurality of antigens may be enriched separately from one another or as a whole. The antigen-specific B cells can then be activated and collected separately from one another or as a whole. The simplicity of VHH offers an advantage for high throughput VHH cloning and expression, and it is relatively easier to identify each corresponding antigen of VHH by deconvoluting a complex immunogen. The complex immunogen can be deconvoluted by methods including but not limited to protein array or immunoprecipitation-based mass spectrometry method or cells, tissue antigen-cDNA library screening method.</p><p id="p-0153" num="0179">It might also be desirable to deplete unwanted B cells through panning before antigen-specific panning to improve the purity of the B-cells sometimes.</p><p id="p-0154" num="0180">VHH<sup>2</sup>, VHH<sup>3</sup>, VH<sup>1</sup>, V&#x3ba; and V&#x3bb; NGS libraries can be prepared from B cells expressing IgG2 (HcAb), IgG3 (HcAb) and IgG1 (conventional Ab), respectively.</p><p id="p-0155" num="0181">Camelids' IgG1 (conventional Ab), IgG2 (HcAb) and IG3 (HcAb), each has a unique gene organization which allows ones to design specific primer sets to amplify their cDNAs separately (e.g. as in <figref idref="DRAWINGS">FIG. <b>3</b></figref>). cDNA amplification can be done by steps of:<ul id="ul0007" list-style="none">    <li id="ul0007-0001" num="0000">    <ul id="ul0008" list-style="none">        <li id="ul0008-0001" num="0182">a) total RNA extraction (TRIOL) and purification (RNeasy kit);</li>        <li id="ul0008-0002" num="0183">b) RNA quantification and optional storage at &#x2212;20&#xb0; C.;</li>        <li id="ul0008-0003" num="0184">c) mRNA capture/RT-PCR (VHH<sup>2</sup>, VHH<sup>3</sup>, VH<sup>1</sup>, V&#x3ba; and V&#x3bb;) with isotype-specific primer sets;</li>    </ul>    </li></ul></p><p id="p-0156" num="0185">NGS libraries for VHH<sup>2</sup>, VHH<sup>3</sup>, VH<sup>1</sup>, V&#x3ba; and V&#x3bb; can be prepared, for example, by Nextera Library through PCR adding NGS adapter and Library indexing.</p><p id="p-0157" num="0186">cDNA in NGS libraries can be sequenced by High throughput sequencing of the library, for example using an Illumina MiSeq300x2 instrument.</p><p id="p-0158" num="0187">Sequences can be structured by a bioinformatics process:&#x2014;quality evaluation using NGSQCTookit, assembly R1/R2 reads, translation and then identifying CDR 1, 2, 3.</p><p id="p-0159" num="0188">VHH<sup>2</sup>, VHH<sup>3</sup>, VH<sup>1</sup>, V&#x3ba; and V&#x3bb; antibodies can be grouped using NGS data of, for example, CDR3 amino acid sequences, to construct phylogenetic lineage clonotypes.</p><p id="p-0160" num="0189">A lineage is defined by a group of sequences which are from same na&#xef;ve B cells (the same V and J assignment) and a lineage can be defined as a group with amino acid sequences in their CDR3 region differing by no more than 1 amino acid (hamming distance is 1 or less, or same CDR3 sequence if total amino acids within 5 aa). It is presumed that the amount of lineages reflects the amount of na&#xef;ve B cells in a library, also the number of epitopes that these antibodies recognize. (<figref idref="DRAWINGS">FIG. <b>4</b></figref>).</p><p id="p-0161" num="0190">In general, lineage size correlates with antibody maturation and clonal expansion. Bioinformatic methods allow structure and visualization of the data for a rational approach to candidate antibodies selection. For each NGS library, up to 10,000 of lineages are possible to be identified by sequences structuring through a bioinformatic process comprising: QC using NGSQCTookit, assembly R1/R2 reads, translation, identifying CDRs1, 2, 3 and then lineage grouping based on CDR3 similarity.</p><p id="p-0162" num="0191">VHH (VHH<sup>2</sup>, VHH<sup>3</sup>) sequences can be further grouped (subgrouped) by their unique sequence signatures.</p><p id="p-0163" num="0192">Camelids have evolved multiple mechanisms to further diversify VHH B-cell repertoire and enlarge antigen-binding capability. Sequence &#x201c;signatures&#x201d; arising from these mechanisms allow one to further group lineages. Such additional criteria for further grouping lineages can reflect subtle different recognitions of antibodies and help to identify epitopes with unique VHH recognition patterns. (<figref idref="DRAWINGS">FIG. <b>5</b></figref>) The signatures of VHH include but are not limited to:<ul id="ul0009" list-style="none">    <li id="ul0009-0001" num="0000">    <ul id="ul0010" list-style="none">        <li id="ul0010-0001" num="0193">i) FR2 hydrophilic region: for most VHH antibodies, FR2 has unique amino acids substitutions for conventional IgG: 37Phe/Tyr, 44Glu, 45Arg, and 47Gly;</li>        <li id="ul0010-0002" num="0194">ii) extended CDR1: many VHHs have the extra hypervariable region (residues 27-30, according to Kabat's numbering) next to CDR1. VHH uses this region together with long CDR3 to increase the surface area interacting with antigen;</li>        <li id="ul0010-0003" num="0195">iii) extra disulfide bond between CDR1-CDR3 or FR2-CDR3: in camel and dromedary, 82% VHH have disulfide bond between CDR1-CDR3, and in Lama and Alpaca, 74% VHHs have disulfide bond between FR2-CDR3;</li>        <li id="ul0010-0004" num="0196">iv) long CDR3: for these VHHs with long CDR3 (&#x2265;15aa), extra disulfide bond is found in many cases;</li>        <li id="ul0010-0005" num="0197">v) extra disulfide bond within CDR3: around 5-10% VHH have an extra disulfide bond within CDR3, which may indicate more conformational recognition pattern;</li>        <li id="ul0010-0006" num="0198">vi) Extra disulfide bond within CDR1;</li>        <li id="ul0010-0007" num="0199">vii) non-classic VHH which have the same V and J germlines as conventional IgG: VHH lineage groups which share the same na&#xef;ve B cells origin (same V and J assignment) with the conventional IgG1, which indicates the same or similar epitope recognition by both VHH and IgG1;</li>        <li id="ul0010-0008" num="0200">viii) non-classic VHH which have unique sequence signatures: for example, conserved Trp118 substituted with Arg118 and or lower hydrophobicity profile in FR3;</li>        <li id="ul0010-0009" num="0201">ix) novel canonical binding loop structure: the hypermutation hotspots residing at key-sites to determine the canonical loop structures create an interesting potential to diversify the VHH structural repertoire. Crystallographic studies accentuate that the CDR1 and CDR2 loops of camel VHHs often deviate from the known canonical structures of the conventional VH<sup>1</sup>. Sequence-based novel Ag-binding loop conformation prediction also supports further grouping the lineage;</li>        <li id="ul0010-0010" num="0202">x) CDR2 length</li>        <li id="ul0010-0011" num="0203">xi) CDR3 length</li>        <li id="ul0010-0012" num="0204">xii) presence of 3 or more positive charges in CDR3 region</li>        <li id="ul0010-0013" num="0205">xiii) the number of cysteines in the amino acid sequence</li>        <li id="ul0010-0014" num="0206">xiv) 2-4 amino acid motifs found in CDR regions. The motif is identified from a 3-d structure of a ligand/receptor complex</li>        <li id="ul0010-0015" num="0207">xv) CDR3 length and identity</li>        <li id="ul0010-0016" num="0208">and</li>        <li id="ul0010-0017" num="0209">xvi) convergent motif or sequence signature among camelids in the same immunization group.</li>    </ul>    </li></ul></p><p id="p-0164" num="0210">Humanization of VHHs (VHH<sup>2</sup>, VHH<sup>3</sup>), VH<sup>1</sup>-V&#x3ba; and VH<sup>1</sup>-V&#x3bb; can be guided by lineage analysis.</p><p id="p-0165" num="0211">The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In some embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen and epitope as the parent antibody in the same lineage.</p><p id="p-0166" num="0212">In some embodiments, the amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody.</p><p id="p-0167" num="0213">In humanization methods, or in other antibody engineering methods, the invention finds use in a variety of therapeutic and diagnostic applications.</p><p id="p-0168" num="0214">Bispecific/biparatopic antibodies or antigen-binding fragments can be produced by a variety of methods including fusion of hybridomas or linking of Fab&#x2032; fragments. See, e.g., Songsivilai &#x26; Lachmarm, <i>Clin. Exp. Immunol. </i>79: 315-321 (1990), Kos-telny et al., <i>J. Immunol. </i>148:1547-1553 (1992). In addition, bispecific antibodies can be formed as &#x201c;diabodies&#x201d; or &#x201c;Janusins.&#x201d; A plurality of VHH variable domains can also be connected by linkers to form bivalent and multivalent antibodies.</p><p id="p-0169" num="0215">VH<sup>1 </sup>and VL<sup>1 </sup>(V&#x3ba; or V&#x3bb;) pairing lineages can be identified by considering VH<sup>1</sup>-VL<sup>1 </sup>&#x201c;anchor&#x201d; amino acid sequences found to pair with one another in antibodies secreted by heterohybridomas and/or flow-sorted single B-cells (illustrated in <figref idref="DRAWINGS">FIG. <b>6</b></figref>).</p><p id="p-0170" num="0216">A challenge for camelid conventional IgG1 development with NGS technology is how to identify original, natural H and L pairs. Two approaches to establish anchor H and L (&#x3ba; and &#x3bb;) lineages are typically used; (1) heterohybridoma and (2) single B-cell sorting. After lineage pairs are further grouped with these anchors, representative sequence H/L pairs from each lineage pairs are selected for DNA synthesis, binding screening and bioactive tests as VHH antibodies.</p><p id="p-0171" num="0217">I. Heterohybridoma Method</p><p id="p-0172" num="0218">Isolate lymphocytes from PBMC or spleen or lymph-notes from immunized Camelids; fuse lymphocytes with mouse myeloma fusion partner cell lines such as SP/20 and generate heterohybridomas; screen supernatants of heterohybridomas with ELISA and bioactive assays; sequence VH<sup>1 </sup>and VL<sup>1 </sup>from the selected heterohybridomas; these pairs of VH and VL are used as anchors to pair VH<sup>1 </sup>and VL<sup>1 </sup>lineages from IgG1 NGS library.</p><p id="p-0173" num="0219">II. Single-B-Cell NGS Method</p><p id="p-0174" num="0220">a) Harvest antigen-specific B-cells after panning and proliferation; b) Single B-cell sorting; c) VH-VL<sup>1 </sup>Linkage PCR to amplify amplicons; d) NGS and identify VH<sup>1</sup>-VL<sup>1 </sup>pair sequences (VH<sup>1</sup>-V&#x3ba; or VH<sup>1</sup>-V&#x3bb;) as anchors through bioinformatics.</p><p id="p-0175" num="0221">This method is able to capture the entire antigen-specific B-cell repertoire from an immunization, including HcAb and conventional IgG1 with NGS and takes advantage of the simplicity of HcAb:<ul id="ul0011" list-style="none">    <li id="ul0011-0001" num="0000">    <ul id="ul0012" list-style="none">        <li id="ul0012-0001" num="0222">a) IgG2/HcAb, IgG3/HcAb, IgG1/&#x3ba; and IgG1/&#x3bb;</li>        <li id="ul0012-0002" num="0223">b) Lineages with different CDR3_different epitopes</li>        <li id="ul0012-0003" num="0224">c) VHH lineages with sequence signatures_different epitopes</li>        <li id="ul0012-0004" num="0225">d) VH-V&#x3ba; or VH-V&#x3bb; lineage pairing with VH-VL anchors generated from a heterohybridoma</li>    </ul>    </li></ul></p><p id="p-0176" num="0226">A lineage of antibodies recognizing a broad spectrum of epitopes of the antigen can be selected (illustrated in <figref idref="DRAWINGS">FIG. <b>7</b></figref>).</p><p id="p-0177" num="0227">Each lineage or lineage pair is presumed to recognize one unique epitope, thus one representative sequence (VHH) or one representative pair (VH<sup>1</sup>-VL<sup>1</sup>) from top 100 lineages/lineage-pairs (e.g., 70 sequences for VHHs and 30 sequence pairs for VH-V&#x3ba; and VH<sup>1</sup>-V&#x3bb; are selected for gene synthesis, binder screening and bioactive tests. The lineage selection criteria (priority factors) include but not limited to:<ul id="ul0013" list-style="none">    <li id="ul0013-0001" num="0000">    <ul id="ul0014" list-style="none">        <li id="ul0014-0001" num="0228">1) lineages from high to low sequences abundancy: the total number of unique cDNA counts (the sequence abundancy) from each lineage range from 2 to 50,000, and the lineage with most abundant sequences may indicate the most extensive clonal expansion after antigen stimulation;</li>        <li id="ul0014-0002" num="0229">2) lineage from high to low amplification factor, dynamic change of sequence abundancy before and after B cells enrichment/proliferation (the amplifying fold could range from 5 to 1,000);</li>        <li id="ul0014-0003" num="0230">3) lineages sequences abundancy change during immunization course, which indicates antigen-specific sequences enrichment and antibody affinity maturation (the sequence abundancy/unique cDNA counts change could range from 2 to 1,000);</li>        <li id="ul0014-0004" num="0231">4) lineages sequences abundancy change before and after depleting certain unwanted B cells if applicable (the sequence abundancy/unique cDNA counts change could range from 2 to 1,000);</li>        <li id="ul0014-0005" num="0232">5) lineages which share the same na&#xef;ve B-cell origin (same V and J assignment) between VHH and VH<sup>1</sup>.</li>        <li id="ul0014-0006" num="0233">6) avoidance of developability liability sequences: there are sequences which consist of some amino acids that can cause developability problems such as thermal stability (hydrophobic core, charge cluster residues and others), chemical stability (deamidation and isomerization), solubility (surface hydrophobicity and others) and heterogeneity (glycosylation) (Tomoyuki Igawa et al. mAbs, 2011). Selection of these lineages or lineage pairs should be avoided.</li>    </ul>    </li></ul></p><p id="p-0178" num="0234">The selection criteria can also be a combination of the above priority factors.</p><p id="p-0179" num="0235">The selected lineage sequences or pair is used for DNA synthesis and constructed into expression vectors such as VHH, scFv, Fab, HcAb, Camelidae IgG1 and human Fc chimeric.</p><p id="p-0180" num="0236">In some cases, both selected VHH lineage and selected VH<sup>1</sup>-VL<sup>1 </sup>lineage pair could share the same na&#xef;ve B-cell origin.</p><p id="p-0181" num="0237">In another aspect, more pairs in the same top ranking lineage pairs in the first round of selection (e.g., 70 sequences for VHHs and 30 sequence pairs for VH<sup>1</sup>-V&#x3ba; or VH<sup>1</sup>-V&#x3bb; are selected for gene synthesis, binder screening and bioactive tests because representative sequence pairs from VH<sup>1</sup>-V&#x3ba; or VH<sup>1</sup>-V&#x3bb; need more combinational tests before the optimal pairs are identified.</p><p id="p-0182" num="0238">More sequences and pairs in the next 100 top ranking lineages (e.g., 70 sequences for VHHs and 30 sequence pairs for VH-V&#x3ba; or VH-V&#x3bb; are selected for gene synthesis, binder screening and bioactive tests if the first 100 antibodies don't produce desired results.</p><p id="p-0183" num="0239">The significance of this method is able to systematically and relationally select representative sequences from each lineage for testing to cover board epitopes with high-resolution. This improves antibody discovery in the following contexts:<ul id="ul0015" list-style="none">    <li id="ul0015-0001" num="0000">    <ul id="ul0016" list-style="none">        <li id="ul0016-0001" num="0240">a) therapeutic antibody discovery with a large pool of candidates for the best affinity, specificity and developability;</li>        <li id="ul0016-0002" num="0241">b) companion diagnostic antibody discovery in parallel and other applications;</li>        <li id="ul0016-0003" num="0242">c) bivalent and multivalent antibodies construction and development;</li>        <li id="ul0016-0004" num="0243">d) antibody heavy and light chain pairs discovery;</li>        <li id="ul0016-0005" num="0244">e) antibodies binding to the same epitopes can be identified by lineage-related sequences (illustrated in <figref idref="DRAWINGS">FIG. <b>8</b></figref>).</li>    </ul>    </li></ul></p><p id="p-0184" num="0245">It is well recognized that the CDR3 sequence is the main determinant for binding to an epitope while CDR1 and CDR2 are more or less involved in determining other binding properties. After screening out the leads (e.g. marked by @ and + in <figref idref="DRAWINGS">FIG. <b>8</b></figref>) from each lineage, one can identify more candidates with different characteristics such as affinity, specificity, functionality, productivity and developability to test and select the most desired antibodies since antibodies from the same lineage are supposed to recognize the same or similar epitope. This step also helps to build-up a big candidate pool for further antibody drug development.</p><p id="p-0185" num="0246">There may be around 10-20% VHH and VH<sup>1 </sup>sharing the same na&#xef;ve B-cells origins. The selected sequences of VHH from the first-round selection can help to identify VH<sup>1</sup>s with the same V(D)J arrangement as VHH, and further test their VH-VL pairs for more selections. Selection criteria include:</p><p id="p-0186" num="0247">1) CDR1 and/or CDR2 differences&#x3e;2aa (amino acid)</p><p id="p-0187" num="0248">2) FR1 and/or 2 and/or 3 and/or 4 differences&#x3e;2aa;</p><p id="p-0188" num="0249">3) sequences sharing the same na&#xef;ve B-cell origin between VHH with conventional VH;</p><p id="p-0189" num="0250">4) VH sequences which can pair with both V&#x3bb; and V&#x3ba;;</p><p id="p-0190" num="0251">The selected sequences or pairs are used for DNA synthesis; and constructed into expression vectors such as VHH, scFv, Fab, HcAb, Camelidae IgG1 and human Fc chimeric.</p><p id="p-0191" num="0252">More sequences and pairs can be selected until the best antibody is identified, and the remaining clones kept as a pool of further candidates.</p><p id="p-0192" num="0253">Humanization of VHHs (VHH<sup>2 </sup>and VHH<sup>3</sup>), VH<sup>1</sup>-V&#x3ba; and VH-V&#x3bb; through lineage analysis.</p><p id="p-0193" num="0254">Non-classic VHH genes sharing the same na&#xef;ve cells with conventional VH, which is helpful to (1) subgroup VHH lineages (2) select HcAb and conventional IgG recognizing the same or similar epitopes (3) facilitate humanization for both HcAb and conventional IgG.</p><p id="p-0194" num="0255">VHH domains typically display a high sequence identity with human type 3 VH domains (VH3), likely accounting for their low immunogenicity (Cortez-Retamozo V, Int J Cancer. 98(3):456-62, 2002). In addition, camelids VH<sup>1</sup>, V&#x3bb; and V&#x3ba; domains of conventional antibodies also reveal significant homologous to their human counterparts in both sequence and structure (Alex Klarenbeek, et al., mAbs 7:4, 693-706; 2015). <figref idref="DRAWINGS">FIG. <b>9</b></figref>. As we know, sequences within the same lineage group share the same or similar CDR3 sequence and recognize the same epitope. Through the functional screening, we can identify these amino acids within the variable region including CDRs and FRs, which are substitutable since they constitute the same biological function even these amino acids are different within the lineage. Thus, we can replace these tolerant positions with human germline antibody amino acids and replaceable amino acids can even be within CDR regions for better humanization.</p><p id="p-0195" num="0256">In addition, as mentioned before, these non-classical VHH (without FR2 hydrophilic amino acids) are derived from the same locus of IGHV3 or IGHV4, D and J genes as conventional VH<sup>1</sup>, the lineages structures between VHH and VH<sup>1 </sup>sequences in these groups are similar and can further support humanization design each other through lineage analysis.</p><p id="p-0196" num="0257">Pharmaceutical Formulations</p><p id="p-0197" num="0258">In another aspect, the present invention provides a composition, e.g., a pharmaceutical composition, containing one or a combination of monoclonal antibodies, or antigen-binding portion(s) thereof, of the present invention, formulated together with a pharmaceutically acceptable carrier. Such compositions may include one or a combination of (e.g., two or more different) antibodies, or immunoconjugates or bispecific molecules of the invention. For example, a pharmaceutical composition of the invention can comprise a combination of antibodies (or immunoconjugates or bispecific antibodies) that bind to different epitopes on the target antigen or that have complementary activities.</p><heading id="h-0006" level="1">EXAMPLES</heading><heading id="h-0007" level="1">Example 1: Identification of a Group of VHH Antibodies Specifically Binding to an Antigen Using the B Cell Isolation and Amplification (BIA)/NGS Sequence Analysis and Single B-Cell Methods</heading><p id="p-0198" num="0259">1A. BIA/NGS</p><p id="p-0199" num="0260">Material and Methods</p><p id="p-0200" num="0261">BIA</p><p id="p-0201" num="0262">A1. Construction of CD40L Expression EL4.TL-2-C</p><p id="p-0202" num="0263">Cell line TIB-181(EL4.IL-2) was obtained from the American Type Culture Collection and stably transfected with a pCMV-6-based vector comprising a cDNA encoding human CD40L and that confers expression of human CD40L. A stable cell line was selected and treated with mitomycin as feeder cells.</p><p id="p-0203" num="0264">A2. Alpaca Conditioned Medium</p><p id="p-0204" num="0265">An unimmunized alpaca is sacrificed and the splenocytes are isolated for alpaca conditioned medium preparation. Activation medium containing 10% FBS, phytohemagglutinin (PHA) and phorbol myristate acetate (PMA) is prepared. 4&#xd7;10<sup>8 </sup>splenocytes are suspended in T175 flask in activation medium and incubated at 37&#xb0; C. 5% CO<sub>2 </sub>for 48 h. After incubation, the supernatant is collected and filtered as alpaca conditioned medium.</p><p id="p-0205" num="0266">A3. Animal Immunization</p><p id="p-0206" num="0267">Antigen (for example, 400 g Keyhole Limpet Cyanin (&#x201c;KLH&#x201d;) in 0.5 mL PBS is emulsified with 0.5 mL complete Freund's adjuvant. The emulsified antigen is subcutaneously injected along the neck and the back of an alpaca. Five injections of &#x2dc;200 &#x3bc;L (or less) are performed. Immunizations are performed 3 times in 14 day intervals</p><p id="p-0207" num="0268">A4. Lymphocytes Isolation from Different Organs</p><p id="p-0208" num="0269">For isolation of PBMCs from blood, EDTA-containing blood samples from an immunized alpaca are diluted twofold with 1&#xd7;DPBS containing 2% FBS. Then the diluted blood is slowly put on a Ficoll-Paque PLUS density gradient media for density centrifugation. The upper layer is drawn off and the lymphocyte layer is transferred to a clean centrifuge tube. The PBMCs are then washed twice with 1&#xd7;DPBS.</p><p id="p-0209" num="0270">For lymphocytes isolation from the spleen, the spleen from an immunized alpaca is washed with 1&#xd7;DPBS and put in a clean dish. Balloon the spleen by injecting the medium until most lymphocytes are released. Then use the bottom of a 20 cc syringe to crush the spleen into pieces. Use of a lot of force when crushing helps get the best possible yield of lymphocytes. All of the released cells are collected by gentle centrifugation, e.g. at 1400 rpm. The supernatant is aspirated and then 5&#xd7; the volume of the pellet of Red Cell Lysis Buffer is added and the sample is left to stand for at least 4 min. Then RPMI 1640 medium is added to terminate the lysis. The lymphocytes are then washed twice with 1&#xd7;DPBS.</p><p id="p-0210" num="0271">For lymphocytes isolation from the lymph nodes, mesenteric lymph nodes and inguinal lymph nodes are collected from an immunized alpaca. Lymphocytes are released by grinding the Lymph nodes in RPMI 1640 medium. The cells are passed through a cell mesh and collected by centrifugation. 5&#xd7; the volume of the pellet of Red Cell Lysis Buffer is added to the sample and the sample is allowed to stand for at least 4 min to remove RBC. Then RPMI 1640 is added to terminate the red cell lysis. The lymphocytes are then washed twice with 1&#xd7;DPBS.</p><p id="p-0211" num="0272">For lymphocytes isolation from the bone marrow, the tibia and radius of an immunized alpaca are opened at both ends of the bone and the bone marrow is taken. Cells are released by grinding the bone marrow in RPMI 1640 medium. The cells are passed through a cell mesh and collected by centrifugation. 5&#xd7; the volume of the pellet of Red Cell Lysis Buffer is added and the sample is allowed to stand for at least 4 min to remove RBC. Then RPMI 1640 medium is added to terminate the lysis and the lymphocytes are washed twice with 1&#xd7;DPBS.</p><p id="p-0212" num="0273">A5. Depletion of Nonspecific Cells</p><p id="p-0213" num="0274">The collected cells are resuspended in RPMI1640 medium with 10% FBS, 1% Penicillin-Streptomycin and 0.05 &#x3bc;M 2-Mercaptoethanol to get a 1 M/mL cell suspension. The cells are preincubated for 1 h at 37&#xb0; C., in a 6 well culture plate for non-specific adhesion of macrophage and monocytes to the plate surface. After pre-incubation, unbound cells are collected and counted.</p><p id="p-0214" num="0275">A6. B Cell Panning</p><p id="p-0215" num="0276">The collected cells are resuspended in RPMI1640 medium with 10% FBS, 1% Penicillin-Streptomycin to get a 1 million/mL cell suspension. The cells are incubated for 1.5 h at 37&#xb0; C., at 5 million per 10 cm dish pre-coated with antigen for specific B cell panning. After incubation, the plated cells are washed with RPMI1640 medium for 2-10 times until only a few cell are found in suspension. All of the unbound cells are collected and counted, the count being designated as A1.</p><p id="p-0216" num="0277">A7. B Cell Culture In Vitro</p><p id="p-0217" num="0278">20 mL B cell medium are added into the dish containing B cells retained by the panning. The B cell medium should contain 10% FBS, 1% Penicillin-Streptomycin, 10% alpaca conditioned medium, various growth factors, for example one or more interleukins, at a concentration of 1 to 50 ng/ml and 2.5M MMC pre-treated feeder cells (EL4.IL-2-C3, expressing alpaca CD40L). B cell only and feeder cell only dishes are also cultured as a control in quality control testing. Cells are cultured in 5% CO<sub>2 </sub>for 8-10 days.</p><p id="p-0218" num="0279">A8. Cell Collection and QC</p><p id="p-0219" num="0280">On day 10, 50 &#x3bc;L supernatant from the B cell cultures are used for ELISA to test the antibody secretion. All cells in co-cultured dishes are collected and counted, this count being deemed A2. Cells in feeder cell only dishes are collected and counted, this count being deemed A3. The B cell amplification fold (BCAF), is calculated by the following formula:</p><p id="p-0220" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>BCAF=(<i>A</i>2&#x2212;<i>A</i>3)/(5<i>M&#x2212;A</i>1)<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0221" num="0281">A9. NGS Library Construction</p><p id="p-0222" num="0282">The B cells from each panning were used to prepare template RNA for NGS cDNA library construction. To calculate sequence enrichment, libraries using B cells before panning were also constructed.</p><p id="p-0223" num="0283">i. RNA Isolation</p><p id="p-0224" num="0284">Extract the RNA from co-cultured B cell using TRIzol method.</p><p id="p-0225" num="0285">Cultured B cells are lysed with TRIZOL Reagent by repetitive pipetting or by passing through a syringe and needle. Use 1 ml of the reagent per 0.5-1&#xd7;10<sup>6 </sup>cells. 20% chloroform is added and the tube is agitated for about 15 sec. The aqueous phase is carefully removed using a pipette. An equal volume of isopropanol is added to the aqueous phase and mixed gently. The sample is centrifuged at maximal speed (12,000 rpm) for 10 min. The isopropanol is removed and the pellet is washed with 1 ml 75% ethanol in DEPC treated water and gentle mixing. The pellet is recentrifuged at 7,000 rpm for 1 min. and the RNA is recovered in approximately 70 &#x3bc;l of RNase-free water.</p><p id="p-0226" num="0286">ii. Reverse Transcription</p><p id="p-0227" num="0287">In 0.2 mL PCR mix, different primers (Random 6 mers, Oligo dT and A1.CH2+A1.CH2.2) are respectively used to amplify 8 reactions. The RNA-primer mix is heated at 65&#xb0; C. for 5 minutes, and then incubated on ice for at least 1 minute. RT reaction mix is prepared and the reverse transcription is conducted at: 30&#xb0; C. for 10 min; 42&#xb0; C. for 50 min; 75&#xb0; C. for 15 min.</p><p id="p-0228" num="0288">iii. cDNA Amplification PCR</p><p id="p-0229" num="0289">Approximately 2 &#x3bc;l cDNA from the reverse transcription is used as template in 50 &#x3bc;l PCR reactions containing 25 &#x3bc;l 2&#xd7; Primer star mix, 18 &#x3bc;l RNase Free dH2O, 1 &#x3bc;l each of primers NGS-leader1_L (GCAGTGGCTGCAGGTGTCCACTCG&#x2014;SEQ ID NO. 63), NGS-leader2_L (GCAGGTCCCCAAGGTGTCCTGTCC&#x2014;SEQ ID NO. 64), NGS-leader3_L (GGTGGTCCTGGCTGCTCT&#x2014;SEQ ID NO. 65), NGS-hinge1_L (TTGTGGTTTTGGTGTCTTGGG&#x2014;SEQ ID NO. 66) and NGS-hinge2_L (GGGGTCTTCGCTGTGGTGCGC&#x2014;SEQ ID NO. 67) and cycled as follows: 98&#xb0; C. for 3 min; 20 cycles of (98&#xb0; C. for 15 s, 58&#xb0; C. for 30 s and 72&#xb0; C. for 30 s); 72&#xb0; C. for 3 min. The resulting amplicons are purified using TIANGEN&#xae; PCR purification kits with a &#x2265;300 bp size cutoff according to the manufacturer's instructions.</p><p id="p-0230" num="0290">iv. Index PCR</p><p id="p-0231" num="0291">Each amplicon sample is individually barcoded in a second &#x2018;tagging&#x2019; 50 &#x3bc;l PCR reaction containing 25 &#x3bc;l 2&#xd7; Primer star mix, 18 &#x3bc;l RNase Free dH2O, 1 &#x3bc;l of each primer pair (e.g. P5-seqF and P7-index1-seqR), and 100 ng first-round PCR as template, then cycled as follows: 98&#xb0; C. for 30 s; 12 cycles of (98&#xb0; C. for 10 s, 65&#xb0; C. for 30 s and 72&#xb0; C. for 30 s); 72&#xb0; C. for 5 min. The final three amplicons (derived from three different reverse primers) are pooled and purified from 1.5% (w/v) agarose gels using a TIANGEN&#xae; PCR purification kits.</p><p id="p-0232" num="0292">A10. NGS Data Analysis</p><p id="p-0233" num="0293">Amplified cDNAs are sequenced using a MiSeq Sequencing System (Illumina, Miseq, 300x2). From each sample, 1-3 million reads are generated. Data are quality checked using the NGS QC toolkit and assembled using FLASH. Assembled sequences are translated to protein sequences and CDR1, CDR2, and CDR3 regions (based on IMGT numbering) are identified computationally. Sequences are clustered into lineages/groups as shown in <figref idref="DRAWINGS">FIG. <b>4</b></figref>. based on the same CDR3 length, CDR3 hamming distance smaller or equal to 1 and same mapped V/J germlines. Sequences are further sub-grouped into clusters based on same CDR3 length and CDR3 identity with 80% or more. For example, a lineage can be defined by clones having a CDR3 length of at least 12 amino acids, a CDR3 hamming distance (in comparison to a reference sequence) of 0 or 1, and having identical V/J region amino acid sequences. Enrichment scores for sequences or sequence groups are calculated using ratio of frequencies between libraries constructed from B cells before and after panning.</p><p id="p-0234" num="0294">Representative clones (20 or more) are selected from different lineages based on lineage priority factors as shown in <figref idref="DRAWINGS">FIG. <b>7</b></figref>, and the antibodies they produce are tested in various binding assays like ELISA, FACS etc. Clones selected from different lineages are found to typically bind to different epitopes of the target protein. To optimize existing clones, additional clones can be selected from the same lineage as shown in <figref idref="DRAWINGS">FIG. <b>8</b></figref>. Clones selected from within a lineage are typically shown to bind to different parts of the same epitope</p><p id="p-0235" num="0295">Selection A: Pick Clones with the Highest Count in a Cluster</p><p id="p-0236" num="0296">As shown in the Table 1 below, Cluster C328 has 357 fold increase in frequency after enrichment. The top count clone in the cluster, NBL505-A1L1-P3R3_355, is a good choice to select for further tests.</p><p id="p-0237" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="13"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="21pt" align="center"/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="28pt" align="center"/><colspec colname="7" colwidth="28pt" align="center"/><colspec colname="8" colwidth="35pt" align="center"/><colspec colname="9" colwidth="49pt" align="center"/><colspec colname="10" colwidth="35pt" align="center"/><colspec colname="11" colwidth="49pt" align="center"/><colspec colname="12" colwidth="35pt" align="center"/><colspec colname="13" colwidth="28pt" align="center"/><thead><row><entry namest="1" nameend="13" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="13" align="center" rowsep="1"/></row><row><entry/><entry/><entry>NBL505-</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry>A1L1-</entry><entry/><entry>4</entry><entry>0.10411</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry>1430</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="10"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="21pt" align="center"/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="28pt" align="center"/><colspec colname="7" colwidth="28pt" align="center"/><colspec colname="8" colwidth="35pt" align="center"/><colspec colname="9" colwidth="168pt" align="center"/><colspec colname="10" colwidth="28pt" align="center"/><tbody valign="top"><row><entry>C328</entry><entry>NBL505</entry><entry>P3R3</entry><entry>1</entry><entry>Fre-</entry><entry>Mis-</entry><entry>1433</entry><entry>1.42367</entry><entry>9.3 AREWYPVGNEPDY</entry><entry>Cdr3</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="13"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="21pt" align="center"/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="28pt" align="center"/><colspec colname="7" colwidth="28pt" align="center"/><colspec colname="8" colwidth="35pt" align="center"/><colspec colname="9" colwidth="49pt" align="center"/><colspec colname="10" colwidth="35pt" align="center"/><colspec colname="11" colwidth="49pt" align="center"/><colspec colname="12" colwidth="35pt" align="center"/><colspec colname="13" colwidth="28pt" align="center"/><tbody valign="top"><row><entry>Name</entry><entry>Project</entry><entry>Lineage</entry><entry>Count</entry><entry>quency</entry><entry>matches</entry><entry>Gaps</entry><entry>Classical</entry><entry>V gene</entry><entry>J gene</entry><entry>Screened clones</entry><entry>Cysteines</entry><entry>length</entry></row><row><entry namest="1" nameend="13" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="13"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="21pt" align="char" char="."/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="28pt" align="char" char="."/><colspec colname="7" colwidth="28pt" align="center"/><colspec colname="8" colwidth="35pt" align="center"/><colspec colname="9" colwidth="49pt" align="center"/><colspec colname="10" colwidth="35pt" align="center"/><colspec colname="11" colwidth="49pt" align="center"/><colspec colname="12" colwidth="35pt" align="center"/><colspec colname="13" colwidth="28pt" align="center"/><tbody valign="top"><row><entry>NBL505-</entry><entry>NBL505</entry><entry>L58</entry><entry>1426</entry><entry>1.41672</entry><entry>10</entry><entry>0</entry><entry>No</entry><entry>IGHV3S30*01</entry><entry>IGHJ4*01</entry><entry/><entry>2</entry><entry>13</entry></row><row><entry>A1L1-</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>P3R3_355</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>NBL505-</entry><entry>NBL505</entry><entry>L58</entry><entry>3</entry><entry>0.00298</entry><entry>9</entry><entry>0</entry><entry>No</entry><entry>IGHV3S30*01</entry><entry>IGHJ4*01</entry><entry/><entry>2</entry><entry>13</entry></row><row><entry>A1L1-</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>P3R3_22351</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>NBL505-</entry><entry>NBL505</entry><entry>L58</entry><entry>2</entry><entry>0.00199</entry><entry>9</entry><entry>0</entry><entry>No</entry><entry>IGHV3S30*01</entry><entry>IGHJ4*01</entry><entry/><entry>2</entry><entry>13</entry></row><row><entry>A1L1-</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>P3R3_54461</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>NBL505-</entry><entry>NBL505</entry><entry>L58</entry><entry>2</entry><entry>0.00199</entry><entry>9</entry><entry>0</entry><entry>No</entry><entry>IGHV3S30*01</entry><entry>IGHJ4*01</entry><entry/><entry>2</entry><entry>13</entry></row><row><entry>A1L1-</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>P3R3_14372</entry></row><row><entry namest="1" nameend="13" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0238" num="0297">Selection B: Pick Clones with Highest Enrichment Score.</p><p id="p-0239" num="0298">By comparing sequences in libraries before and after enrichment (e.g. by panning or flow-sorting), an enrichment score can be calculated based on sequence frequency before and after enrichment. To increase the chance of picking clones secreting functional VHHs, the enrichment score can be used to prioritize clone picking. In Table 2 below, clone NBL505-A1L2-P3R2_5559 is selected based on the Fold Enrichment.</p><p id="p-0240" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="266pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 2</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Sequence Enrichment In C473(NBL505-A1L2-P3R2)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="21pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="49pt" align="center"/><colspec colname="7" colwidth="42pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry>Screened</entry><entry/><entry>C258(NBL505-</entry><entry>Fold</entry></row><row><entry>Name</entry><entry>Count</entry><entry>Frequency</entry><entry>Clones</entry><entry>Picked?</entry><entry>A1L2)</entry><entry>Enrichment</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="21pt" align="center"/><colspec colname="3" colwidth="42pt" align="char" char="."/><colspec colname="4" colwidth="35pt" align="left"/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="49pt" align="center"/><colspec colname="7" colwidth="42pt" align="center"/><tbody valign="top"><row><entry>NBL505-A1L2-</entry><entry>14</entry><entry>0.0041</entry><entry/><entry>No</entry><entry>0.02222</entry><entry>0.185</entry></row><row><entry>P3R2_13391</entry><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>NBL505-A1L2-</entry><entry>42</entry><entry>0.01229</entry><entry/><entry>Yes</entry><entry>0.00379</entry><entry>3.243</entry></row><row><entry>P3R2_5559</entry><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0241" num="0299">1B. Single B Cell</p><p id="p-0242" num="0300">B1. Sorting of Ag Specific Single B Cell from Immunized Alpaca PBMC</p><p id="p-0243" num="0301">Peripheral Blood Mononuclear Cells (PBMCs) are obtained from an immunized alpaca by Ficoll density gradient centrifugation (GE) and split into tubes containing 200&#xd7;10<sup>6 </sup>cells for immunostaining. The cells are incubated with 200 &#x3bc;L KLH-biotin diluted to 5 &#x3bc;g/mL in MACS buffer (PBS plus 2% FBS plus 2 mM EDTA) for 30 min at 4&#xb0; C. and then washed twice with 5 ml ice-cold MACS buffer. Then the cells are stained with rabbit anti-llama IgG (H&#x26;L), APC-Streptavidin and live/dead dye. Stained samples were then collected on an Moflo Cell Sorter Cytometer (Beckman) and single IgG+ KLH+ Live+ cells were collected in individual PCR tubes containing 10 &#x3bc;L buffer containing 8 uL lysis buffer (Tiandz), 1 mM dNTP (Takara), 3.75 &#x3bc;M Random 6 mers (Takara) and 1.25 &#x3bc;M Oligo dT primer (Takara) per well.</p><p id="p-0244" num="0302">B2. Single Cell RT-PCR and B Cell Cloning</p><p id="p-0245" num="0303">The collected antigen specific alpaca B cells are lysed in the collection tubes, followed by heating to 65&#xb0; C. for 5 min. After cooling to 4&#xb0; C., total RNA from the lysed single cell is reverse transcribed in a final volume of 20 &#x3bc;L of 4 &#x3bc;L 5&#xd7; PrimeScript II Buffer (Takara), 20 U RNase Inhibitor (Takara), 200 U PrimeScript II RTase (Takara) and 4.5 uL RNase Free water (Takara) for 50 min at 42&#xb0; C., after an initial step of 10 min at 30&#xb0; C. allowing random hexamers hybridization. The reaction is stopped by incubation for 15 min at 72&#xb0; C.</p><p id="p-0246" num="0304">Variable regions of the rearranged heavy chain (HC) locus, lambda (LC&#x3bb;) or kappa (LC&#x3ba;) light chain loci are next amplified separately from each single cell cDNA by two rounds of nested PCR. For each variable segment, the first round of PCR is performed on 3 &#x3bc;L of cDNA at 98&#xb0; C. for 5 min, 98&#xb0; C. for 15 s, 55&#xb0; C. for 1 min for HC (62&#xb0; C. for LC&#x3ba; and 58&#xb0; C. for LC&#x3bb;) and 1 min at 72&#xb0; C. for 40 cycles followed by a final elongation step at 72&#xb0; C. for 7 min in 2&#xd7; PrimeStar MAX Buffer (Takara) and 100 nM of primers in a 40- &#x3bc;L reaction volume. 4 &#x3bc;L of the first amplification products were further amplified by a second round of PCR. The second round of PCR protocol consists of a denaturation step at 98&#xb0; C. for 5 min and then 40 amplification cycles (30 s at 98&#xb0; C., 30 s at 58&#xb0; C. for HC, 62&#xb0; C. for LC&#x3ba;, 58&#xb0; C. for LC&#x3bb;, and 1 min at 72&#xb0; C.) and a final step at 72&#xb0; C. for 7 min with 2&#xd7; PrimeStar MAX Buffer (Takara) and 100 nM of primers in a 50-&#x3bc;L reaction volume. PCR products from each single cell are detected on a 1.5% agarose GelRed gel. PCR products from each well were purified by filtration through a commercially available purification kit (Tiangen).</p><p id="p-0247" num="0305">Ligation is performed in a total volume of 20 &#x3bc;L with 10 uL of Genbuilder plus cloning-Ligase (Genscript), 100 ng of digested and purified PCR product and 100 ng of linearized vector. Electrocompetent <i>E. coli </i>TOP10 bacteria are transformed with 20 &#x3bc;l of the ligation products. Colonies are screened by PCR using PET-SEQ-F (TGCTGGTCTGCTGCTCCTCGC&#x2014;SEQ ID NO. 68) as the forward primer and PET-SEQ-R as the reverse primer (ACCGTCTATCAGGGCGATGG&#x2014;SEQ ID NO. 69), respectively. The expected insert band is approximately 700 bp in length. To ensure a consensus variable gene sequence is identified, for each plate, plasmid DNAs from ten colonies are isolated and sequenced.</p><p id="p-0248" num="0306">Using the single B cell sorting method described above and purified Epidermal Growth Factor Receptor as an antigen, a group of 11 clones was identified that each express a VHH antibody that specifically binds to EGFR with high affinity. See, <figref idref="DRAWINGS">FIG. <b>10</b></figref>.</p><p id="p-0249" num="0307">Using the panning B cell enrichment method described above and mesothelin (MSLN) as an antigen, a set of clones were picked from NGS data with lineage and CDR3 length and identity grouping methods. Among the clones of 12 sequences most abundant in the library, 7 clones were shown to be potent MSLN binders. (See Table 3, below.) Importantly, MSLN is composed of three domains; and antibodies of 5 of the MSLN binding clones specifically bind to an epitope in domain 1 of MSLN. In addition, the antibody of one of the picked clones specifically binds to domain 2 and the antibody of one of the clones specifically binds only to domain 3. Therefore, with a single effort of lineage grouping and picking, one can identify clones recognizing a broad spectrum of epitopes of a full length antigen. This will provide more opportunity to pick clones in the treatment of different condition for antigen binding, or give more options for bispecific combinations. Furthermore, this method can also identify clones which are shown to behave either as a blocker or nonblocker for the antigen-ligand complex. For example, among the 7 MSLN binding clones, antibodies from 2 clones are identified which bind to either domain 2 or 3 of MSLN but do not inhibit CA125 binding to MSLN. In contrast, the 5 domain 1 epitope binders are shown to prevent CA125 binding to MSLN. The present disclosed methods are efficiently able to systematically and relationally select antibodies for testing to cover a broad range of epitopes with high-resolution.</p><p id="p-0250" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="266pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 3</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Selected MSLN-binding clones</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="63pt" align="center"/><colspec colname="2" colwidth="21pt" align="center"/><colspec colname="3" colwidth="119pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="35pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>MSLN ELISA Binding </entry><entry>Com-</entry><entry/></row><row><entry/><entry/><entry>(supernatant)</entry><entry>petition</entry><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="63pt" align="center"/><colspec colname="2" colwidth="21pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="49pt" align="center"/><colspec colname="6" colwidth="28pt" align="center"/><colspec colname="7" colwidth="35pt" align="center"/><tbody valign="top"><row><entry/><entry>full </entry><entry>epitope</entry><entry>epitope</entry><entry>epitope</entry><entry>with</entry><entry/></row><row><entry>clones</entry><entry>length</entry><entry>domain 1</entry><entry>domain 2</entry><entry>domain 3</entry><entry>CA125</entry><entry>Notes</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row><row><entry>NBL501#001</entry><entry>Y</entry><entry>N</entry><entry>N</entry><entry>Y</entry><entry>N</entry><entry>domain 3</entry></row><row><entry>(SEQ ID NO. 1)</entry><entry/><entry/><entry/><entry/><entry/><entry>binders</entry></row><row><entry>NBL501#002(SEQ</entry><entry>Y</entry><entry>Y</entry><entry>N</entry><entry>N</entry><entry>Y</entry><entry>domain 1 </entry></row><row><entry>ID NO. 2)</entry><entry/><entry/><entry/><entry/><entry/><entry>binders</entry></row><row><entry>NBL501#003</entry><entry>N</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry>(SEQ ID NO. 3)</entry><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>NBL501#004(SEQ</entry><entry>Y</entry><entry>Y</entry><entry>N</entry><entry>N</entry><entry>Y</entry><entry>domain 1 </entry></row><row><entry>ID NO. 4)</entry><entry/><entry/><entry/><entry/><entry/><entry>binders</entry></row><row><entry>NBL501#005</entry><entry>Y</entry><entry>Y</entry><entry>N</entry><entry>N</entry><entry>Y</entry><entry>domain 1 </entry></row><row><entry>(SEQ ID NO. 5)</entry><entry/><entry/><entry/><entry/><entry/><entry>binders</entry></row><row><entry>NBL501#006</entry><entry>N</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry>(SEQ ID NO. 6)</entry><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>NBL501#007(SEQ</entry><entry>N</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry>ID NO. 7)</entry><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>NBL501#008</entry><entry>Y</entry><entry>Y</entry><entry>N</entry><entry>N</entry><entry>Y</entry><entry>domain 1 </entry></row><row><entry>(SEQ ID NO. 8)</entry><entry/><entry/><entry/><entry/><entry/><entry>binders</entry></row><row><entry>NBL501#009(SEQ</entry><entry>Y</entry><entry>N</entry><entry>Y</entry><entry>N</entry><entry>N</entry><entry>domain 2 </entry></row><row><entry>ID NO. 9)</entry><entry/><entry/><entry/><entry/><entry/><entry>binders</entry></row><row><entry>NBL501#010</entry><entry>N</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry>(SEQ ID NO. 10)</entry><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>NBL501#011</entry><entry>N</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry>(SEQIDNO. 11)</entry><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>NBL501#012</entry><entry>Y</entry><entry>Y</entry><entry>N</entry><entry>N</entry><entry>Y</entry><entry>domain 1 </entry></row><row><entry>(SEQ ID NO. 12)</entry><entry/><entry/><entry/><entry/><entry/><entry>binders</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0251" num="0308">In a further instance of identification of clones producing antigen-specific antibodies, clones producing anti-KLH antibodies were found by the following procedure.</p><p id="p-0252" num="0309">Antigen-specific B-cell isolation. In this further experiment, one alpaca named #009 is immunized with commercially available KLH (Keyhole Limpet Hemocyanin) in a standard immunization regime with 200 &#x3bc;g KLH in Complete Freud's adjuvant once, and then 100 &#x3bc;g KLH (sigma) in incomplete Freud's adjuvant every 2 weeks (Sigma). After evaluation of the antisera by ELISA of serial diluted samples, 100-200 mL blood is drawn for isolation of peripheral blood mononuclear cells (PBMC) using a Ficoll-Paque density gradient technique (GE) according to the instructions from the manufacturer. The isolated PBMCs (viability&#x3e;95%) are resuspended in complete RPMI1640 media to get a 10<sup>6</sup>/mL cell suspension. 4 mL of the PBMC suspension is added to each well of a 6-well plate and incubated for 1 hour to trap nonspecific binding cells. Then the unbound cells are collected and resuspended to 10<sup>6</sup>/mL in complete RPMI1640 media. 5 mL of the cell suspension are added to a 10 cm high-binding petri dish (protein binding capacity&#x3e;500 ng/cm<sup>2</sup>) pre-coated with antigen for 1.5 hour with gentle shaking at 50 rpm, 37&#xb0; C. After incubation, unbound cells are washed away with 1&#xd7;DPBS for 2-10 times to remove nonspecific binding cells. Mitomycin treated EL4.IL-2-C3 feeder cells (stably expressing alpaca CD40L) resuspended in B cell medium are added to the dish at 0.5&#xd7;10<sup>6 </sup>cells/mL for B cell in vitro co-culture. The final volume is 20 mL in each 10 cm dish. The B cell co-culture medium contains 10% FBS (fetal bovine serum), 1% Penicillin-Streptomycin, 10% alpaca conditioned media from cultures of alpaca blank PBMCs, and various growth factors, for example one or more interleukins, at a concentration of from 1 to 50 ng/ml.</p><p id="p-0253" num="0310">After 10 days' co-culture, 50 &#x3bc;L supernatant are used for ELISA to test the antibody secretion and specificity of binding to the KLH immunogen. Meanwhile, co-cultured cells are collected and counted for total cell number. B cell amplification after B-cell isolation and amplification is calculated by total cell number minus that of feeder cell control. To compare this enriched cell number with the initial cell amount added, we can calculate the amplification of antigen specific B cells. As shown in <figref idref="DRAWINGS">FIG. <b>11</b></figref>, B-cells from 5 different co-culture dishes showed consistent antigen-specific VHH antibody secretion. The antigen specific B cells in PBMC were amplified 4- to 6-fold after B-cell isolation and amplification (BIA).</p><p id="p-0254" num="0311">After BIA, three NGS libraries are constructed using mRNA of co-cultured cells. Oligo-dT, Random hexamer and CH2-specific primers are used in reverse transcription, respectively. (Maass D R, Sepulveda J, Pernthaner A, Shoemaker C B. Alpaca (<i>Lama pacos</i>) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J Immunol Methods. 2007; 324(1-2):13-25.) These cDNA are then subjected to two rounds of PCR reactions. All these three libraries were sent to Genscript, Nanjing, China for sequencing on a MiSeq Sequencing System (Illumina, Miseq, 300x2) using a 30% PhiX genomic DNA spike in 4-5 million reads were generated for each sample. Data are quality checked with NGS QC Toolkit and assembled using FLASH. Sequences are clustered into lineages/groups as shown in <figref idref="DRAWINGS">FIG. <b>4</b></figref>, based on same CDR3 length, CDR3 hamming distance smaller or equal to 1 and same mapped V/J germlines. Sequences are further sub-grouped into clusters based on same CDR3 length and CDR3 identity with 80% or more. Over 800 groups were generated for each library. Several lineage priority factors are applied here to select clones from these groups: sequence abundance, classical VHH vs non classical VHH and CDR3 length. 20 clones are selected from 20 different groups and they are synthesized, expressed, and purified. The bioinformatic data relating to the picked clones are presented in Tables 4 through 6 below. The complete amino acid sequence of the antibody expressed by each of the picked clones is given as contiguous sequences of each domain (FR1, CDR1, etc.)</p><p id="p-0255" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="399pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 4</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Bioinformatic data of selected anti-KLH VHH clones</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="11"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="28pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><colspec colname="6" colwidth="42pt" align="center"/><colspec colname="7" colwidth="49pt" align="center"/><colspec colname="8" colwidth="35pt" align="center"/><colspec colname="9" colwidth="21pt" align="center"/><colspec colname="10" colwidth="35pt" align="center"/><colspec colname="11" colwidth="28pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>Expression</entry><entry>Cys</entry></row><row><entry>No</entry><entry>Name</entry><entry>Cluster</entry><entry>Count</entry><entry>Frequency</entry><entry>Mismatches</entry><entry>V gene</entry><entry>1 gene</entry><entry>Hinge</entry><entry>(mg/mL)</entry><entry>residues</entry></row><row><entry namest="1" nameend="11" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="11"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="28pt" align="center"/><colspec colname="4" colwidth="28pt" align="char" char="."/><colspec colname="5" colwidth="42pt" align="char" char="."/><colspec colname="6" colwidth="42pt" align="char" char="."/><colspec colname="7" colwidth="49pt" align="center"/><colspec colname="8" colwidth="35pt" align="center"/><colspec colname="9" colwidth="21pt" align="center"/><colspec colname="10" colwidth="35pt" align="char" char="."/><colspec colname="11" colwidth="28pt" align="char" char="."/><tbody valign="top"><row><entry>1-</entry><entry>NGS602-</entry><entry>C28</entry><entry>122359</entry><entry>4.44872</entry><entry>8</entry><entry>IGHV3S57*01</entry><entry>IGHJ4*01</entry><entry>L</entry><entry>256.7</entry><entry>2</entry></row><row><entry>SEQ ID NO. 43</entry><entry>OLIGO_30</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>2-</entry><entry>NGS602-</entry><entry>C15</entry><entry>76621</entry><entry>2.78578</entry><entry>13</entry><entry>IGHV3-3*01</entry><entry>IGHJ4*01</entry><entry>L</entry><entry>213.4</entry><entry>2</entry></row><row><entry>SEQ ID NO. 44</entry><entry>OLIGO_152</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>3-</entry><entry>NGS602-</entry><entry>C43</entry><entry>65893</entry><entry>2.39573</entry><entry>11</entry><entry>IGHV3-3*01</entry><entry>IGHJ4*01</entry><entry>L</entry><entry>200</entry><entry>2</entry></row><row><entry>SEQ ID NO. 45</entry><entry>OLIGO_185</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>4-</entry><entry>NGS602-</entry><entry>C329</entry><entry>61590</entry><entry>2.23928</entry><entry>6</entry><entry>IGHV3-3*01</entry><entry>IGHJ6*01</entry><entry>L</entry><entry>190</entry><entry>2</entry></row><row><entry>SEQ ID NO. 46</entry><entry>OLIGO_186</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>5-</entry><entry>NGS602-</entry><entry>C104</entry><entry>57830</entry><entry>2.10258</entry><entry>15</entry><entry>IGHV3S53*01</entry><entry>1GHJ4*01</entry><entry>L</entry><entry>113.4</entry><entry>2</entry></row><row><entry>SEQ ID NO. 47</entry><entry>OLIGO_205</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>6-</entry><entry>NGS602-</entry><entry>C196</entry><entry>51491</entry><entry>1.87211</entry><entry>10</entry><entry>IGHV3-3*01</entry><entry>IGHJ4*01</entry><entry>L</entry><entry>213.4</entry><entry>2</entry></row><row><entry>SEQ ID NO. 48</entry><entry>OLIGO_50</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>7-</entry><entry>NGS602-</entry><entry>C43</entry><entry>50104</entry><entry>1.82168</entry><entry>12</entry><entry>IGHV3-3*01</entry><entry>IGHJ4*01</entry><entry>L</entry><entry>210</entry><entry>2</entry></row><row><entry>SEQ ID NO. 49</entry><entry>OLIGO_12</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>8-</entry><entry>NGS602-</entry><entry>C35</entry><entry>47677</entry><entry>1.73344</entry><entry>15</entry><entry>IGHV3-3*01</entry><entry>IGHJ4*01</entry><entry>L</entry><entry>203.4</entry><entry>2</entry></row><row><entry>SEQ ID NO. 50</entry><entry>OLIGO_55</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>9-</entry><entry>NGS602-</entry><entry>C189</entry><entry>45548</entry><entry>1.65603</entry><entry>5</entry><entry>IGHV3-3*01</entry><entry>IGHJ4*01</entry><entry>L</entry><entry>106.7</entry><entry>2</entry></row><row><entry>SEQ ID NO. 51</entry><entry>OLIGO_221</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>10-</entry><entry>NGS602-</entry><entry>C71</entry><entry>45395</entry><entry>1.65047</entry><entry>13</entry><entry>IGHV3S9*01</entry><entry>IGHJ4*01</entry><entry>L</entry><entry>223.4</entry><entry>2</entry></row><row><entry>SEQ ID NO. 52</entry><entry>OLIGO_151</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>11-</entry><entry>NGS602-</entry><entry>C137</entry><entry>44920</entry><entry>1.6332</entry><entry>10</entry><entry>IGHV3-3*01</entry><entry>IGHJ4*01</entry><entry>L</entry><entry>253.4</entry><entry>2</entry></row><row><entry>SEQ ID NO. 53</entry><entry>OLIGO_35</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>12-</entry><entry>NGS602-</entry><entry>C27</entry><entry>33302</entry><entry>1.21079</entry><entry>6</entry><entry>IGHV3-3*01</entry><entry>IGHJ4*01</entry><entry>L</entry><entry>90</entry><entry>2</entry></row><row><entry>SEQ ID NO. 54</entry><entry>OLIGO_28</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>13-</entry><entry>NGS602-</entry><entry>C5</entry><entry>31565</entry><entry>1.14764</entry><entry>13</entry><entry>IGHV3-3*01</entry><entry>IGHJ4*01</entry><entry>L</entry><entry>140</entry><entry>2</entry></row><row><entry>SEQ ID NO. 55</entry><entry>OLIGO_72</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>14-</entry><entry>NGS602-</entry><entry>C170</entry><entry>30695</entry><entry>1.11601</entry><entry>8</entry><entry>IGHV3S53*01</entry><entry>IGHJ7*01</entry><entry>L</entry><entry>120</entry><entry>2</entry></row><row><entry>SEQ ID NO. 56</entry><entry>OLIGO_2</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>15-</entry><entry>NGS602-</entry><entry>C176</entry><entry>27772</entry><entry>1.00973</entry><entry>9</entry><entry>IGHV3-3*01</entry><entry>IGHJ4*01</entry><entry>L</entry><entry>273.4</entry><entry>2</entry></row><row><entry>SEQ ID NO. 57</entry><entry>OLIGO_42</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>16-</entry><entry>NGS602-</entry><entry>C175</entry><entry>24345</entry><entry>0.88513</entry><entry>11</entry><entry>IGHV3-3*01</entry><entry>IGHJ4*01</entry><entry>L</entry><entry>203.4</entry><entry>2</entry></row><row><entry>SEQ ID NO. 58</entry><entry>OLIGO_31</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>17-</entry><entry>NGS602-</entry><entry>C226</entry><entry>23772</entry><entry>0.8643</entry><entry>11</entry><entry>IGHV3S53*01</entry><entry>IGHJ7*01</entry><entry>S</entry><entry>113.4</entry><entry>2</entry></row><row><entry>SEQ ID NO. 59</entry><entry>OLIGO_359</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>18-</entry><entry>NGS602-</entry><entry>C70</entry><entry>23543</entry><entry>0.85597</entry><entry>8</entry><entry>IGHV3-3*01</entry><entry>IGHJ4*01</entry><entry>L</entry><entry>243.4</entry><entry>4</entry></row><row><entry>SEQ ID NO. 60</entry><entry>OLIGO_149</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>19-</entry><entry>NGS602-</entry><entry>C102</entry><entry>22956</entry><entry>0.83463</entry><entry>7</entry><entry>IGHV3S58*01,</entry><entry>1GHJ6*01</entry><entry>L</entry><entry>276.7</entry><entry>2</entry></row><row><entry>SEQIDNO.61</entry><entry>OLIGO_266</entry><entry/><entry/><entry/><entry/><entry>IGHV3-3*01</entry><entry/><entry/><entry/><entry/></row><row><entry>20-</entry><entry>NGS602-</entry><entry>C132</entry><entry>21287</entry><entry>0.77395</entry><entry>11</entry><entry>IGHV3S58*01</entry><entry>IGHJ4*01</entry><entry>L</entry><entry>220</entry><entry>2</entry></row><row><entry>SEQ ID NO. 62</entry><entry>OLIGO_169</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry namest="1" nameend="11" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0256" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="378pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;5</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Bioinformatic&#x2003;data&#x2003;of&#x2003;selected&#x2003;anti-KLH&#x2003;clones&#x2003;(cont'd)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="112pt" align="left"/><colspec colname="4" colwidth="42pt" align="left"/><colspec colname="5" colwidth="77pt" align="left"/><colspec colname="6" colwidth="42pt" align="left"/><tbody valign="top"><row><entry>No-SEQ&#x2003;ID&#x2003;NO.</entry><entry>Name</entry><entry>Fr1</entry><entry>CDR1</entry><entry>Fr2</entry><entry>CDR2</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row><row><entry>1-</entry><entry>NGS602-</entry><entry>QVQLVESGGGTVQAGGSLRLSCAAS</entry><entry>GLTFGSYA</entry><entry>MEWYRQAPGKERELVAT</entry><entry>ISSGGNT</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;43</entry><entry>OLIGO_30</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>2-</entry><entry>NGS602-</entry><entry>QVQLVESGGGLVQAGDSLRLSCAAS</entry><entry>GDNFSRYT</entry><entry>FGWFRQAPGKEREFVAV</entry><entry>INWSGSYT</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;44</entry><entry>OLIGO_152</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>3-</entry><entry>NGS602-</entry><entry>QVQLVESGGGLVQAGGSLRLSCAAS</entry><entry>GRTSSRYV</entry><entry>MGWFRQSPGKEREFVAA</entry><entry>ISANGRST</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;45</entry><entry>OLIGO_185</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>4-</entry><entry>NGS602-</entry><entry>QVQLAESGGGLVQAGDSLRLSCAAS</entry><entry>GRSVSSYA</entry><entry>MGWFRQAPGKEREFVAA</entry><entry>ISWSGEST</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;46</entry><entry>OLIGO_186</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>5-</entry><entry>NGS602-</entry><entry>RVQLVESGGGLVQPGGSLRLSCTAS</entry><entry>GLPLNTAA</entry><entry>MSWYRQTPGKERELVAS</entry><entry>ISITGDST</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;47</entry><entry>OLIGO_205</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>6-</entry><entry>NGS602-</entry><entry>QVQLVESGGGLVQVGGSLRLSCVAS</entry><entry>GLTFSNYA</entry><entry>MGWFRQAPGKEREFVTA</entry><entry>INWSGAIK</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;48</entry><entry>OLIGO_50</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>7-</entry><entry>NGS602-</entry><entry>QVQLVESGGGSVQAGGSLRLSCAAS</entry><entry>GRTFGRHV</entry><entry>MAWFRQAPGREREFVAA</entry><entry>ISGNGRVT</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;49</entry><entry>OLIGO_12</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>8-</entry><entry>NGS602-</entry><entry>QVQLTESGGGLVQAGASLRLSCVAS</entry><entry>PDTPSTYT</entry><entry>IAWFRRAPGKERDFVAN</entry><entry>IARAGTTI</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;50</entry><entry>OLIGO_55</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>9-</entry><entry>NGS602-</entry><entry>QVQLVESGGGLVQAGESLRLSCVAS</entry><entry>GRTFSSYA</entry><entry>MGWFRQAPGQEREFVAR</entry><entry>ISRRGTNT</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;51</entry><entry>OLIGO_221</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>10-</entry><entry>NGS602-</entry><entry>EVQLVESGGGLVQPGGSLRLSCTAS</entry><entry>GFTLSTSP</entry><entry>VSWARQAPGKGPEWLAG</entry><entry>IYSDGRT</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;52</entry><entry>OLIGO_151</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>11-</entry><entry>NGS602-</entry><entry>QVSLVESGGGLVQAGGSLRLSCAAS</entry><entry>GRTFRRSA</entry><entry>MGWFRRPPGKEREFVAA</entry><entry>ITSSGGSI</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;53</entry><entry>OLIGO_35</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>12-</entry><entry>NGS602-</entry><entry>QVQLVESGGGLVRAGGSLRLSCAAS</entry><entry>GRAFSSYP</entry><entry>MGWFRRAPGKEREFVAA</entry><entry>ISLSGSKQ</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;54</entry><entry>OLIGO_28</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>13-</entry><entry>NGS602-</entry><entry>QVELVESGGALVQAGGSLKLSCVDS</entry><entry>GRSFSSYV</entry><entry>VAWFRQAPGKEREFVAR</entry><entry>VSASGAIR</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;55</entry><entry>OLIGO_72</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>14-</entry><entry>NGS602-</entry><entry>QVQLVESGGGLVQPGGSLRLSCAAS</entry><entry>ESIRSIYA</entry><entry>MGWYRQAPGKQRELVAL</entry><entry>VTDDGST</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;56</entry><entry>OLIGO_2</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>15-</entry><entry>NGS602-</entry><entry>QVQLVESGGGLVQAGGSLRLSCLFS</entry><entry>GTFGIYG</entry><entry>MGWFRQAPGKAREFVAG</entry><entry>VSRHGLTT</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;57</entry><entry>OLIGO_42</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>16-</entry><entry>NGS602-</entry><entry>QVQLVESGGGLVQAGDSLRLSCTAS</entry><entry>GTTFDRYH</entry><entry>MGWFRQAPGMERHVVAH</entry><entry>ISWSGANT</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;58</entry><entry>OLIGO_31</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>17-</entry><entry>NGS602-</entry><entry>QVQLVESGGGLVQPGGSLRLSCAAS</entry><entry>GYSLSFYA</entry><entry>MGWYRQSPGKQREVVAR</entry><entry>IAGPGVT</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;59</entry><entry>OLIGO_359</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>18-</entry><entry>NGS602-</entry><entry>QVQLVESGGGLVQAGDSLRLSCAAS</entry><entry>GRTFSSYA</entry><entry>MAWFRRPPGKAREFVAL</entry><entry>IRWSNGRT</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;60</entry><entry>OLIGO_149</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>19-</entry><entry>NGS602-</entry><entry>QVQLVESGGGLVQAGGSLRLSCAAS</entry><entry>GRTFFTYP</entry><entry>MGWFRQAPGKERQFVAA</entry><entry>ISGNGDSI</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;61</entry><entry>OLIGO_266</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>20-</entry><entry>NGS602-</entry><entry>RVQLVESGGGLVQAGGALRLSCVGS</entry><entry>GFTFRDTA</entry><entry>MAWFRQSPGKEREFVAG</entry><entry>FSILS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;62</entry><entry>OLIGO_169</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0257" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="385pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;6</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Bioinformatic&#x2003;data&#x2003;of&#x2003;selected&#x2003;clones&#x2003;(cont'd)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="133pt" align="left"/><colspec colname="4" colwidth="91pt" align="left"/><colspec colname="5" colwidth="56pt" align="left"/><tbody valign="top"><row><entry>No</entry><entry>Name</entry><entry>Fr3</entry><entry>Cdr3</entry><entry>Fr4</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry>1-</entry><entry>NGS602-</entry><entry>HYLASVKGRFTISRDNDKNTLYLQMNSLKPE</entry><entry>AAKYGWTGIWYAPSDYVH</entry><entry>LGPGTQVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;43</entry><entry>OLIGO_30</entry><entry>DTAVYYC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>2-</entry><entry>NGS602-</entry><entry>YVADSVAGRFTMSRDNAKHLVYLQMDSLNTG</entry><entry>AAHWDYGSSSRRQREYDY</entry><entry>WGQGTQVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;44</entry><entry>OLIGO_152</entry><entry>DTAVYYC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>3-</entry><entry>NGS602-</entry><entry>NYAGSVNGRFKISRDGAKDKVDLQMNSLKPE</entry><entry>ATNMAFSSSSNFPANYDV</entry><entry>WGQGTQVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;45</entry><entry>OLIGO_185</entry><entry>DTAVYFC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>4-</entry><entry>NGS602-</entry><entry>HYADSVKGRFTISRDNAENTVYLQMNSLKPE</entry><entry>ASYLSGHYYFGIGRDPPFGS</entry><entry>WGQGTQVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;46</entry><entry>OLIGO_186</entry><entry>DTAVYYC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>5-</entry><entry>NGS602-</entry><entry>TYADSVKGRFTISRDNVKNIVYLQMDILKPE</entry><entry>TRAPWDYKY</entry><entry>WGQGTQVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;47</entry><entry>OLIGO_205</entry><entry>DTAVYYC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>6-</entry><entry>NGS602-</entry><entry>NYGDSAKGRFTISRDNALNMLYLQMNRLKPE</entry><entry>AARQGNMGDLVVKSGDY</entry><entry>WGQGTQVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;48</entry><entry>OLIGO_50</entry><entry>DTAVYYC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>7-</entry><entry>NGS602-</entry><entry>NYALSMKGRFTISRDNANDMVYLQMDGLKPE</entry><entry>ATRMAFDSDSNFPATYDV</entry><entry>WGQGTQVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;49</entry><entry>OLIGO_12</entry><entry>DTAVYSC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>8-</entry><entry>NGS602-</entry><entry>TYADSVKGRFTISKDNARNTVYLQMNNLTPA</entry><entry>AAYSPGSIIARDSTQYRY</entry><entry>WGQGTRVTVSE</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;50</entry><entry>OLIGO_55</entry><entry>DTAIYYC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>9-</entry><entry>NGS602-</entry><entry>YYADSVRGRFTISRDNAKNTVYLQMNSLKPE</entry><entry>AADRSDVFEKDPGYYDY</entry><entry>WGQGAQVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;51</entry><entry>OLIGO_221</entry><entry>DTAVYYC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>10-</entry><entry>NGS602-</entry><entry>SNLVSLRGRFTISRDNAKNTVYLQMNSLLPE</entry><entry>AIGAAAVGGL</entry><entry>RGQGTQVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;52</entry><entry>OLIGO_151</entry><entry>DTALYYC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>11-</entry><entry>NGS602-</entry><entry>YDPDIAKDRFTISRDNSKTSVYLQMNNLKPE</entry><entry>SLKTTYSGGPYDYTKGPEYD</entry><entry>WGQGTQVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;53</entry><entry>OLIGO_35</entry><entry>DTAVYYC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>12-</entry><entry>NGS602-</entry><entry>YYVDSVKGRFTISRDNAKNTVSLQMNSLKPE</entry><entry>AALKDGEPPAVDY</entry><entry>WGQGTQVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;54</entry><entry>OLIGO_28</entry><entry>DTAVYYC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>13-</entry><entry>NGS602-</entry><entry>IYADSVRGRFTISRDNTKATVYLQMNSLKSE</entry><entry>AAGGVSTAVHPFKPTSYDF</entry><entry>WGQGTQVTVSV</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;55</entry><entry>OLIGO_72</entry><entry>DTAVFFC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>14-</entry><entry>NGS602-</entry><entry>DYVDSVKGRFTVSRDSAKNTVYLQMNSLKPE</entry><entry>YVEGSTHYDPVREY</entry><entry>WGKGTLVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;56</entry><entry>OLIGO_2</entry><entry>DTAVYHC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>15-</entry><entry>NGS602-</entry><entry>QYADSVKGRFTISRDNAKNTMYLQMNSLKPE</entry><entry>ARSRLSASLLVTASDYDY</entry><entry>WGQGTQVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;57</entry><entry>OLIGO_42</entry><entry>DTADYYC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>16-</entry><entry>NGS602-</entry><entry>YVADSMKGRFTISRDNAKNTAYLQINNLKFE</entry><entry>AAGSYLAVPGSRWDY</entry><entry>WGQGTQVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;58</entry><entry>OLIGO_31</entry><entry>DTALYYC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>17-</entry><entry>NGS602-</entry><entry>NYADSVMGRFTISRDNAKNMVYLQMNSLEPE</entry><entry>NAGGTRWSVGDY</entry><entry>WGKGTLVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;59</entry><entry>OLIGO_359</entry><entry>DTAVYYC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>18-</entry><entry>NGS602-</entry><entry>AVVDSVKGRFTASRDNAKNTGYLQMDSLKSE</entry><entry>AACDQALDPPRCND</entry><entry>WGQGTQVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;60</entry><entry>OLIGO_149</entry><entry>DTAVYYC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>19-</entry><entry>NGS602-</entry><entry>DYADSVKGRFTISRDNAKNTLYLQMNSLKPE</entry><entry>NAVITHDYTRPLFAS</entry><entry>WGQGTQVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;61</entry><entry>OLIGO_266</entry><entry>DAALYYC</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>20-</entry><entry>NGS602-</entry><entry>RYADSVKGRFTISRDNDKNTVYLQMNSLKPE</entry><entry>AAGDGTIASVLTTSGVNF</entry><entry>WGQGTQVTVSS</entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;62</entry><entry>OLIGO_169</entry><entry>DTAVYYC</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0258" num="0312">Validation of antigen-specific binding of the antibodies is done by ELISA. The library is surveyed based on subgrouping signatures (sequence abundance, classical VHH vs non classical VHH and CDR3 length). In this example, only one clone is selected from each cluster. In this example most of the selected clones produce a classical VHH instead of a nonclassical VHH. Amino acid sequences having both of long and short hinge sequences are included in the selected clones in this example, as is one clone with an additional pair of disulfide bonds within CDR3 than usual VHH sequences. With such clone picking strategy, we achieved 100% successful rate in selecting clones with binding activity. As shown in the ELISA assay, all 20 clones selected showed specific binding activity to the KLH antigen KLH (<figref idref="DRAWINGS">FIG. <b>13</b></figref>). 18 of them had an average binding EC of 0.465 nm (except No 6 and No 9 as outlier). 3 clones (nos. 1, 3 and 13) are shown to be potent KLH binders, with an EC 50 at 67, 77 and 72 pmol/L, respectively. Most of the leads are shown to have a sub-nanomolar potency. Thus, cloned B-cells secreting potent KLH binding antibodies can be identified via BIA and NGS. To confirm the correlation result between CDR3 length and binding activity, clones with different CDR3 length are included in the list. The shortest CDR3 length that is seen is 9 amino acids, whereas the longest one is 21. The average CDR3 length of the 20 VHH antibodies is 16 amino acids. As shown in <figref idref="DRAWINGS">FIG. <b>42</b></figref>, a positive correlation is observed between CDR3 length and clone ELISA activity.</p><p id="p-0259" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 7</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Anti-KLH ELISA of selected clones</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="28pt" align="left"/><colspec colname="2" colwidth="70pt" align="left"/><colspec colname="3" colwidth="98pt" align="center"/><tbody valign="top"><row><entry/><entry>No.</entry><entry>Clone</entry><entry>EC50 (nanomole/L)</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="28pt" align="left"/><colspec colname="2" colwidth="70pt" align="left"/><colspec colname="3" colwidth="98pt" align="char" char="."/><tbody valign="top"><row><entry/><entry>&#x2002;1</entry><entry>NGS602-OLIGO_30</entry><entry>0.067</entry></row><row><entry/><entry>&#x2002;2</entry><entry>NGS602-OLIGO_152</entry><entry>0.638</entry></row><row><entry/><entry>&#x2002;3</entry><entry>NGS602-OLIGO_185</entry><entry>0.077</entry></row><row><entry/><entry>&#x2002;4</entry><entry>NGS602-OLIGO_186</entry><entry>0.280</entry></row><row><entry/><entry>&#x2002;5</entry><entry>NGS602-OLIGO_205</entry><entry>1.156</entry></row><row><entry/><entry>&#x2002;6</entry><entry>NGS602-OLIGO_50</entry><entry>NA</entry></row><row><entry/><entry>&#x2002;7</entry><entry>NGS602-OLIGO_12</entry><entry>0.181</entry></row><row><entry/><entry>&#x2002;8</entry><entry>NGS602-OLIGO_55</entry><entry>0.241</entry></row><row><entry/><entry>&#x2002;9</entry><entry>NGS602-OLIGO_221</entry><entry>220.400</entry></row><row><entry/><entry>10</entry><entry>NGS602-OLIGO_151</entry><entry>0.409</entry></row><row><entry/><entry>11</entry><entry>NGS602-OLIGO_35</entry><entry>0.291</entry></row><row><entry/><entry>12</entry><entry>NGS602-OLIGO_28</entry><entry>0.707</entry></row><row><entry/><entry>13</entry><entry>NGS602-OLIGO_72</entry><entry>0.072</entry></row><row><entry/><entry>14</entry><entry>NGS602-OLIGO_2</entry><entry>1.740</entry></row><row><entry/><entry>15</entry><entry>NGS602-OLIGO_42</entry><entry>0.342</entry></row><row><entry/><entry>16</entry><entry>NGS602-OLIGO_31</entry><entry>1.008</entry></row><row><entry/><entry>17</entry><entry>NGS602-OLIGO_359</entry><entry>0.610</entry></row><row><entry/><entry>18</entry><entry>NGS602-OLIGO_149</entry><entry>0.147</entry></row><row><entry/><entry>19</entry><entry>NGS602-OLIGO_266</entry><entry>0.195</entry></row><row><entry/><entry>20</entry><entry>NGS602-OLIGO_169</entry><entry>0.213</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0008" level="1">Example 2: Discovery of an Antibody that Blocks PD-1:PD-L1 Complexation by Epitope Prediction</heading><p id="p-0260" num="0313">Overview of the Experimental Approach</p><p id="p-0261" num="0314">Workflow for discovery of an antibody that blocks a ligand:receptor binding interaction (complexation) is illustrated in <figref idref="DRAWINGS">FIG. <b>14</b></figref>. The workflow begins with identification of three dimensional structures of the ligand and receptor, and/or of the structure of their complex, by computational or crystallographic methods. Portions of both of the receptor and ligand that form the binding interface can be determined by examination of the interface of the &#x201c;docked&#x201d; proteins. Amino acids that interact to establish or stabilize the bound complex can be determined by examination of the structure. Data from experiments that change amino acids at the interface and look at the effect of such a change on the binding strength of the complex can contribute to determining the amino acids that interact to form and stabilize the complex.</p><p id="p-0262" num="0315">Short linear amino acid sequence portions of 2 to 4 amino acids of the ligand or of the receptor that lie at the interface of the complex are selected and then an NGS amino acid sequence library is searched to identify antibody cDNA clones that encode the selected short amino acid sequences in a CDR part of the sequence, preferably in a CDR3 portion of the antibody sequence. The screening peptide sequence with 2-4 amino acids length is set as a key word for searching CDR3 sequences from NGS database, and the satisfactory VHH sequences and their abundances are obtained.</p><p id="p-0263" num="0316">Sequences identified as present in the NGS library above a selected threshold of abundance are selected for gene synthesis and expressed in HEK293 cells fused with a human IgG4-FC tag. The expressed proteins are purified and then subjected to functional testing, e.g. for antigen binding and inhibition of PD-1:PD-L1 complex formation</p><p id="p-0264" num="0317">PD-1/PD-L1 Structure Analysis</p><p id="p-0265" num="0318">The structure of PD-1/PD-L1 complex was downloaded from the PDB database (PDB ID: 4ZQK). PYMOL software is used for structure analysis. The structure showed that PD-L1 covered two peptides of PD-1 (<figref idref="DRAWINGS">FIG. <b>15</b></figref>), the loop sequence close to PD-L1 is SFVLNWYRMSPSNQTDKLAA (SEQ ID NO. 138), the loop sequence close to PD-1 is YLCGAISLAPKAQIKESLR (SEQ ID NO. 139). The polar contact-residue regions observed in PD-1/PD-L1 crystal structures are selected. Polar contacts between PD-1 and PD-L1 are shown in PYMOL by using &#x2018;actions-find-polar contacts-to others excluding solvent&#x2019;.</p><p id="p-0266" num="0319"><figref idref="DRAWINGS">FIG. <b>15</b></figref> shows the interface of the PD-1:PD-L1 complex (the data of the complex are publically available&#x2014;Protein DataBase ID No: 4ZQK), and two adjacent peptides of PD-1 that are potential &#x201c;blocking&#x201d; peptides that inhibit complex formation are shown. <figref idref="DRAWINGS">FIG. <b>16</b></figref> illustrates results of an interaction analysis between the PD-1 protein and the two adjacent peptides; amino acids that interact between the SFV . . . SLR peptide of PD-1 and the AFT . . . RIT peptide of PD-L1 at the interface of their complex are identified by connecting lines.</p><p id="p-0267" num="0320">Through the above analysis, the polar contact residues of PD-L1 were determined, and they are F-D-Q-ADYKR (SEQ ID NO. 144). Because there are very long amino acid intervals (&#x3e;2 amino acids) in F-D-Q-A, only the peptide ADYKR (SEQ ID NO. 143) fits the selection strategy. Two to four amino acid peptides are chosen for VHH selection. Then the peptides ADYK (SEQ ID NO. 68), DYKR (SEQ ID NO. 142), ADY, DYK, YKR, AD, DY, YK and KR are set for screening criteria from NGS database (Table 4).</p><p id="p-0268" num="0321">Additional structures of PD-1 complexed by a variety of antibodies are available and are also downloaded from the PDB database and analyzed in the same manner as above. Complexes between PD-1 and a variety of anti-PD-1 antibodies and the short peptides identified as potential blocking peptides by the interaction analysis as described above of the complexes are listed in Table 8.</p><p id="p-0269" num="0000"><tables id="TABLE-US-00008" num="00008"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="84pt" align="left"/><colspec colname="3" colwidth="70pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="3" rowsep="1">TABLE 8</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>PDB ID</entry><entry>Complex</entry><entry>Screening peptides</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>4ZQK</entry><entry>PD-1/PD-L1</entry><entry>ADY</entry></row><row><entry/><entry>4ZQK</entry><entry>PD-1/PD-L1</entry><entry>DYK</entry></row><row><entry/><entry>4ZQK</entry><entry>PD-1/PD-L1</entry><entry>YKR</entry></row><row><entry/><entry>4ZQK</entry><entry>PD-1/PD-L1</entry><entry>DY</entry></row><row><entry/><entry>5WT9</entry><entry>PD-1/nivolumab</entry><entry>NDD</entry></row><row><entry/><entry>5WT9</entry><entry>PD-1/nivolumab</entry><entry>DDY</entry></row><row><entry/><entry>5WT9</entry><entry>PD-1/nivolumab</entry><entry>DD</entry></row><row><entry/><entry>6J14</entry><entry>PD-1/GY-14</entry><entry>NTD</entry></row><row><entry/><entry>6J15</entry><entry>PD-1/GY-5</entry><entry>FYY</entry></row><row><entry/><entry>6J15</entry><entry>PD-1/GY-5</entry><entry>YYF</entry></row><row><entry/><entry>6JBT</entry><entry>PD-1/toripalimab</entry><entry>YWY</entry></row><row><entry/><entry>6JBT</entry><entry>PD-1/toripalimab</entry><entry>WY</entry></row><row><entry/><entry>5GGS</entry><entry>PD-1/pembrolizumab</entry><entry>YRF</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0270" num="0322">Attention is focused on the CDR3 sequences, because the CDR3 in VHH is the main binding region to antigens, and in VHH antibodies the CDR3 portion is longer than in a conventional (VHVL) antibody, and the longer CDR3 provides VHH antibodies a large binding area. CDR3 sequences including screening peptides were extracted from the NGS database and their abundance was counted to eliminate the repetitive sequences. It is found that 2-4 amino acids are appropriate to search the NGS database; two amino acids might be too short (resulting in an unmanageable number of hits), and four amino acids might restrict the number of choices unduly. Accordingly, 3 amino acid strings were selected to search the NGS database.</p><p id="p-0271" num="0323">Prior publications have described protocols for antibody discovery by panning phage surface VHH display libraries. But this method tends to obtain only VHH clones with high abundance in a library, and results in losing some low abundance VHHs. Based on the keyword search using different screening peptide strings, a series of VHH sequences of varying abundance (percentage of all clones that carry a DNA encoding a selected amino acid sequence) are selected from the NGS database. The CDR3 portion of the amino acid sequence encoded in selected clones with different abundance tare presented in Table 9.</p><p id="p-0272" num="0000"><tables id="TABLE-US-00009" num="00009"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;9</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>cDNA&#x2003;clones&#x2003;selected&#x2003;as&#x2003;possible</entry></row><row><entry>blocking&#x2003;antibodies</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="84pt" align="left"/><colspec colname="4" colwidth="21pt" align="left"/><tbody valign="top"><row><entry/><entry>Screening</entry><entry>CDR3</entry><entry/></row><row><entry>Clone&#x2003;ID</entry><entry>peptide</entry><entry/><entry>Count</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="84pt" align="left"/><colspec colname="4" colwidth="21pt" align="center"/><tbody valign="top"><row><entry>504#SS1</entry><entry>ADYK</entry><entry>AASTMVVTTVAADYKY</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;4</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;13)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;69)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS2</entry><entry>ADY</entry><entry>AAGLKADYGDSYVDTSTRNY</entry><entry>&#x2003;3302</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;14)</entry><entry/><entry>NY</entry><entry/></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;70)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS3</entry><entry>ADY</entry><entry>AADYNRLQIGQRSRDYDY</entry><entry>&#x2003;&#x2003;&#x2003;16</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;15)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;71)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS4</entry><entry>ADY</entry><entry>AGRPFGLQLDTHQADYNI</entry><entry>&#x2003;&#x2003;&#x2003;61</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;16)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;72)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS5</entry><entry>ADY</entry><entry>GVDRRQYGLGIPPLADY</entry><entry>&#x2003;&#x2003;&#x2003;30</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;17)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;73)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS6</entry><entry>ADY</entry><entry>VADYRVWGTRIAGTKYDS</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;3</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;18)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;74)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS7</entry><entry>DYK</entry><entry>AADGDASDRSYAPPRDYKYE</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>Y</entry><entry/></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;19)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;75)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS8</entry><entry>DYK</entry><entry>AADNVGDSWYSDDYKY</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;2</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;20)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;76)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS9</entry><entry>DYK</entry><entry>NARPTFGAYYSDYKSGVDY</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;2</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;21)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;77)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS10</entry><entry>DYK</entry><entry>NRGNYYRDYKPEF</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;2</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;22)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;78)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS11</entry><entry>DYK</entry><entry>TTEVACYSDYKSTQISRI</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;2</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;23)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;79)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS12</entry><entry>YKR</entry><entry>NYKRGHYPDGVSTYEY</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;4</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;24)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;80)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS13</entry><entry>YKR</entry><entry>SYKRGRYPDGVSTLEY</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;3</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;25)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;81)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS14</entry><entry>NDD</entry><entry>ANSTYFNDDPEYDR</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;2</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;26)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;82)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS15</entry><entry>NDD</entry><entry>NAGRLSYGGSYYPNDDY</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;3</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;27)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;83)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS16</entry><entry>NDD</entry><entry>NTDYTFAKLTAPDRRNDD</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;2</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;28)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;84)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS17</entry><entry>DDY</entry><entry>NADTIATMTDDY</entry><entry>&#x2003;&#x2003;&#x2003;15</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;29)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;85)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS18</entry><entry>DDY</entry><entry>NATRPRDDYYYTGGFLYY</entry><entry>&#x2003;&#x2003;&#x2003;11</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;30)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;86)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS19</entry><entry>DDY</entry><entry>RPYSDYVTYDPDDYDY</entry><entry>11351</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;31)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;87)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS20</entry><entry>NTD</entry><entry>NTDPDYSDYDDMYVRS</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;9</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;32)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;88)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS21</entry><entry>NTD</entry><entry>AATNSNTDWRTYTEYNY</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;2</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;33)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;89)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS22</entry><entry>FYY</entry><entry>AAKFTSSSFYYRSPREYSS</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;3</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;34)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;90)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS23</entry><entry>FYY</entry><entry>AAKNVPGFYYSDYANHEYDY</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;4</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;35)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;91)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS24</entry><entry>YYF</entry><entry>NAPKGGSYYFPAVGGYDY</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;7</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;36)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;92)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS25</entry><entry>YYF</entry><entry>RVESQDYYFDYDRDS</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;2</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;37)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;93)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS26</entry><entry>YWY</entry><entry>ATGYWYTPGD</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;4</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;38)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;94)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS27</entry><entry>YWY</entry><entry>NAKRYWYDY</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;5</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;39)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;95)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS28</entry><entry>YRF</entry><entry>AADFDTYRFCSGFGPDAYSS</entry><entry>&#x2003;&#x2003;&#x2003;11</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;40)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;96)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS29</entry><entry>YRF</entry><entry>AVLVDSTYRF</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;2</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;41)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;97)</entry><entry/></row><row><entry> </entry></row><row><entry>504#SS30</entry><entry>YRF</entry><entry>NADISRYRFSRGDY</entry><entry>&#x2003;&#x2003;&#x2003;&#x2003;5</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;42)</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO.&#x2003;98)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0273" num="0324">CDR3 Sequence Selection from NGS Database</p><p id="p-0274" num="0325">We determined a series of screening peptides with amino acids length of 2-4. We supposed that CDR3 contains the screening peptides may bind with PD-1 and block PD-L1. Because the CDR3 in VHH is the main binding region with antigens, it is s longer than conventional antibody and the longer CDR3 provides VHH large binding area. CDR3 sequences including screening peptides were extracted from the NGS database and the abundance was counted to wipe out the repetitive sequences. Due to different screening peptides, we found that 2-4 amino acids were appropriate but what needs illustration is that 2 AA may be too short, and 4 AA may restrict the choose number, 3 amino acids length screening peptides were the best choice.</p><p id="p-0275" num="0326">Antibody Expression and Purification</p><p id="p-0276" num="0327">Nucleic acids encoding the selected VHH antibody sequences are synthesized and inserted into a pCDNA 3.4 vector fused with IgG4-FC tag with a (G4S)<sub>3 </sub>linker. The recombinant plasmids are confirmed by sequencing. Then the VHH-FC constructs are transformed in HEK293 cells.</p><p id="p-0277" num="0328">Transformed cells are cultured for 5-7 days to obtain the recombinant proteins. Then the recombinant VHH antibodies are purified from filtered culture supernatants. The protein concentration of the obtained antibodies is measured by UV-absorbance at 280 nm. The purity of the purified recombinant antibodies is evaluated by Coomassie-staining of sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE) and high-performance liquid chromatography (HPLC).</p><p id="p-0278" num="0329">ELISA Binding Assay</p><p id="p-0279" num="0330">2 &#x3bc;g/ml of PD-1 protein is coated on 96-well plates overnight for ELISA binding assay. Recombinant VHH-FC proteins are added to the wells and allowed to stand for a period of time, then 1 &#x3bc;g/ml of HRP-conjugated anti-FC antibody is added as detection antibody and the assay reagents are added. The absorbance is read at 450 nm. Binding of nivolumab serves as a positive control and plates coated with BSA are used as the negative control group.</p><p id="p-0280" num="0331">ELISA Blocking Assay</p><p id="p-0281" num="0332">Each well of 96-well microtiter plates is coated with 2 &#x3bc;g/ml of PD-1 protein in PBS and blocked with 1% BSA. Purified VHH-FC protein at a concentration of 5 &#x3bc;g/ml is added to each well.</p><p id="p-0282" num="0333">Then 2 &#x3bc;g/ml of biotin labeled PD-L1 protein is added to each well. The PD-L1 proteins are detected with RP-conjugated anti-human IgG and TMB as substrate. The intensity of the developed color is measured at 450 nm. Wells with no added PD-1 and no added VHH-FC are negative and positive controls, respectively.</p><p id="p-0283" num="0334">Thirty clones were selected and VHH antibodies are purified from the selected clones. Thirty clones are selected for expression and purification as described above. 19 clones exhibited good expression of the recombinant VHH antibody.</p><p id="p-0284" num="0335">Purified VHH antibodies from the 19 clones are assessed for binding to PD-L1 and for inhibition of formation of a PD-1:PD-L1 complex by ELISA as described above. Results are shown in Tables 10 and 11, respectively:</p><p id="p-0285" num="0000"><tables id="TABLE-US-00010" num="00010"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 10</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>PD-L1 binding activity of VHH antibodies </entry></row><row><entry>expressed from selected cDNA clones</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="154pt" align="center"/><tbody valign="top"><row><entry/><entry>Mean Measurement Value (OD450)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><tbody valign="top"><row><entry>Clone ID</entry><entry>2 &#x3bc;g/mL</entry><entry>0.2 &#x3bc;g/mL</entry><entry>0.02 &#x3bc;g/mL</entry><entry>0.002 &#x3bc;g/mL</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="28pt" align="char" char="."/><colspec colname="3" colwidth="42pt" align="char" char="."/><colspec colname="4" colwidth="42pt" align="char" char="."/><colspec colname="5" colwidth="42pt" align="char" char="."/><tbody valign="top"><row><entry>SS1</entry><entry>0.04</entry><entry>0.03</entry><entry>0.03</entry><entry>0.03</entry></row><row><entry>SS2</entry><entry>3.10</entry><entry>3.12</entry><entry>2.25</entry><entry>0.59</entry></row><row><entry>SS5</entry><entry>3.06</entry><entry>3.18</entry><entry>2.79</entry><entry>1.56</entry></row><row><entry>SS7</entry><entry>1.07</entry><entry>0.24</entry><entry>0.05</entry><entry>0.03</entry></row><row><entry>SS8</entry><entry>0.04</entry><entry>0.03</entry><entry>0.03</entry><entry>0.03</entry></row><row><entry>SS9</entry><entry>0.04</entry><entry>0.03</entry><entry>0.03</entry><entry>0.03</entry></row><row><entry>SS10</entry><entry>0.04</entry><entry>0.03</entry><entry>0.03</entry><entry>0.03</entry></row><row><entry>SS11</entry><entry>3.16</entry><entry>3.03</entry><entry>1.52</entry><entry>0.24</entry></row><row><entry>SS12</entry><entry>0.07</entry><entry>0.04</entry><entry>0.03</entry><entry>0.03</entry></row><row><entry>SS13</entry><entry>0.03</entry><entry>0.03</entry><entry>0.03</entry><entry>0.03</entry></row><row><entry>SS14</entry><entry>0.04</entry><entry>0.03</entry><entry>0.03</entry><entry>0.04</entry></row><row><entry>SS15</entry><entry>0.05</entry><entry>0.04</entry><entry>0.04</entry><entry>0.04</entry></row><row><entry>SS16</entry><entry>0.05</entry><entry>0.03</entry><entry>0.04</entry><entry>0.03</entry></row><row><entry>SS22</entry><entry>0.04</entry><entry>0.03</entry><entry>0.03</entry><entry>0.04</entry></row><row><entry>SS23</entry><entry>3.00</entry><entry>2.91</entry><entry>1.22</entry><entry>0.19</entry></row><row><entry>SS25</entry><entry>0.04</entry><entry>0.03</entry><entry>0.03</entry><entry>0.03</entry></row><row><entry>SS28</entry><entry>3.06</entry><entry>2.77</entry><entry>0.93</entry><entry>0.14</entry></row><row><entry>SS29</entry><entry>0.35</entry><entry>0.06</entry><entry>0.04</entry><entry>0.04</entry></row><row><entry>SS30</entry><entry>0.04</entry><entry>0.03</entry><entry>0.03</entry><entry>0.04</entry></row><row><entry>1194-z0-IgG4</entry><entry>3.10</entry><entry>3.00</entry><entry>1.36</entry><entry>0.17</entry></row><row><entry>NBL507-</entry><entry>0.05</entry><entry>0.04</entry><entry>0.04</entry><entry>0.04</entry></row><row><entry>BMK2-H4-IgG4</entry><entry/><entry/><entry/><entry/></row><row><entry>Blank</entry><entry>0.03</entry><entry>0.03</entry><entry>0.03</entry><entry>0.04</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0286" num="0000"><tables id="TABLE-US-00011" num="00011"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 11</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Blocking activity of selected VHH clones</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="161pt" align="center"/><tbody valign="top"><row><entry/><entry>Mean Measurement Values of Antibodies at </entry></row><row><entry/><entry>Different Concentrations (OD450)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><tbody valign="top"><row><entry>Clone ID</entry><entry>9.75 &#x3bc;g/mL</entry><entry>2.42 &#x3bc;g/mL</entry><entry>0.6l &#x3bc;g/mL</entry><entry>0.15 &#x3bc;g/mL</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="42pt" align="char" char="."/><colspec colname="3" colwidth="42pt" align="char" char="."/><colspec colname="4" colwidth="35pt" align="char" char="."/><colspec colname="5" colwidth="42pt" align="char" char="."/><tbody valign="top"><row><entry>SS1</entry><entry>3.17</entry><entry>3.26</entry><entry>3.15</entry><entry>3.19</entry></row><row><entry>SS2</entry><entry>3.31</entry><entry>3.31</entry><entry>3.23</entry><entry>3.34</entry></row><row><entry>SS5</entry><entry>0.08</entry><entry>0.14</entry><entry>1.65</entry><entry>3.18</entry></row><row><entry>SS7</entry><entry>3.26</entry><entry>3.31</entry><entry>3.35</entry><entry>3.32</entry></row><row><entry>SS8</entry><entry>3.27</entry><entry>3.33</entry><entry>3.28</entry><entry>3.27</entry></row><row><entry>SS9</entry><entry>3.32</entry><entry>3.46</entry><entry>3.36</entry><entry>3.42</entry></row><row><entry>SS10</entry><entry>3.32</entry><entry>3.28</entry><entry>3.24</entry><entry>3.27</entry></row><row><entry>SS11</entry><entry>2.87</entry><entry>2.92</entry><entry>3.13</entry><entry>3.18</entry></row><row><entry>SS12</entry><entry>3.28</entry><entry>3.27</entry><entry>3.20</entry><entry>3.22</entry></row><row><entry>SS13</entry><entry>3.33</entry><entry>3.29</entry><entry>3.33</entry><entry>3.34</entry></row><row><entry>SS14</entry><entry>3.36</entry><entry>3.27</entry><entry>3.25</entry><entry>3.22</entry></row><row><entry>SS15</entry><entry>3.68</entry><entry>3.57</entry><entry>3.69</entry><entry>3.53</entry></row><row><entry>SS16</entry><entry>3.26</entry><entry>3.22</entry><entry>3.35</entry><entry>3.48</entry></row><row><entry>SS22</entry><entry>3.28</entry><entry>3.32</entry><entry>3.34</entry><entry>3.47</entry></row><row><entry>SS23</entry><entry>3.28</entry><entry>3.29</entry><entry>3.31</entry><entry>3.47</entry></row><row><entry>SS25</entry><entry>3.17</entry><entry>3.36</entry><entry>3.30</entry><entry>3.32</entry></row><row><entry>SS28</entry><entry>3.27</entry><entry>3.31</entry><entry>3.28</entry><entry>3.32</entry></row><row><entry>SS29</entry><entry>3.31</entry><entry>3.39</entry><entry>3.36</entry><entry>3.35</entry></row><row><entry>SS30</entry><entry>3.28</entry><entry>3.29</entry><entry>3.26</entry><entry>3.33</entry></row><row><entry>1194-z0-IgG4</entry><entry>0.10</entry><entry>0.32</entry><entry>2.60</entry><entry>3.23</entry></row><row><entry>NBL507-</entry><entry>3.15</entry><entry>3.24</entry><entry>3.24</entry><entry>3.32</entry></row><row><entry>BMK2-H4-IgG4</entry><entry/><entry/><entry/><entry/></row><row><entry>Blank</entry><entry>3.23</entry><entry>3.31</entry><entry>3.24</entry><entry>3.19</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0287" num="0336">1194-z0-IgG4 is a positive control antibody known to have activity of blocking PD-1.PD-L1 complexation. NBL507-BMK2-H4-IgG4 is an irrelevant antibody used as a negative control.</p><p id="p-0288" num="0337">Seven of the selected clones produced VHH antibodies that have substantial activity of binding to PD-1, and five of these with the strongest binding were selected for testing for activity of blocking PD-1:PD-L1 complex formation. Clone SS5 is found to exhibit stronger complexation inhibition even than the positive control 1194-z0-IgG4.</p><p id="p-0289" num="0338">From the results obtained, it appears that the collection of clones expressing antibodies having a CDR3 sequence that is represented among all clones that are selected in at least ten (10) copies has a high probability of including at least one clone expressing a VHH antibody that will specifically bind to the antigen and will block complexation of the antigen with its specific protein binding partner. For example, in the experiment disclosed herein, 100% of clones having their CDR3 sequence represented in greater than 10 copies among the picked clones express a VHH antibody that binds to PD-1, and 33% of them express a VHH antibody that will block binding of PD-1 to PD-L1. In contrast only 25% of clones having their CDR3 sequence present in less than 10 copies among the picked clones express a VHH antibody that binds to PD-1 and none of the picked clones express a VHH antibody that will block PD-1 binding to PD-L1.</p><p id="p-0290" num="0339">In additional experiments conducted as above, 30 clones for expression and purification are picked as described above. 19 clones are shown to have good expression of recombinant VHH antibody. Among them, 7 showed strong binding to human PD-1. The overall success rate for identifying clones secreting antigen binding VHH antibodies NGS guided clone selection is 37%.</p><heading id="h-0009" level="1">Example 3: Development of Sequence Signatures and Clone Selection Rules</heading><p id="p-0291" num="0340">Convergent (overlapping) sequences between animals under BCMA immunization. In this experiment, two alpacas named 507-A1 (A1) and 507-A2 (A2) are immunized with human recombinant BCMA protein. Animals A1 and A2 receive an equal amount of recombinant human BCMA using the same immunization regime. 93 and 40 VHH sequences with unique CDR3 amino acid sequences are found as promising leads for animals A1 and A2, respectively. Between animals, selecting clones double-blinded as to the immunization and clone identification, there are 20 sequences with CDR3 sequences shared by both animals. Table 12 shows the 20 unique CDR3 sequences shared by both animals.</p><p id="p-0292" num="0000"><tables id="TABLE-US-00012" num="00012"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;12</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>CDR3&#x2003;sequences&#x2003;of&#x2003;overlapping&#x2003;clones</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="105pt" align="left"/><colspec colname="2" colwidth="91pt" align="left"/><tbody valign="top"><row><entry/><entry>CDR3</entry><entry/></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry>AIGAPDPFNYSGWRRNL</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;99</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>AIGISPHYGSDWYALR</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;100</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>AIGLSPGYRDPNL</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;101</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>AIGLSPGYRDPNL</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;102</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>ALGAMREGVYSDL</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;103</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>AVGAPLVSSPYRS</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;104</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>AVGAWYEKRKKKEKGL</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;105</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>AVGIVVPYSEDAWYSTL</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;106</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>GIGRWYDQRKKEEGL</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;107</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>NAAPWGSYHPQTDIVS</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;108</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>NAAPWGSYSPGPGDIAS</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;109</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>NGAPWGDHAPVVGS</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;110</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>NGAPWGDIAPVAVS</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;111</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>NPAPWGDYTATDFHS</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;112</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>QLGIHPGAF</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;113</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>QVGRYVSGVDYQP</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;114</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>QVGRYVSGVYYQP</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;115</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>VIGRGGYAMGDRRL</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;116</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>VIGRRGYAMGDRTL</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;117</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>VVGRRGYAMGSRQL</entry><entry>SEQ&#x2003;ID&#x2003;NO.&#x2003;118</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0293" num="0341">The relationship among CDR3 sequences from animals A1 and A2 is shown as a Venn diagram in <figref idref="DRAWINGS">FIG. <b>18</b></figref>.</p><p id="p-0294" num="0342">Antibody sequences shared between VHH2 (long-hinged) and VHH3 (short-hinged) sequences. In the A1 alpaca, 6 VHH sequences can be found having either a long region or a short hinge region. As shown in <figref idref="DRAWINGS">FIG. <b>19</b>A</figref> an original pool of 249 sequences is found and 135 of them are found to have hinge sequences. Among these 26 nonredundant sequences with long hinge sequences and 89 with short hinge sequences are found. Of these, 19 unique CDR3 sequences have long hinge sequences, and 53 unique CDR3 sequences have short hinge sequences. Among these two groups, 6 CDR3 sequences are found to be shared.</p><p id="p-0295" num="0343">Similar consideration of the amino acid sequences of clones from animal A2 identifies 2 sequences that are shared by A2 animals in both the long-hinged or short hinged pool as shown in <figref idref="DRAWINGS">FIGS. <b>20</b>A and <b>20</b>B</figref>.</p><p id="p-0296" num="0344">Altogether, 8 sequences in A1 and A2 animals are found to be in both of a long hinge sequence pool and in a short hinge sequence pool.</p><p id="p-0297" num="0345">Convergent sequences between traditional antibodies in alpaca (VH) and VHH2/VHH3. 19 single chain antibodies are identified from the 2 animals that show good binding to human BCMA. Surprisingly, the 2 VHH sequences shared by long and short hinge pools, named as lAl and 1D2, are also shared by the leads from the traditional VH repertoire. The number of sequences shared by the different classes of antibodies are shown in <figref idref="DRAWINGS">FIG. <b>21</b>A</figref>. The 8 VHH CDR3 sequences shared by either a long or a short hinge are shown in <figref idref="DRAWINGS">FIG. <b>21</b>B</figref>, with the highlighted sequences being shared by all VH/VHH2 and VHH3.</p><p id="p-0298" num="0346">Shared sequences are shown to be potent BCMA binders. To test if overlapping sequences are preferred signatures, the antibodies expressed by the 8 convergent VHH clones shared by VHH2 and VHH3 are purified. All found to be potent BCMA binders, either by ELISA or by flow cytometry. The highlighted sequences in <figref idref="DRAWINGS">FIG. <b>21</b>B</figref> (SEQ ID NOS. 117 and 118), named as lAl and 1D2, are shared by both VH and VHH antibodies. The 8 convergent VHH antibodies are found to bind cells of tumor cell line RPMI8226 that overexpress BCMA, but not to 293T cells that are negative for BCMA expression. ELISA showed similar results using either His- or Fc-conjugated human BCMA as the coating antigen (Table 13).</p><p id="p-0299" num="0000"><tables id="TABLE-US-00013" num="00013"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="441pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 13</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>BCMA binding by selected antibodies</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="9"><colspec colname="1" colwidth="91pt" align="center"/><colspec colname="2" colwidth="77pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="35pt" align="center"/><colspec colname="6" colwidth="42pt" align="center"/><colspec colname="7" colwidth="35pt" align="center"/><colspec colname="8" colwidth="42pt" align="center"/><colspec colname="9" colwidth="35pt" align="center"/><tbody valign="top"><row><entry/><entry>FACS on different Cell</entry><entry>ELISA</entry><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>(MFI)</entry><entry>(OD450)</entry><entry/><entry/><entry/><entry/><entry/><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="10"><colspec colname="1" colwidth="91pt" align="center"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><colspec colname="6" colwidth="35pt" align="center"/><colspec colname="7" colwidth="42pt" align="center"/><colspec colname="8" colwidth="35pt" align="center"/><colspec colname="9" colwidth="42pt" align="center"/><colspec colname="10" colwidth="35pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>293T-</entry><entry>BCMA-His</entry><entry>BCMA-</entry><entry>Anti-His</entry><entry>human IgG</entry><entry/><entry>MW</entry><entry>extinction</entry></row><row><entry>Sample ID</entry><entry>RPMI8226</entry><entry>EGFR</entry><entry>1 ug/mL</entry><entry>Fc 1 ug/mL</entry><entry>1 ug/mL</entry><entry>1 ug/mL</entry><entry>PI</entry><entry>(kDa)</entry><entry>coefficient</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="10"><colspec colname="1" colwidth="91pt" align="center"/><colspec colname="2" colwidth="42pt" align="char" char="."/><colspec colname="3" colwidth="35pt" align="char" char="."/><colspec colname="4" colwidth="42pt" align="char" char="."/><colspec colname="5" colwidth="42pt" align="char" char="."/><colspec colname="6" colwidth="35pt" align="char" char="."/><colspec colname="7" colwidth="42pt" align="char" char="."/><colspec colname="8" colwidth="35pt" align="char" char="."/><colspec colname="9" colwidth="42pt" align="char" char="."/><colspec colname="10" colwidth="35pt" align="char" char="."/><tbody valign="top"><row><entry>NBL507-A1L1-P1R2-1A1-</entry><entry>2418</entry><entry>230</entry><entry>2.37</entry><entry>2.47</entry><entry>2.10</entry><entry>0.03</entry><entry>8.66</entry><entry>12.9</entry><entry>1.68</entry></row><row><entry>(1)-PME207-SEQF_A01.seq</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>NBL507-A1L1-P1R2-1D2-</entry><entry>1263</entry><entry>222</entry><entry>2.32</entry><entry>2.35</entry><entry>0.57</entry><entry>0.02</entry><entry>8.91</entry><entry>12.8</entry><entry>1.16</entry></row><row><entry>(9)-PME207-SEQF_A02.seq</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>NBL507-A1L1-P1R2-1E2-</entry><entry>2553</entry><entry>227</entry><entry>2.37</entry><entry>2.53</entry><entry>2.44</entry><entry>0.03</entry><entry>8.72</entry><entry>12.6</entry><entry>1.92</entry></row><row><entry>(10)-PME207-SEQF_B02.seq</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>NBL507-A1L1-P1R2-1B6-</entry><entry>864</entry><entry>216</entry><entry>2.25</entry><entry>2.52</entry><entry>1.96</entry><entry>0.03</entry><entry>7.96</entry><entry>12.7</entry><entry>1.70</entry></row><row><entry>(31)-PME207-SEQF_G04.seq</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>NBL507-A1L1-P1R2-1B8-</entry><entry>1808</entry><entry>219</entry><entry>2.27</entry><entry>2.47</entry><entry>1.79</entry><entry>0.01</entry><entry>6.76</entry><entry>12.7</entry><entry>1.90</entry></row><row><entry>(44)-PME207-SEQF_D06.seq</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>NBL507-A1L1-P1R2-1G8-</entry><entry>4172</entry><entry>236</entry><entry>2.42</entry><entry>2.60</entry><entry>2.06</entry><entry>0.01</entry><entry>8.68</entry><entry>13.1</entry><entry>1.54</entry></row><row><entry>(48)-PME207-SEQF_H06.seq</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>NBL507-A2L1-P1R2-1C1-</entry><entry>764</entry><entry>222</entry><entry>2.28</entry><entry>3.12</entry><entry>0.71</entry><entry>0.03</entry><entry>6.77</entry><entry>12.8</entry><entry>1.81</entry></row><row><entry>(273)-PME207-</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>SEQF_E11.seq</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>NBL507-A2L1-P1R2-1H1-</entry><entry>532</entry><entry>222</entry><entry>2.11</entry><entry>3.30</entry><entry>0.98</entry><entry>0.04</entry><entry>7.95</entry><entry>12.7</entry><entry>1.70</entry></row><row><entry>(275)-PME207-</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>SEQF_G11.seq</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry namest="1" nameend="10" align="left" id="FOO-00001">NBL507-A1L1-P1R2-1A1-(1)-PME207-SEQF_A01 SEQ ID NO. 131</entry></row><row><entry namest="1" nameend="10" align="left" id="FOO-00002">NBL507-A1L1-P1R2-1D2-(9)-PME207-SEQF_A02 SEQ ID NO. 132</entry></row><row><entry namest="1" nameend="10" align="left" id="FOO-00003">NBL507-A1L1-P1R2-1E2-(10)-PME207-SEQF_B02 SEQ ID NO. 133</entry></row><row><entry namest="1" nameend="10" align="left" id="FOO-00004">NBL507-A1L1-P1R2-1B6-(31)-PME207-SEQF_G04 SEQ ID NO. 134</entry></row><row><entry namest="1" nameend="10" align="left" id="FOO-00005">NBL507-A1L1-P1R2-1B8-(44)-PME207-SEQF_D06 SEQ ID NO. 135</entry></row><row><entry namest="1" nameend="10" align="left" id="FOO-00006">NBL507-A1L1-P1R2-1G8-(48)-PME207-SEQf_H06 &#x2014;</entry></row><row><entry namest="1" nameend="10" align="left" id="FOO-00007">NBL507-A2L1-P1R2-1C1-(273)-PME207-SEQF_E11 SEQ ID NO. 136</entry></row><row><entry namest="1" nameend="10" align="left" id="FOO-00008">NBL507-A2L1-P1R2-1H1-(275)-PME207-SEQF_G11 SEQ ID NO. 137</entry></row></tbody></tgroup></table></tables></p><p id="p-0300" num="0347">Overlapping sequence signature. Finally, the 2 sequences shared by VH/VHH2/VHH3 are also be found in both of the A1 and A2 animals (see <figref idref="DRAWINGS">FIG. <b>22</b></figref>). Therefore, picking those sequences which are found in multiple animals/VH/VHH germlines is considered to be a useful signature of antibodies that exhibit strong, specific binding to their antigen.</p><p id="p-0301" num="0348">Data to support additional signatures. The affinity of classical VHH and nonclassical VHH for binding to human BCMA is examined. Classical VHH have higher affinity than nonclassical VHH. The results are shown in <figref idref="DRAWINGS">FIG. <b>23</b></figref>; P&#x3c;0.05.</p><p id="p-0302" num="0349">Additional Signature Statistics</p><p id="p-0303" num="0350">FR2 hydrophilic region: for most of VHH antibodies, FR2 has unique amino acid substitutions compared to conventional IgG: 37Phe/Tyr, 44Glu, 45Arg, and 47Gly. <figref idref="DRAWINGS">FIG. <b>24</b></figref> shows the proportion of clones having these FR2 unique amino acids of VHH antibodies in each of three libraries, each against a different antigen (NBL501 (anti-MSLN), NBL504 (anti-PD1) and NBL602 (anti-KLH)). Surprisingly, we only found up to 8% of the whole VHH repertoire of clones in these three libraries includes this particular FR2 substitution pattern. The frequency of the individual substitutions at position 37, 44, 45 and 47 (Kabat numbering) in the FR2 unique sequences is also examined, and these data are shown in <figref idref="DRAWINGS">FIG. <b>25</b></figref>.</p><p id="p-0304" num="0351">Interestingly, the unique sequence substitutions are quite diversified. While at position 44 and 45, Glu and Arg are predominant amino acids, the positions 37 and 47 are variable. In the NBL501 anti-MSLN project, 70% of Tyr and 10% of Phe occupied position 37. In contrast, in anti-PD1 (NBL504) and anti-KLH projects (NBL602), 37Phe reached 70%, with 37Tyr is found at about 25%. A consistent high percentage of Leu instead of Glycine in position 47 is observed, and there are also a significant percentage of clones having Phe and Trp in this position. The signature amino acid Gly only accounts for less than 10% of the frequency in this position. Therefore, a signature for alpaca VHH FR2 is proposed as 37Phe/Tyr, 44Glu, 45Arg, and 47Gly/Leu/Phe</p><p id="p-0305" num="0352">Extended CDR1 and CDR2: VHHs have an extra hypervariable region (residues 27-30, according to Kabat's numbering) next to CDR1. VHH antibodies with this region together with a long CDR3 region have increased the surface area interacting with antigen. However, antibodies having this signature are not often seen.</p><p id="p-0306" num="0353">The CDR2 domain is normally 5-9 amino acids in length. However, many clones contain a &#x201c;long CDR2&#x201d; with a length of 14-17 amino acids. Importantly, VHH containing a long CDR2 are found to have a higher binding affinity for their antigen than those with a shorter CDR2. ELISA data from antibodies from three different libraries are shown in <figref idref="DRAWINGS">FIG. <b>27</b></figref>.</p><p id="p-0307" num="0354">Extra disulfide bond within CDR3: around 5-10% of VHH antibodies have an extra disulfide bond within the CDR3 domain, which may indicate that the epitope bound by the antibody is a more &#x201c;conformational&#x201d; recognition site that is formed from the three-dimensional structure of the antigen rather than a short length of a linear amino acid sequence. About 2-19% of CDR3 contain intra-disulfide bonds. <figref idref="DRAWINGS">FIG. <b>28</b></figref> shows the proportion in the three libraries of antibodies having an extra disulfide bond within the CDR3 domain (identified as an additional Cys residue&#x2014;i.e. 2 cysteine amino acids in CDR3). The NBL504 anti-PD1 library contains a high percentage antibodies having a long CDR3 domain, and it contains significantly more CDR3 intra-disulfide bonds than the other two libraries, which have such clones at about 2%.</p><p id="p-0308" num="0355">Extra disulfide bond between CDR1 and CDR2: Although low in frequency, antibodies having an extra disulfide bond between CDR1 and CDR2 can be found, as an extra Cys amino acid CDR1 or CDR2. See, <figref idref="DRAWINGS">FIGS. <b>29</b> and <b>30</b></figref>.</p><p id="p-0309" num="0356">Extra disulfide bond between CDR1-CDR3 or FR2-CDR3: In camel and dromedary, 82% of VHH antibodies have a disulfide bond between CDR1 and CDR3, and in Llama and Alpaca, 74% of VHH antibodies have a disulfide bond between FR2-CDR3. 70-80% of the VHH antibody sequences do not contain additional disulfide bonds. 10-25% of the VHH sequences might contain an additional disulfide bond (4 cysteines in the sequence). Interestingly, 5-10% of the VHH antibody sequences contain an unpaired cysteine. How and if these VHH antibodies can pair with another VHH antibody by forming a disulfide bond between unpaired cysteines is unknown. A total of up to 7 cysteine in a single VHH sequence has been observed. These data suggest that up to 3 intra-domain disulfide bonds can be formed with a remaining unpaired cysteine. <figref idref="DRAWINGS">FIG. <b>31</b></figref> shows analysis of the number of cysteine residues in amino acid sequences of selected VHH antibodies in three different libraries.</p><p id="p-0310" num="0357">Extra disulfide bond between CDR1 and CDR3 can be seen but this is rare. See <figref idref="DRAWINGS">FIG. <b>32</b></figref>.</p><p id="p-0311" num="0358">Most of the extra disulfide bonds in VHH antibodies are between FR2/CDR2-CDR3. Consistent with the total cysteine number calculation, most of the additional disulfide bonds are between FR2/CDR2 (depending on nomenclature of either IMGT or KABAT) and CDR3. The additional paired cysteines are between 2-9 percent of all the VHH sequences in the NGS database. See, <figref idref="DRAWINGS">FIG. <b>33</b></figref>.</p><p id="p-0312" num="0359">A significant negative correlation of the supernatant OD value by a clone to the number of cysteines in its amino acid sequence is observed (see, <figref idref="DRAWINGS">FIG. <b>34</b></figref>). Accordingly, in picking clones, it is recommended to usually avoid an odd numbers of cysteine in the VHH amino acid sequence. Furthermore, itis preferred to avoid picking VHH sequences containing more than 1 pair of cysteine sequences. The extra disulfide bonds can either affect the expression yield of the VHH or have a negative effect on the affinity of binding. Thus, additional disulfide bonds can adversely affect the developability of downstream manufacturing of nanobodies.</p><p id="p-0313" num="0360">Long CDR3: In a PD1 NGS library (NBL504), up to 86% of the VHH clones have a &#x201c;long CDR3&#x201d; domain having more than 15 amino acids. See, <figref idref="DRAWINGS">FIG. <b>35</b></figref>.</p><p id="p-0314" num="0361"><figref idref="DRAWINGS">FIG. <b>36</b></figref>, <figref idref="DRAWINGS">FIG. <b>37</b></figref> and <figref idref="DRAWINGS">FIG. <b>38</b></figref> show that there is a positive correlation between length of the CDR3 domain and antibody affinity assayed by FACS for VHH anti-BCMA antibodies binding to the surface of cells from two different cell lines (CHO.K1 and RPMI8226) expressing BCMA and by ELISA using supernatant. All correlations have p value equal to 0.001 or smaller. CDR3 length is consistently shown to have a significant correlation with binding affinity of the antibody to its antigen. Accordingly it is preferable to select antibodies having a CDR3 domain length longer than 14 amino acids if there are a large number of clones that might be picked.</p><p id="p-0315" num="0362">CDR3 variants with a similar length are observed to be likely binding to a similar epitope of a single antigen. We have observed a narrow range of CDR3 length for a populations of VHH antibodies binding to nearly identical epitopes or the same epitope of a certain antigen. See, <figref idref="DRAWINGS">FIG. <b>39</b></figref>.</p><p id="p-0316" num="0363">Furthermore, antibodies binding to the same epitopes can be identified by lineage-related sequences. For example, clones with CDR3 length difference of 0 or 1 amino acids. Clones 1182, 1202 and 1734 are picked from same lineage of anti-PD1 antibodies, and they all compete with Keytruda for PD1 binding (see, <figref idref="DRAWINGS">FIG. <b>40</b></figref>). It is seen that clones picked from related lineages with a same length of CDR3 are in the same bin. The experiments disclosed herein suggest that lineage-related clones having same length CDR3 domains will have an increased chance of binding to exactly the same epitope. In picking clones based on NGS data it is preferred to reduce the number of such redundant clones in the selected pool.</p><p id="p-0317" num="0364">Non-classic VHH which have the same V and J germlines as conventional IgG: VHH lineage groups that share the same na&#xef;ve B-cell origin (same V and J assignment) with conventional IgG1, are indicated as recognizing the same or a similar epitope whether being a VHH antibody or an IgG1 antibody. In the 507 library there are 2 out of 81 sequences that are shared by VHH2/VHH3/VH, about 2.5% of the clones.</p><p id="p-0318" num="0365">Non-classic VHH which have unique sequence signatures&#x2014;conserved Trp118 substituted with Arg118 and or lower hydrophobicity profile in FR3: Trp 118 can be found in each of the NBL501, NBL504 and NBL602 libraries, with a percentage up to 3%. See, <figref idref="DRAWINGS">FIG. <b>41</b></figref>.</p><p id="p-0319" num="0366">Overall, the data described above suggest the following clone selection rules:<ul id="ul0017" list-style="none">    <li id="ul0017-0001" num="0000">    <ul id="ul0018" list-style="none">        <li id="ul0018-0001" num="0367">1. If a single animal is immunized, pick the VHH sequences shared by VHH2 and VHH3. If the VHVL is investigated, pick those shared between VH and VHH.</li>        <li id="ul0018-0002" num="0368">2. Convergent motif or sequence signature: different animals in the same experimental group could convergently generate the same motif or sequence signature through the same VDJ assignment. Paratope coded by these motifs or sequence signatures may target the functional epitopes. If multiple animals are immunized, pick convergent sequences shared between animals.</li>        <li id="ul0018-0003" num="0369">3. FR2 hydrophilic region: for most of VHH antibodies, FR2 has unique amino acids substitutions for conventional IgG: 37Phe/Tyr, 44Glu, 45Arg, and 47Gly/Leu/Phe.</li>        <li id="ul0018-0004" num="0370">4. Non-classic VHH which have unique sequence signatures: conserved Trp118 substituted with Arg118 and or lower hydrophobicity profile in FR4.</li>        <li id="ul0018-0005" num="0371">5. Classical VHH have higher affinity than nonclassical. When picking clones, we should prefer picking classical VHHs. Nonclassic VHH which do not contain FR2 signatures.</li>        <li id="ul0018-0006" num="0372">6. Avoiding picking clones with odd number of cysteines in the sequence: We have picked one clone for synthesis with 3 cysteines. It failed to express. Several screened clones with 3 cysteines have below average expression.</li>        <li id="ul0018-0007" num="0373">7. In conventional antibodies, people found continues residues of positive or negative charges in CDR3 will cause folding issue. In VHH, we have picked one clone with 3 Rs in CDR3, the clone failed to express. Several screened clones with three continue positive charges (K or R or mix of them) have below average expression. Avoid picking clones with 3 or more continue positive charges in CDR3.</li>        <li id="ul0018-0008" num="0374">8. To avoid clones with positive charge at N-terminus. We picked such two clones and both of them failed to express. Almost no screened clones with positive charge at the n-terminus.</li>        <li id="ul0018-0009" num="0375">9. Some alpaca has VHH with long CDR2 (17 aa instead of 8/9), clones with such long CDR2 appear to have high binging affinity.</li>        <li id="ul0018-0010" num="0376">10. For some projects, CDR3 length has positive correlation with binding affinity, pick long CDR3 clusters with priority.</li>        <li id="ul0018-0011" num="0377">11. For the related cluster with a similar CDR3 length, avoid picking too many redundant candidates as we found that homologus CDR3 at a similar length lead to binding to a similar epitopes.</li>        <li id="ul0018-0012" num="0378">12. Convergent motif or sequence signature: different animals in the same experimental group could convergently generate the same motif or sequence signature through the same VDJ assignment. Paratope coded by these motifs or sequence signatures may target the functional epitopes.</li>        <li id="ul0018-0013" num="0379">13. Novel canonical binding loop structure: the hypermutation hotspots residing at key-sites to determine the canonical loop structures create an interesting potential to diversify the VHH structural repertoire. Crystallographic studies accentuate that the CDR1 and CDR2 loops of camel VHHs often deviate from the known canonical structures of the conventional VH. Sequence-based new Ag-binding loop conformation prediction should support further grouping the lineage (Laura S. Mitchell, Lucy J. Colwell, Comparative analysis of nanobody sequence and structure data, Proteins. 2018; 86:697-706).</li>    </ul>    </li></ul></p><heading id="h-0010" level="1">REFERENCES</heading><p id="p-0320" num="0000"><ul id="ul0019" list-style="none">    <li id="ul0019-0001" num="0380">Daley L P, Kutzler M A, et al. Effector functions of camelid heavy-chain antibodies in immunity to West Nile virus. Clin. Vaccine Immunol. 17:239-46, 2010.</li>    <li id="ul0019-0002" num="0381">McCoy L E, et al. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J. Exp. Med. 2012.</li>    <li id="ul0019-0003" num="0382">Cristina Basilico, et al. Four individually druggable MET hotspots mediate HGF-driven tumor progression, The Journal of Clinical Investigation, Volume 124 Number 7 July, 2014.</li>    <li id="ul0019-0004" num="0383">Basvan der Woninga, et al. DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops, MABS, VOL. 8, NO. 6, 1126-1135, 2016.</li>    <li id="ul0019-0005" num="0384">Laura M. Griffin et al. Analysis of heavy and light chain sequences of conventional camelid antibodies from <i>Camelus dromedarius </i>and <i>Camelus bactrianus </i>species, Journal of Immunological Methods Volume 405, Pages 35-46, March 2014.</li>    <li id="ul0019-0006" num="0385">Adhdi Arbabi-Ghahroudi, et al. camelid single-Domain Antibodies: Historical Perspective and Future Outlook, Frontiers in Immunology, Vol 8, 2017.</li>    <li id="ul0019-0007" num="0386">Viet Khong Nguyen, et al. Camel heavy-chain antibodies: diverse germline VHH and specific mechanism enlarge the antigen-binding repertoire The EMBO Journal Vol. 19 No. 5 2000</li>    <li id="ul0019-0008" num="0387">Mehdi Arbabi-Ghahroudi. Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook. Front. Immunol., 20 Nov. 2017.</li>    <li id="ul0019-0009" num="0388">Nguyen V K, et al. Heavy-chain antibodies in Camelidae; a case of evolutionary innovation. Immunogenetics 54:39-47, 2002.</li>    <li id="ul0019-0010" num="0389">Conrath K E, et al. Emergence and evolution of functional heavy-chain antibodies in Camelidae. Dev Comp Immunol 27:87-103, 2003.</li>    <li id="ul0019-0011" num="0390">Nick Deschacht, et al. A Novel Promiscuous Class of Camelid Single-Domain Antibody Contributes to the Antigen-Binding Repertoire, The Journal of Immunology. 184(10) 5696-5704, May 2010.</li>    <li id="ul0019-0012" num="0391">Cortez-Retamozo V, et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer. 98(3):456-62, 2002.</li>    <li id="ul0019-0013" num="0392">Alex Klarenbeek, et al. Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform, mAbs 7:4, 693-706; 2015.</li>    <li id="ul0019-0014" num="0393">Tomoyuki Igawa, et al. Engineering the variable region of therapeutic IgG antibodies. mAbs 3:3, 243-252; 2011.</li>    <li id="ul0019-0015" num="0394">Laura S. Mitchell, Lucy J. Colwell, Comparative analysis of nanobody sequence and structure data, Proteins. 2018; 86:697-706.</li>    <li id="ul0019-0016" num="0395">Maass D R, Sepulveda J, Pernthaner A, Shoemaker C B. Alpaca (<i>Lama pacos</i>) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J Immunol Methods. 2007; 324(1-2):13-25.</li></ul></p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230002757A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A method generating a camelid antibody specific for an antigen, comprising:<claim-text>a) enriching and proliferating B-cells from immunized camelids specific to the antigen;</claim-text><claim-text>b) generating antibody NGS libraries comprising VHH<sup>2</sup>, VHH<sup>3</sup>, and VH<sup>1 </sup>chain sequences from the antigen-specific B-cells;</claim-text><claim-text>c) grouping antibody sequences of VHH<sup>2</sup>, VHH<sup>3</sup>, and VH<sup>1 </sup>chain in the NGS libraries by lineages;</claim-text><claim-text>d) ranking the lineages from step c) by one or more lineage priority factors;</claim-text><claim-text>e) selecting a representative sequence from a lineage comprising a VHH<sup>2 </sup>or VHH<sup>3 </sup>with a top ranking from step d) in the NGS library; and</claim-text><claim-text>f) testing an antibody comprising the selected sequence from step e) to determine if the antibody binds to the antigen or portion thereof.</claim-text></claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. A The method for generating a camelid antibody according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein minimal CDR3 distance of a specific CDR3 is equal or less than 1 among the group of CDR3s from a lineage, wherein minimal CDR3 distance of a specific CDR3 is the smallest hamming distance of such CDR3 comparing with all other CDR3 of the same length.</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. A The method for generating a camelid antibody according to <claim-ref idref="CLM-00001">claim 1</claim-ref> further comprising lineage subgrouping with VHH unique features selected from a group consisting of<claim-text>i) FR2 hydrophilic region,</claim-text><claim-text>ii) extended CDR1,</claim-text><claim-text>iii) extra disulfide bond between CDR1-CDR3 or FR2-CDR3,</claim-text><claim-text>iv) extra disulfide bond within CDR3,</claim-text><claim-text>v) long CDR3 (&#x2265;15 aa),</claim-text><claim-text>vi) Extra disulfide bond within CDR1,</claim-text><claim-text>vii) Non-classic VHH which have the same V and J germlines as conventional IgG1,</claim-text><claim-text>viii) Non-classic VHH which have predetermined sequence signatures,</claim-text><claim-text>ix) Novel canonical binding loop structure, and</claim-text><claim-text>x) Convergent motif or sequence signature.</claim-text></claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The method for generating a camelid antibody according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the lineage priority factors are selected from a group consisting of lineages from high to low sequences abundancy, lineages from high to low amplification factor, lineages sequences abundancy change during immunization course, lineages sequences abundancy change before and after depleting certain unwanted B cells, Lineages which share the same na&#xef;ve B-cell origin between VHH and VH<sup>1</sup>, avoidance of developability liability sequences, and a combination thereof.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The method for generating a camelid antibody according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein first top 100 lineages of VHH<sup>2</sup>, and VHH<sup>3 </sup>are chosen in e).</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The method for generating a camelid antibody according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the antibody in f) is expressed by prokaryotic or eukaryotic cells.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The method for generating a camelid antibody according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising monitoring immune responses of camelid antibodies IgG2 (HcAb), IgG3 (HcAb) and IgG1 (conventional IgG).</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The method for generating a camelid antibody according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising repeating e)-f) to optimize a sequence within the same lineage group of the selected VHH<sup>2 </sup>or VHH<sup>3 </sup>heavy chain only antibodies.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. A method generating a camelid antibody specific for an antigen, comprising:<claim-text>a) enriching and proliferating B-cells from immunized camelids specific to the antigen,</claim-text><claim-text>b) generating antibody NGS libraries comprising VHH<sup>2</sup>, VHH<sup>3</sup>, VH<sup>1 </sup>and VL<sup>1 </sup>chain sequences from said antigen-specific B-cells,</claim-text><claim-text>c) grouping sequences of VHH<sup>2</sup>, VHH<sup>3</sup>, VH<sup>1 </sup>and VL<sup>1 </sup>in the NGS libraries by lineages,</claim-text><claim-text>d) pairing VH<sup>1</sup>/VL<sup>1 </sup>lineage according to anchor binders generated by single B-cell sorting and heterohybridoma approaches,</claim-text><claim-text>e) ranking lineages and lineage pairs from step c) and step d) by one or more lineage priority factors,</claim-text><claim-text>f) selecting a representative sequence or sequence pair from a lineage of VHH<sup>2 </sup>or VHH<sup>3 </sup>and a lineage pair of VH<sup>1</sup>/VL<sup>1 </sup>respectively with a top ranking from step e) in the NGS library,</claim-text><claim-text>g) testing an antibody comprising the selected sequence pair or sequence from step f) to determine if the antibody binds to the antigen or portion thereof.</claim-text></claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. The method for generating a camelid antibody according to <claim-ref idref="CLM-00009">claim 9</claim-ref>, wherein anchors for IgG1 repertoire are generated with single B-cells sorting and heterohybridoma approaches.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The method for generating a camelid antibody according to <claim-ref idref="CLM-00009">claim 9</claim-ref>, wherein the ranking of lineage pairs in step e) is based on lineage priority factors of VH<sup>1 </sup>lineages of said lineage pairs.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The method for generating a camelid antibody according to <claim-ref idref="CLM-00010">claim 10</claim-ref>, wherein one representative sequence of VHH or one representative pair VH<sup>1</sup>/VL<sup>1 </sup>from the 100 top-ranked lineages or lineage pair groups is selected as an anchor.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The method for generating a camelid antibody according to <claim-ref idref="CLM-00012">claim 12</claim-ref>, wherein the 100 lineages or lineage pair groups comprise 70 VHHs lineage group and 30 VH<sup>1</sup>/V&#x3ba; or VH<sup>1</sup>/V&#x3bb; lineage group pairs.</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. The method for generating a camelid antibody according to <claim-ref idref="CLM-00010">claim 10</claim-ref>, wherein the lineage priority factors are selected from a group consisting of lineages from high to low sequences abundancy, lineages from high to low amplification factor, lineages sequences abundancy change during immunization course, lineages sequences abundancy change before and after depleting certain unwanted B cells, Lineages which share the same na&#xef;ve B-cell origin between VHH and VH<sup>1</sup>, avoidance of developability liability sequences, and a combination thereof.</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. The method for generating a camelid antibody according to <claim-ref idref="CLM-00009">claim 9</claim-ref>, further comprising repeating f)-g), wherein VHH clones have a feature selected from a group consisting of<claim-text>i) FR2 hydrophilic region,</claim-text><claim-text>ii) extended CDR1,</claim-text><claim-text>iii) extra disulfide bond between CDR1-CDR3 or FR2-CDR3,</claim-text><claim-text>iv) extra disulfide bond within CDR3,</claim-text><claim-text>v) long CDR3 (&#x2265;15 aa),</claim-text><claim-text>vi) extra disulfide bond within CDR1,</claim-text><claim-text>vii) non-classic VHH which have the same V and J germlines as conventional IgG,</claim-text><claim-text>viii) non-classic VHH which have predetermined sequence signatures,</claim-text><claim-text>xi) novel canonical binding loop structure, and</claim-text><claim-text>x) convergent motif or sequence signature.</claim-text></claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. A method for generating a humanized VHH<sup>2 </sup>or VHH<sup>3 </sup>antibody specific for an antigen comprising<claim-text>a. enriching and proliferating B-cells from immunized camelids specific to the antigen,</claim-text><claim-text>b) generating antibody NGS libraries comprising VHH<sup>2</sup>, VHH<sup>3</sup>, VH<sup>1 </sup>chain sequences from antigen-specific B-cells,</claim-text><claim-text>c) grouping sequences of VHH<sup>2</sup>, VHH<sup>3</sup>, VH<sup>1 </sup>in the NGS library by lineages,</claim-text><claim-text>d) identifying a substitutable position in a parent VHH<sup>2</sup>, VHH<sup>3 </sup>antibody or VH<sup>1 </sup>sharing the same na&#xef;ve B-cell origin by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same epitope as the parent antibody in the same lineage,</claim-text><claim-text>e) substituting amino acids at one or more of the substitutable positions of the parental VHH<sup>2</sup>, VHH<sup>3 </sup>antibody with correspondingly positioned amino acids in the human antibody.</claim-text><claim-text>f) testing an antibody comprising the substituted residues within the selected sequences to determine if the antibody binds to the antigen or a portion thereof.</claim-text></claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. The method for generating a humanized VHH antibody according to <claim-ref idref="CLM-00016">claim 16</claim-ref>, wherein the substitutable position is in the CDRs regions.</claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. The method for generating a humanized VHH antibody according to <claim-ref idref="CLM-00016">claim 16</claim-ref>, wherein the substitutable position is in the FRs regions.</claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. The method for generating a camelid antibody according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the antigen is a complex immunogen, further comprising: using an antibody which has been determined in step (f) to bind with the complex immunogen to identify individual antigens included in the complex immunogen by protein array, cells/tissue antigen cDNA library, or mass spectrometry-based immunoprecipitation.</claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. The method for generating camelid antibody according to <claim-ref idref="CLM-00009">claim 9</claim-ref>, further comprising applying the selected VHH sequences to guide VH<sup>1</sup>-VL<sup>1 </sup>pair selection for these clones which share the same na&#xef;ve B-cell origin, wherein the selection criteria comprise one or more of 1) the same CDR3 sequences between VHH and VH<sup>1</sup>; 2) CDR1 and CDR2 differences; and 3) FR1, FR2, FR3 and FR4 differences.</claim-text></claim><claim id="CLM-21-23" num="21-23"><claim-text><b>21</b>-<b>23</b>. (canceled)</claim-text></claim><claim id="CLM-00024" num="00024"><claim-text><b>24</b>. An isolated camelid antibody or antigen-binding portion generated by the method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim></claims></us-patent-application>